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SUMMARY  
 
Keywords: Streptococcus pyogenes, CovRS, SpeB, skin and soft tissue infections  
Streptococcus pyogenes (Group A Streptococcus, GAS) is among the most 
prevalent bacterial pathogens of humans and it is responsible for a wide range of 
infections, from pharyngitis and impetigo to life-threatening conditions such as 
necrotizing fasciitis and streptococcal toxic shock syndrome. However, until today, 
despite many years of research, there is still no consensus regarding which are the 
genotypic or phenotypic characteristics that confer to an isolate a certain tissue 
preference or a more invasive potential. The nasopharyngeal mucosa and skin are 
considered the primary sources of isolates responsible for invasive infections. This 
suggests a further ability of these isolates to invade and survive in deeper tissues. In the 
last years, spontaneous mutations occurring in the covRS two-component regulatory 
system have been considered a possible explanation for the transition from localized to 
systemic infection. It is estimated that this system controls directly or indirectly the 
expression of 10-15% of the GAS genome. As a consequence of these mutations, 
among the distinct patterns of expression of several virulence factors, the 
downregulation of the extracellular cysteine protease SpeB, has been considered crucial 
for the switch to a hypervirulent phenotype. The downregulation of SpeB has also been 
described as a consequence of mutations in a stand-alone transcriptional regulator 
named RopB. However, contrasting results were reported whether covRS mutations 
were more prone to occur in certain lineages, namely those more frequently associated 
with invasive infections or if they occur in a similar proportion among invasive and 
non-invasive isolates. To address these questions, in the present thesis, we determined 
the sequence of the covRS and ropB of 191 isolates from invasive infection and 
pharyngitis and evaluated the production of SpeB, as well of NAD glycohydrolase 
(NADase) and streptolysin S (SLS), which are two virulence factors supposed to be 
under the influence of CovRS. Moreover, skin and soft tissue infections (SSTI) are 
frequently considered the focal points for the development of invasive disease. 
However, most of the knowledge about GAS skin isolates is from studies that intended 
to find differences between isolates recovered from invasive and non-invasive infections 
generically. The majority of these studies use isolates recovered from SSTI but mostly 
from pharyngitis and compared those together against the isolates recovered from 
 x 
invasive infections, resulting in few data regarding isolates recovered from SSTI. 
Therefore, we characterized by multiple typing methods a total of 320 isolates from 
SSTI recovered in Portugal and performed the comparison with invasive isolates 
recovered during the same period which were previously characterized. All SSTI 
isolates were also tested for SpeB activity and for those without detectable SpeB 
activity we determined the sequence of covRS and ropB genes.  
Overall, we found that isolates with null covS alleles, which are predicted to 
eliminate the protein function have a significant association with invasive infections 
comparative with isolates from pharyngitis and SSTI. Additionally, none of these 
isolates, as expected, had SpeB activity, and, with few exceptions, they showed an 
increased activity of both NADase and SLS that could explain their potentially higher 
invasiveness. Even so, this mechanism was found to be uncommon, corresponding to 
only 10% of invasive isolates, which could be due to an overall fitness cost of these 
mutations. Moreover, null covS alleles were not more prevalent among isolates from 
clones frequently associated with invasive infection such as emm1 and emm64 and 
instead they were distributed throughout diverse genetic backgrounds. The few 
exceptions regarded the levels of NADase and SLS points to the complexity of the 
regulatory networks among distinct GAS lineages. Additionally, no null covR alleles 
were detected in our isolates and ropB null alleles were found in a low fraction of GAS 
isolates and were not associated with any infection type. Regarding SpeB activity, it 
was detected in a similar proportion in isolates recovered from the different sources, and 
therefore its absence was not associated to any type of infection, suggesting that its 
abrogation cannot by itself explain the higher ability of certain clones to cause invasive 
disease. Among SSTI isolates, we found that emm89 type isolates were the most 
prevalent and were significantly associated with these infections when compared with 
invasive isolates. In contrast, emm1, emm3, and emm64 isolates were associated with 
invasive infections. Within emm89 isolates, SSTI were only associated to those that lack 
the hasABC locus, corresponding to a recently emerged acapsular clade (clade 3) that 
also carries a variant of the ngs-ifs-slo locus. These results suggest that for some 
unknown reason these isolates may have an increased potential to cause SSTI. As a 
consequence of known differences in the emm-type between isolates causing these two 
types of infections, we also found significant associations between the ability to bind to 
different host proteins. This ability was presumed by inferring the emm-cluster through 
the emm-type results. The emm-cluster is a recent classification based on the entire 
xi 
 
sequence of the emm gene (M protein) where each cluster shares binding motifs to host 
proteins and other structural properties. Therefore, the ability to bind fibrinogen and 
albumin were significantly associated with invasive isolates, whereas the ability to bind 
to C4BP and IgG were associated with SSTI isolates. Differences in the presence of 
superantigen (SAg) genes, SAg profiles and in the distribution of sequence types (ST) 
determined by Multilocus Sequence Typing (MLST) were also noted. The possible 
impact of these differences in the ability of the isolates to cause these distinct infections 
remains to be clarified. Moreover, within each emm type the same MLST defined 
lineages and SAg profiles could be found in both types of infection, questioning the 
possibility that these characteristics dictate the tissue tropism of each isolate.     
In summary, the results described in this thesis indicate that isolates responsible 
for SSTI are genetically distinct from those recovered from normally sterile sites and 
while some GAS clones have more capacity to invade deeper tissues, others are more 
prone to cause SSTI. Moreover, the significant presence of null covS mutations among 
invasive isolates and the fact that no association was observed regarding the absence of 
SpeB activity in isolates from different types of infections, suggests that the role of 
spontaneous mutations impairing the CovRS activity is probably related with the 
regulation of others virulence factors under its control in addition to SpeB.  
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RESUMO 
 
Palavras-Chave: Streptococcus pyogenes, CovRS, SpeB, infeções da pele e tecidos 
moles 
 
As bactérias da espécie Streptococcus pyogenes estão entre os principais agentes 
bacterianos responsáveis por infeções no Homem. São também frequentemente 
denominadas por estreptococos pertencendo ao Grupo A de Lancefield, por aglutinarem 
com o soro A da classificação de Lancefield, uma investigadora cujos trabalhos foram 
cruciais para o atual conhecimento sobre esta espécie. Uma das características mais 
particulares desde agente é a capacidade de causar um grande espectro de infeções 
variando relativamente ao local e à gravidade. Pode causar desde doenças autolimitadas 
da faringe e pele, como faringo-amigdalites e lesões de impetigo, a infeções invasivas 
frequentemente associadas a elevada morbilidade e mortalidade, como são o caso da 
fasceíte necrosante e a síndrome do choque tóxico. Também de referir que o seu 
principal impacto mundial advém das complicações autoimunes, hoje em dia ainda com 
elevada prevalência nos países em desenvolvimento, onde estão incluídas a febre 
reumática e a glomerulonefrite. Assim sendo, para causar esta variedade de infeções, 
este microrganismo tem que se adaptar a diferentes ambientes. A orofaringe e a pele são 
consideradas como os principais focos de estirpes
1
 invasivas, o que implica que estas 
estirpes têm que invadir e sobreviver nos tecidos celulares subcutâneos. Porém, mesmo 
depois de décadas de investigação, ainda não há consenso relativamente a quais são as 
características moleculares ou fenotípicas que conferem a uma estirpe um maior 
potencial invasivo ou uma determinada preferência por um local anatómico.  
Em 2006, um estudo com um modelo murganho de infeção da pele e tecidos 
moles sugeriu a ocorrência de mutações espontâneas num sistema regulador durante o 
processo de infeção como uma explicação para a transição da infeção localizada para 
sistémica. Vários estudos foram publicados de seguida a apoiar esta hipótese, incluindo 
alguns que descreveram a presença destas mutações em estirpes recolhidas de infeções 
no Homem. O sistema regulador em causa é constituído por dois componentes e 
denomina-se de CovRS. Estima-se que este sistema controle direta ou indiretamente 
cerca de 10 a 15% de todo o genoma de S. pyogenes. Entre as alterações verificadas na 
                                                          
1
 Neste resumo, a palavra estirpe é utilizada para referir um microrganismo isolado de um determinado 
 produto biológico 
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expressão de vários fatores de virulência, a abolição da atividade de uma protease 
extracelular denominada SpeB tem sido considerada como um evento crucial para uma 
maior virulência. Teoricamente, na ausência de SpeB, são preservados vários fatores de 
virulência presentes na superfície bacteriana que contribuem para o processo invasivo. 
Adicionalmente, a diminuição da atividade de SpeB tem também sido descrita como 
resultado de mutações num outro regulador, designado RopB. Porém, enquanto alguns 
estudos defendem que as mutações nestes reguladores ocorrem mais frequentemente em 
estirpes recolhidas de infeções invasivas, outros defendem que estas ocorrem na mesma 
proporção em estipes de infeções não invasivas. Alguns defendem ainda que estas 
mutações estão limitadas às linhagens frequentemente associadas a infeções invasivas. 
De modo a abordar estas questões, determinámos as sequências dos genes covRS e ropB 
de 191 estirpes recolhidas de infeções invasivas e de amigdalites. Determinámos 
também, a atividade de SpeB de cada uma destas estirpes e os respetivos valores de 
NAD glicohidrolase e de estreptolisina S que são dois fatores de virulência 
aparentemente também sob o controlo do regulador CovRS. Por sua vez, as infeções da 
pele e tecidos moles são frequentemente consideradas como um foco para o 
desenvolvimento de infeções invasivas. Porém, a informação disponível sobre estirpes 
da pele é escassa porque a maioria do conhecimento atual advém de estudos cujo 
objetivo é a identificação de diferenças entre estirpes recolhidas de infeções invasivas e 
não invasivas. Os estudos em questão tendem a analisar as características das estirpes 
isoladas da pele em conjunto com estirpes recolhidas de exsudados faríngeos, o que 
resulta numa difícil avaliação das características específicas desta população. Desta 
forma, caracterizámos 320 estirpes recolhidas de infeções da pele e tecidos moles em 
Portugal através de vários métodos de tipagem e procedemos à sua comparação com 
estirpes invasivas recolhidas durante o mesmo período previamente trabalhadas. 
Avaliámos ainda, para as 320 estipes, a presença de atividade de SpeB e naquelas que 
não apresentavam atividade, determinámos as respetivas sequências dos genes covRS e 
do ropB.  
Verificámos existir uma associação significativa entre estirpes cujas mutações se 
preveem eliminar a função proteica do CovS e as infeções invasivas, comparativamente 
com estirpes recolhidas de faringo-amigdalites e de infeções da pele e tecidos moles. 
Adicionalmente, assim como esperado, nenhuma destas estirpes apresentava atividade 
SpeB e, salvo algumas exceções, apresentavam um aumento dos níveis de atividade de 
NAD glicohidrolase e de estreptolisina S. Embora estas diferenças sejam concordantes 
xv 
 
com uma maior capacidade invasiva, este mecanismo apenas foi detetado em 10% das 
estirpes invasivas analisadas. Pensa-se que estas mutações possam estar associadas a um 
elevado “fitness cost”, dificultando por exemplo a capacidade de colonização e de 
transmissão, o que pode explicar a sua reduzida prevalência. Verificou-se ainda que 
estas mutações se encontram dispersas por estirpes de diversas linhagens e não estão 
apenas restritas às mais frequentemente associadas a infeções invasivas, como estirpes 
do tipo emm1 e emm64. As exceções detetadas nos valores de atividade de NAD 
glicohidrolase e estreptolisina S realçam a complexidade já conhecida dos mecanismos 
de regulação de S. pyogenes e as potenciais diferenças entre estirpes de linhagens 
distintas. Relativamente ao covR, não foi detetada nenhuma mutação que se preveja 
eliminar a função proteica. Por sua vez, para o gene ropB, este tipo de mutações foram 
detetadas num reduzido número de estirpes e não foram associadas a nenhum tipo de 
infeção. No que se refere à atividade de SpeB, esta foi detetada na maioria das estirpes e 
numa proporção semelhante em estirpes de diferentes origens, pelo que a sua ausência 
não foi associada a nenhum tipo de infeção. Estes resultados sugerem que a ausência de 
SpeB por si só não explica a maior capacidade de certas estirpes para causar infeção 
invasiva.  
 Estirpes do tipo emm89 eram as mais prevalentes e estavam significativamente 
associadas às infeções da pele e tecidos moles, quando comparadas com as estirpes 
invasivas. Por outro lado, estirpes do tipo emm1, emm3 e emm64 foram 
significativamente associadas a infeções invasivas. Porém, de entre as estirpes do tipo 
emm89, as infeções da pele e tecidos moles apenas foram associadas às estirpes que não 
têm o locus hasABC, responsável pela síntese da cápsula de ácido hialurónico. Estas 
estipes correspondem a uma linhagem recente sem cápsula que possui uma variante do 
locus ngs-ifs-slo. Estes resultados sugerem que, por alguma razão ainda desconhecida, 
estas estirpes podem apresentar uma maior apetência para causar infeções da pele e 
tecidos moles. Refletindo os tipos de emm associados a cada tipo de infeção, outras 
associações significativas foram detetadas, nomeadamente a presumida capacidade de 
ligação a diferentes proteínas do Homem durante o processo de infeção. Esta 
capacidade foi presumida deduzindo os “clusters” de emm através dos tipos de emm. Os 
“clusters” correspondem a uma classificação mais recente que se baseia na totalidade da 
sequência do gene emm, ao contrário dos tipos de emm que se baseiam apenas numa 
porção deste. Segundos os autores, as estirpes de cada “cluster” partilham zonas de 
ligação a proteínas do hospedeiro. Assim sendo, enquanto a capacidade de ligação ao 
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fibrinogénio e à albumina foram significativamente associadas às estirpes invasivas, a 
capacidade de ligação ao C4BP e IgG foram associadas às estirpes da pele e tecidos 
moles. Também foram notadas diferenças na presença de genes codificantes de 
superantigénios, nos perfis de superantigénios e nos “sequence types” determinados 
através de “Multilocus Sequence Typing”. Embora se tenham verificado diversas 
diferenças entre estirpes com diferentes origens, permanece por esclarecer se estas 
influenciam a apresentação da doença e qual o mecanismo subjacente para que isto 
ocorra. Por sua vez, ao considerar estirpes do mesmo tipo de emm, verificaram-se os 
mesmos perfis de superantigénios e os mesmos “sequence types” em estirpes de ambos 
os tipos de infeção, o que sugere que é pouco provável que estes indicadores estejam 
relacionados com a preferência de cada estipe para um determinado local anatómico ou 
a um maior potencial invasivo.  
 Resumidamente, os resultados descritos nesta tese indicam que as estirpes 
responsáveis por infeções da pele e tecidos moles são uma população geneticamente 
distinta das estirpes recolhidas de locais normalmente estéreis e enquanto algumas 
linhagens têm uma maior capacidade invasiva outras são mais propensas a causar 
infeções da pele e tecidos moles. Por fim, o facto de se ter verificado uma presença 
significativa de mutações no covS que se preveem que eliminem a função proteica entre 
as estirpes invasivas associado ao facto de não se identificarem diferenças na atividade 
SpeB entre estirpes de infeções distintas, sugere que o mecanismo subjacente às 
mutações espontâneas no CovRS como causa de maior virulência, pode estar 
relacionado com outros fatores de virulência sob o controlo deste sistema para além do 
SpeB.  
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THESIS OUTLINE   
 
The work described in the present thesis intended to evaluate the importance of 
CovRS and RopB regulators among Streptococcus pyogenes isolates recovered from 
distinct types of infections including in isolates from skin and soft tissue infections that 
were fully characterized through several typing methods and compared with 
contemporary invasive isolates.  
The thesis comprises 4 chapters, organized as follows: 
Chapter 1 corresponds to the general introduction that highlights the importance 
of Streptococcus pyogenes including a historical overview, the infections for which it is 
responsible and their burden, a description of the best known virulence factors, their 
mechanisms of action, their contribution to virulence and some of their regulators. It 
also includes a brief description of typing methods, therapeutic management of 
infections and mechanisms of antimicrobial resistance.  
Chapter 2 is dedicated to the study of CovRS and RopB regulators and the 
consequences of their variability in several virulence factors, for which we specifically 
screened the strains. In this study, we used a collection of isolates from pharyngitis and 
from invasive infections to evaluate potential differences.  
Chapter 3 consists in a detailed characterization of a collection of isolates 
recovered from skin and soft tissues infections using several typing methods and their 
comparison with a collection of invasive isolates recovered during the same period that 
were previously characterized. We also screened skin and soft tissue isolates for the 
presence of protease activity and sequenced covRS and ropB in a subset of isolates in 
order to understand their importance in this type of infections and to compare it with the 
results described in chapter 2.   
Chapter 4 corresponds to the general discussion. In this chapter is provided a 
summary of the main results obtained in this thesis and its integrated discussion. It also 
includes perspectives for future work.   
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General Introduction 
 
3 
1. HISTORICAL BACKGROUND   
 
According to a review about history of streptococcal research (Ferretti and 
Kohler, 2016), the first potential description of streptococcal infections dates to the 4
th
 
century BC, in the original writings of Hippocrates where are described the symptoms 
of childbed fever and erysipelas. In 1874, an Austrian surgeon named Theodor Billroth, 
described “small organisms as found in either isolated or arranged in pairs, sometimes 
in chains of four to twenty or more links (Streptococcus; Gr. Strepto, a chain and 
coccus, a berry)” in cases of erysipelas and wound infections. In 1879, Louis Pasteur 
established the real importance of streptococci when he isolated the microorganism 
from the uteruses and blood of women with puerperal fever and demonstrated that 
Streptococcus was the etiological agent responsible for the disease. At that time, 
puerperal fever was the cause of high mortality among women and newborns. The name 
“Streptococcus pyogenes” (Gr., pyo, pus, and genes, forming) came from Julius 
Rosenbach in 1884, due to his observations of bacteria recovered from suppurative 
lesions. Meanwhile, other names also emerged such as eryespaltis, scarlatinae, and 
puerperalis, mostly according to the disease associated. However, in 1932, due to the 
lack of unique characteristics of the microorganisms isolated from specific diseases, 
Andrews & Christie suggested that all previous species names be included in the single 
name Streptococcus pyogenes. Since 1903, with the introduction of blood agar plates by 
Hugo Schottmüller that is possible to differentiate streptococci based on their type of 
hemolysis. Those with a clear zone surrounding a colony were termed Streptococcus 
haemolyticus. Then, in 1933, Rebecca Lancefield developed the classification system, 
that is currently used, which allowed the differentiation of Streptococcus haemolyticus 
isolates in distinct groups (Lancefield, 1933). Streptococcus pyogenes corresponds to 
Lancefield group A antigen and therefore the name Group A Streptococcus (GAS) is 
commonly used as an alternative. 
 
2. GENERAL FEATURES 
 
Streptococcus pyogenes is a Gram positive bacterium. Individual cells are 
presented as spherical cocci with 1 to 2µm in diameter arranged in short chains in 
clinical specimens. When grown in liquid media longer chains are observed (Figure 1). 
It is a facultative anaerobe, catalase negative, with optimal growth on blood-enriched 
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agar media (Murray et al., 2013). After overnight incubation at 35-37°C on blood agar 
plates, characteristic white colonies with 1 to 2 mm surrounded by large clear zones of 
β-hemolysis are observed (Figure 1). Among the species belonging to the Streptococcus 
genus, three distinct patterns of hemolysis are observed: α-hemolysis (partial or green 
hemolysis), β-hemolysis (complete hemolysis), and γ-hemolysis (absence of hemolysis).  
 
Figure 1. Streptococcus pyogenes. A- Chains with Gram stain. B- Colonies in blood 
agar with a surrounding area of β-hemolysis. Both images were reproduced from 
(Murray et al., 2013). 
A minority of Streptococcus pyogenes strains exhibiting α-hemolysis and γ-
hemolysis on blood agar were also reported, which were associated with the lack of 
ability to produce streptolysin S (SLS) (discussed later) (Yoshino et al., 2010). Some 
strains are covered by a hyaluronic acid capsule that is antigenically indistinguishable 
from the hyaluronic acid in mammalian connective tissues (discussed later) (Murray et 
al., 2013). Additionally, within the cell wall of Streptococcus pyogenes is the group-
specific carbohydrate, which is a dimmer of N-acetylglucosamine and rhamnose. This 
carbohydrate comprises about 10% of the dry weight of the cell and is the base of the 
serological classification developed by Rebecca Lancefield in 1933, which identifies 
Streptococcus pyogenes as Lancefield’s group A streptococci (Lancefield, 1933). After 
the enzymatic extraction of the carbohydrate, a latex agglutination test with each 
specific group serum allows the identification of Streptococcus pyogenes (group A), 
Streptococcus agalactiae (group B), and other species (groups C, F and G) (Murray et 
al., 2013). There are some strains of Streptococcus dysgalactiae subsp. equisimilis and 
Streptococcus anginosus group that share the same group-specific carbohydrate with 
Streptococcus pyogenes reacting positively with group A serum, however these are 
uncommonly recovered from human infections (Facklam et al., 2002).   
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Susceptibility to bacitracin was another test used for the identification of 
Streptococcus pyogenes. However, since the report of bacitracin resistant Streptococcus 
pyogenes isolates, including in Portugal, this test is no longer reliable (Malhotra-Kumar 
et al., 2003; Pires et al., 2009; Silva-Costa et al., 2008). Another biochemical feature 
associated with Streptococcus pyogenes is its pyrrolidonylarylamidase (PYR) activity 
that can be tested by the PYR test. Among β-hemolytic streptococci, there are strains 
from other species susceptible to bacitracin or positive for the PYR test. However, 
Streptococcus pyogenes is the only species reported of having these both characteristics 
(Facklam, 2002).  
 
3. INFECTIONS AND THEIR CONSEQUENCES 
 
GAS is responsible for a variety of pyogenic infections ranging from mild 
superficial infections of the respiratory tract and skin, such as pharyngitis and impetigo, 
to extremely severe invasive infections, such as necrotizing fasciitis and streptococcal 
toxic shock syndrome (STSS) (Cunningham, 2000; Walker et al., 2014). GAS 
infections have also been related to the development of postinfection autoimmune 
sequelae, which are responsible for high morbidity and mortality worldwide. These 
conditions include, mainly, acute rheumatic fever (ARF) and rheumatic heart disease 
(RHD), as well as acute poststreptococcal glomerulonephritis (APSGN) (Walker et al., 
2014; Cunningham, 2000). Before the advent of antibiotics, streptococcal diseases such 
as scarlet fever, erysipelas, and puerperal fever were considered major health problems 
for centuries, however their incidence and mortality rates started to fall just before 
penicillin’s widespread use after the Second World War, suggesting that other factors, 
such as the host, the pathogen and the environment contributed to the decrease of the 
impact of these diseases (Efstratiou and Lamagni, 2016). Since the 1980s, it was 
observed a resurgence of severe invasive GAS infections with several reports of both 
suppurative and non-suppurative S. pyogenes sequelae. This re-emergence in the 
incidence of invasive GAS infections was associated mainly with the rise of the M1 
clone, which is dominant among invasive S. pyogenes isolates in most developed 
countries (Efstratiou and Lamagni, 2016; Cunningham, 2000). 
In addition to the wide range of suppurative infections and non-suppurative 
complications, GAS can also asymptomatically colonize the nasopharyngeal mucosa 
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and skin. Each of these sites represents the primary reservoirs of GAS (Cunningham, 
2000). The ability of GAS to survive in human saliva is thought to allow the 
transmission from infected persons or asymptomatic carriers via respiratory droplets 
(Shelburne et al., 2005). Additionally, the ability of GAS to colonize and persist in the 
skin allows transmission from person-to-person through skin contact. Furthermore, 
there are reports of GAS disease by food-borne outbreaks (Walker et al., 2014).  
According to the World Health Organization (WHO), GAS was considered the 
ninth leading infectious cause of human mortality, mainly attributed to invasive 
infections and RHD in developing countries where transmission is promoted by poor 
living conditions and where there is no access to a prompt and adequate antimicrobial 
treatment (Carapetis et al., 2005).    
 
3.1. Pharyngitis and Scarlet fever 
GAS is the most common bacterial cause of pharyngitis, accounting for over 600 
million cases annually among people aged over 4 years (Bisno, 2001; Carapetis et al., 
2005). In temperate climates, the incidence of streptococcal pharyngitis is highest 
during winter and early spring occurring most commonly among school-age children 
between 5 and 15 years of age, although all ages groups are susceptible (Wessels, 
2011). The clinical symptoms of GAS pharyngitis include a sudden-onset of a sore 
throat, pain on swallowing, fever, chills, malaise, and headache (Bisno, 2001). 
Symptoms such as abdominal pain, nausea and vomiting can also be present, 
particularly in younger children (Bisno, 2001; Wessels, 2011). The signs that are 
frequently observed are tonsillopharyngeal erythema, patchy exudates, soft palate 
petechiae, beefy red and swollen uvula, and anterior cervical lymphadenitis (Bisno, 
2001; Choby, 2009). Occasionally, GAS pharyngitis is also accompanied by scarlet 
fever, also known as scarlatina. This syndrome is thought that occur after a pharyngeal 
infection with a strain that secretes bacteriophage-encoded streptococcal pyrogenic 
exotoxins (SPE), mainly SpeA, SpeC and SSA (Silva-Costa et al., 2014). Although 
uncommon, scarlet fever may occur due to GAS infections at other sites (Cunningham, 
2000). Scarlet fever signs occur within 1 or 2 days after the manifestations of clinical 
symptoms of pharyngitis and include a characteristic diffuse erythematous rash that 
appears first on the upper chest and then spreads to the extremities sparing the area 
around the mouth, palms and soles, and a yellowish-white coating covering the tongue 
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that when is shed reveals a red and raw surface, which is commonly named “strawberry 
tongue”. The rash disappears in the next 5 to 7 days followed by the desquamation of 
the superficial skin layer (Murray et al., 2013).  
Usually, uncomplicated GAS pharyngitis is self-limiting even without specific 
treatment. Fever resolves within 3 to 5 days and throat pain resolves within 1 week 
(Wessels, 2011). However, occasionally untreated GAS pharyngitis can result in 
suppurative and nonsuppurative complications and therefore an adequate antibiotic 
therapy is recommended (Shulman et al., 2012). Suppurative complications include 
bacteremia, cervical lymphadenitis, endocarditis, mastoiditis, meningitis, otitis media, 
peritonsillar/retropharyngeal abscess and pneumonia (Choby, 2009).  
Transmission occurs by person-to-person contact, probably through nasal 
secretions or saliva droplets from carriers or infected individuals. Therefore, the highest 
incidence occurs among people attending crowded places such as schools and military 
training facilities (Cunningham, 2000). It is estimated that in developed countries, 
approximately 15% of school-age children and 4-10% of adults may suffer from a 
symptomatic episode of GAS pharyngitis annually (Carapetis et al., 2005). In 
developing countries, these values are presumably 5 to 10 times higher (Carapetis et al., 
2005). 
 
3.2. Impetigo   
Impetigo (pyoderma) is a contagious, purulent skin infection of the superficial 
epidermis that manifests itself as numerous vesicles that rapidly progress into pustules, 
which then enlarge and rupture to form the characteristic thick, honey-colored crusts 
(Bisno and Stevens, 1996). Generally, pyoderma lesions occur on exposed areas such as 
the face and extremities (Bisno and Stevens, 1996). They are commonly accompanied 
by regional lymphadenopathy (Bisno and Stevens, 1996).  
Impetigo usually heals spontaneously within two weeks without scarring. 
However, treatment relieves the discomfort, improves cosmetic appearance and 
prevents the spread of the organism (Cole and Gazewood, 2007). It is the third most 
common skin disease in children and, additionally to GAS, it can also be caused by 
Staphylococcus aureus (Sladden and Johnston, 2004). Transmission occurs through 
direct skin contact and most often affects children between 2 to 6 years old, particularly 
those who live in tropical and subtropical climates in areas with poor hygiene and 
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crowded living conditions (Sladden and Johnston, 2004). Accordingly, the highest 
prevalence is reported among aboriginal Australians and Pacific Islands nations 
(Carapetis et al., 2005). Overall, in less developed countries, its estimated burden is 
over 111 million cases of pyoderma annually among children under 15 years (Carapetis 
et al., 2005). 
 
3.3. Invasive infections  
Additionally to superficial infections, GAS has the ability to penetrate epithelial 
surfaces and produce several invasive disease manifestations ranging from less severe 
forms, such cellulitis, to diseases associated with high morbidity and mortality rates, 
such as necrotizing fasciitis or STSS (Cole et al., 2011; Walker et al., 2014). Others 
infections include bacteremia, puerperal sepsis, septic arthritis, pneumonia, meningitis, 
abscesses, osteomyelitis, endocarditis and peritonitis (Walker et al., 2014). It is 
estimated that there are over 660 000 cases of GAS invasive infections each year, of 
which 97% occur in less developed countries, and over 160 000 deaths (Carapetis et al., 
2005). 
Cellulitis and erysipelas are two conditions, both manifested by local signs of 
inflammation such as warmth, erythema, and pain, usually accompanied by fever and 
leukocytosis (Bisno and Stevens, 1996). Portals of entry may include local trauma or 
abrasions and psoriatic, eczematous, or tinea lesions (Bisno and Stevens, 1996). 
Erysipelas involves the superficial layers of the skin, while cellulitis affects the 
subcutaneous tissues. In contrast to cellulitis, in erysipelas, there is commonly a distinct 
demarcation of the area of inflammation, which rises above the surrounding normal 
skin. Although the two conditions are readily distinguishable when they occur in their 
typical form, there is a range of possible tissue involvement which can make this 
distinction difficult (Bisno and Stevens, 1996). Erysipelas on the legs and feet account 
for up to 85% of cases and in only about 5% of cases are the blood cultures positive 
(Chartier and Grosshans, 1990; Bisno and Stevens, 1996). Facial erysipelas may occur 
after GAS pharyngitis (Bisno and Stevens, 1996). 
Necrotizing fasciitis, also popularly known as “flesh-eating disease”, is a severe 
GAS infection involving the skin, subcutaneous and deep soft tissue, and muscle. 
Within hours to a few days, the infection can progress for a small skin lesion, usually 
mistaken as an insect bite, to a highly lethal condition. This occurs as a result of rapid 
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bacterial growth and spread along the fascial sheaths that separate adjacent muscle 
groups, which are then breached, with the progression of infection, resulting in severe 
necrosis of adjacent tissues (Olsen and Musser, 2010). Rapid surgical debridement of 
infected tissue in the initial stages (12-24h) of the disease has been demonstrated to be 
essential for patient survival (Olsen and Musser, 2010). However, initially, patients 
most often present nonspecific signs such as fever, vomiting, and diarrhea which delays 
the correct diagnosis and contributes to the high morbidity and mortality associated to 
necrotizing fasciitis (Olsen and Musser, 2010). Mortality rates are reported to be 24%, 
32% and 16% among necrotizing fasciitis cases in United States, Europe, and Japan, 
respectively (Lamagni et al., 2008; O'Loughlin et al., 2007; Lin et al., 2013). The most 
frequently affected anatomical sites are the lower and upper extremities. However, cases 
in the head, neck, upper torso, and abdominal wall were also reported (Olsen and 
Musser, 2010). The progression of the disease can lead to a widespread muscle cell 
death named necrotizing myositis which is associated with a poor outcome (Olsen and 
Musser, 2010). 
Several GAS infections may be further complicated by the development of STSS. 
However, there is a closer association with necrotizing fasciitis, which is present in 50% 
of the patients with STSS (Bisno and Stevens, 1996). The diagnostic criteria for STSS 
requires the isolation of GAS from a normally sterile site and hypotension that is 
refractory to adequate volume resuscitation, plus at least two of the following 
conditions: renal dysfunction, respiratory distress, hepatic dysfunction, coagulopathy, 
erythroderma, soft tissue necrosis with pain, tissue destruction and skin discoloration 
(Reglinski and Sriskandan, 2014). The development of STSS has been associated with 
the host response to superantigen (SAg) production by GAS (discussed later). STSS is 
responsible for high rates of mortality with 44% of patients dying within a week of 
developing the disease (Lamagni et al., 2008). Blood cultures are positive in about 60% 
to 100% of patients with STSS (McCormick et al., 2001).  
Major risk factors for invasive GAS infections and STSS include disease or injury 
compromising the mucosal surface or skin barrier such as chicken pox, decubitus ulcers, 
penetrating injuries, minor cuts, burns, splinters and surgical procedures, childbirth, 
animal bites, and intravenous drug abuse (Bisno and Stevens, 1996; Olsen and Musser, 
2010). However, in about one-half of STSS cases, there is no obvious point of entry 
(McCormick et al., 2001). It is hypothesized that these cases are often preceded by blunt 
trauma, muscle strain, hematoma or joint effusion at the infection site what could 
CHAPTER I 
 
10 
promote the seeding of bacteria at the site of injury in a patient with a transient 
bacteremia as a consequence of a superficial infection or colonization of the throat or 
skin (McCormick et al., 2001; Johansson et al., 2010; Stevens, 2000). According to this 
hypothesis, symptoms of a sore throat may occasionally precede STSS (Bisno and 
Stevens, 1996). 
 
3.4. Acute rheumatic fever and rheumatic heart disease 
ARF is a delayed systemic disorder that can occur within 1 to 5 weeks following 
an untreated GAS pharyngitis (Cunningham, 2000). Major clinical manifestations based 
on the updated Jones criteria include inflammation of the joints (migratory 
polyarthritis), of the heart (carditis), of the central nervous system (Sydenham´s chorea), 
and of the skin (erythema marginatum and/or subcutaneous nodules) (Cunningham, 
2008). This disease is an autoimmune complication and results partially from the 
molecular mimicry between the M protein on GAS surface (discussed later) and 
components of human tissues, such as host cardiac myosin, which leads to the 
production of cross-reactive antibodies and T cells responsible for tissue destruction 
(Cunningham, 2008). Although arthritis is the most frequent manifestation, present in 
60 to 80% of the cases, carditis, which is present in 30% to 45%, is the most serious 
because it affects the myocardium and the heart valves, and frequently results in mitral 
and/or aortic regurgitation, manifested in a heart murmur upon auscultation, that 
ultimately leads to valve replacement or death (Cunningham, 2000; Lee et al., 2009). 
Sydenham’s chorea is a neurological disorder, present in 10% of ARF cases manifested 
as involuntary movements, muscle weakness, and emotional disturbances. Erythema 
marginatum and subcutaneous nodules are less frequently observed. Erythema 
marginatum has been described in 2% of the cases and is characterized as a distinct red 
circinate rash (Cunningham, 2000; Lee et al., 2009). The high rates of morbidity and 
mortality associated with ARF are mostly due to the long-term damage of the heart, 
resulting in RHD. It is estimated that RHD affects over 2.4 million children aged 5 to 14 
and a total of at least 15.6 million people worldwide, with 282000 new cases and 
233000 deaths annually (Carapetis et al., 2005). The highest prevalence is found in 
indigenous populations and developing countries (Carapetis et al., 2005). Streptococcal 
strains which commonly cause pyoderma do not lead to rheumatic fever (Bisno and 
Stevens, 1996). 
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3.5. Acute poststreptococcal glomerulonephritis 
APSGN is an immune-mediated disorder mainly affecting the kidneys. Clinical 
presentation includes edema, hypertension, hematuria, urinary sediment abnormalities, 
and decreased serum complement levels, with little fever (Cunningham, 2000). 
Although some GAS antigens have been proposed to be related with APSGN, the exact 
nephritogenic components underlining the disease remain to be elucidated (Walker et 
al., 2014). In fact, the nephritogenicity of GAS appears to be partially related with 
specific M protein serotypes, however not all strains the same M serotype are 
nephritogenic. APSGN is particularly associated with pyoderma and skin infections 
which occur in the summer of southern and temperate climates, however, both 
pharyngeal and skin infections can trigger the disease. The latency periods differ 
according to the type of preceding infection. After a skin infection, it may be 3 to 6 
weeks, while after a throat infection it may be 1 to 2 weeks (Cunningham, 2000). 
Recurrences are rare. If supportive care is provided, long term renal damage due to 
APSGN is uncommon, with a mortality of 1% of the total cases. Even so, it is estimated 
that there are over 470 000 cases of APSGN each year, affecting mostly children and 
young adults, with approximately 5000 deaths, 97% of which in less developed 
countries (Carapetis et al., 2005; Cunningham, 2000). 
 
3.6. Pediatric autoimmune neuropsychiatric disorders 
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections, commonly named PANDAS, are very controversial. PANDAS include rare 
obsessive-compulsive disorders and Tourette´s syndrome in children and have been 
hypothesized to be a consequence of GAS infection. While some studies suggest that 
there may be an overlap in the immunopathogenic mechanisms of PANDAS and 
Sydenham chorea, others support that these identities are not related (Kirvan et al., 
2006; Murphy et al., 2010; Walker et al., 2014).  
 
3.7. Poststreptococcal reactive arthritis  
Other reported immune sequel of GAS infections is referred to as 
poststreptococcal reactive arthritis, which is distinct from the migratory polyarthritis 
observed in ARF (Jansen et al., 1999). Usually, no cardiac involvement is observed in 
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patients with reactive arthritis (Iglesias-Gamarra et al., 2001). The molecular 
mechanism is also not understood, although apparently it is also related to a possible 
molecular mimicry between the M protein and proteins in cartilage and synovium 
(Baird et al., 1991). 
 
4. CARRIAGE  
 
Although GAS is not considered part of the normal microbiota, pharyngeal 
carriage can occur without clinical symptoms of disease (Cunningham, 2000). While 
pharyngitis can resolve in 7-10 days, asymptomatic carriage can persist for weeks or 
even months (Martin et al., 2004). This can occur following resolution of clinical 
disease or with no antecedent history of clinical symptoms (Martin et al., 2004). The 
definition of a GAS carrier is an asymptomatic individual with a positive throat culture 
and no serologic response (Martin et al., 2004). However, most of the carriage studies 
do not look for serological response due to the technical issues related with the 
screening. The prevalence of carriage is variable according with the type of the study, 
reaching higher rates among longitudinal studies. According to data from a meta-
analysis that highlight the substantial differences among studies, the prevalence of GAS 
carriage among children older than 5 years with no signs or symptoms of pharyngitis 
was 12% (Shaikh et al., 2010). In the Lisbon area, it was reported an asymptomatically 
colonization rate of 10.7% in children and 3.3% in adults between 2000-2006 (Pires et 
al., 2011). 
The underlining mechanisms why some GAS isolates cause pharyngitis while 
others persist asymptomatically in the upper respiratory tract remain unclear. The 
correction of a mutation in a regulator responsible for a hyperencapsulated phenotype in 
M18 isolates resulted in reduced in vivo pharyngeal carriage duration in a murine model 
and was associated with a drop in bacterial airborne transmission during infection, 
supporting the potential role of capsule in the establishment of the carrier state (Lynskey 
et al., 2013). However, it was also reported that the asymptomatic carriage of GAS is 
associated with the elimination of capsule production due to spontaneous mutations in 
the capsule encoding has operon (Flores et al., 2014). The authors suggested that 
increased capsule production could contribute to acute symptomatic infection, but when 
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the infection resolves, loss of capsule allows for greater adherence and internalization 
resulting in a better adaptation to the colonization of the human host and persistence.  
Skin carriage, has been reported in endemic conditions, however, there is very 
little information about it (Bessen et al., 2014).   
 
5. VIRULENCE FACTORS 
   
The first step of bacterial infection is adhesion to the host. Numerous cell-surface 
proteins have been reported in GAS that work as adhesins promoting the interaction 
with multiple host components, such as extracellular matrix proteins (ECM) including 
fibronectin, collagen, and laminin (Walker et al., 2014). Among the best studied are 
fibronectin binding proteins, such as M and M-like proteins, PrtF1, PrtF2, SOF and 
FbaA (Yamaguchi et al., 2013). Moreover, the presence of lipoteichoic acid (LTA) on 
the cell surface has been proposed to contribute to the initial adherence of GAS to cell 
surfaces through the establishment of weak hydrophobic interactions that promote long 
distance attachment through long surface appendages, such as pili. This weak 
interaction is then replaced by stronger binding events after closer contact between GAS 
and the host cell (Hasty et al., 1992; Walker et al., 2014). 
After adherence, in order to overcome host immune defenses, GAS have a large 
number of virulence factors, including some that also work as adhesins, with a wide 
variety of roles, including resistance to opsonophagocytosis by inhibiting complement 
deposition and activation, resistance to antimicrobial peptides and impairment of 
neutrophil killing mechanisms (Walker et al., 2014). For several virulence factors 
distinct roles have been reported, which are often associated with distinct mechanisms 
of action and that in some cases are apparently contradictory.  
In the next section is the description of some of the best known GAS virulence 
factors as well of others that are referred throughout the thesis.   
 
5.1. M protein  
 The M protein is a major surface protein encoded by the emm gene and a major 
virulence factor of GAS. It is α-helical coiled-coil dimer composed of two polypeptide 
chains anchored in the cell membrane, traversing the cell wall and appearing as fibrils 
on the cell surface (Bisno et al., 2003). The C (carboxy) terminal end of the molecule, 
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which is highly conserved, is attached to the cell wall by a LXPTG motif (Fischetti et 
al., 1990). Upstream of the LPXTG motif is the wall spanning domain, which is rich in 
proline and glycine (Smeesters et al., 2010a). The N (amino) terminal part of the 
molecule extends into the environment, and the tip is constituted by a hypervariable 
region which varies among different clinical isolates (Smeesters et al., 2010b; Bisno et 
al., 2003). Antigenic differences in this region constitute the basis for the Lancefield 
serological typing scheme developed 50 years ago to identify different GAS strains 
(Lancefield, 1962). More than 80 distinct serotypes were identified. Currently, with 
molecular technologies, this classification has been replaced by a sequence-based emm 
typing (discussed later). Briefly, it is performed through the PCR amplification of the 5’ 
end of the emm gene that corresponds to the hypervariable region of the protein.  
The M protein 6 (M6) was the first to be studied and provided an archetypal 
example of an M protein. Virtually, all M proteins are composed of a common 
framework, including a conserved signal peptide, the hypervariable amino terminus, a 
less variable central domain, and the highly conserved carboxy-terminus. Each chain of 
M6 protein comprises four repeat blocks (A, B, C and D repeats), each differing in size 
and amino acids sequence (Smeesters et al., 2010b). Sequence conservation increases 
from A repeats to D repeats. The hypervariable region of the M6 protein is constituted 
by the non-helical part with 11 amino acids, along with a segment of the adjacent region 
A (Smeesters et al., 2010b; Bisno et al., 2003).  
Lying immediately upstream and downstream of the emm gene, which is present 
in all GAS isolates, are two paralogous emm-like genes referred to as mrp and enn, 
respectively. Both these genes encode proteins similar to the M protein (M-like 
proteins), which form fibrils on the cell surface and have also a cell-wall spanning 
domain. However, this peptidoglycan-spanning domain is not identical for all M and M-
like proteins. Therefore, based on the nucleotide sequences encoding the peptidoglycan-
spanning domains it was possible to identify four major distinct forms or subfamilies 
(SF) of emm and emm-like genes: emm belong either to SF-1 or SF-2, mrp is always SF-
4, and enn is SF-1 or SF-3. Furthermore, these subfamilies were found mostly (>99%) 
distributed into five distinct possible chromosomal arrangements, named emm patterns 
A through E (Bessen et al., 2014; Hollingshead et al., 1994; Hollingshead et al., 1993; 
Bessen et al., 1997). Due to the structural similarity between pattern A, B, and C, they 
were grouped together and are commonly referred to as pattern A-C. All isolates of this 
pattern have an SF-1 emm gene and lack mrp.  Both patterns D and E have mrp and an 
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SF-3 form of enn. However, while pattern D has and SF-1 form of the emm gene, 
pattern E has a SF-2 form. The SF-1 form of the emm gene corresponds to a longer 
peptidoglycan-spanning domain than the SF-2, suggesting that isolates of pattern A-C 
and D have ticker cell walls than those belonging to emm-pattern E (Bessen et al., 
2014). Furthermore, a significant correlation between emm-pattern and preferred tissue 
site of infection was observed (Bessen et al., 1996). While GAS isolates of the emm 
pattern A-C showed a statistically significant association with pharyngitis (throat 
specialists), isolates of the emm pattern D were associated with impetigo (skin 
specialists). GAS isolates of the emm pattern E were associated to both sites and 
therefore referred to as generalists (Bessen et al., 1996). These observations led to the 
theory that there must be intrinsic properties related to emm patterns that are responsible 
for the tissue site preference (GAS tissue tropism). Moreover, isolates recovered from 
normally sterile sites belong mainly to emm pattern A-C, suggesting that these isolates 
are probably transmitted to new hosts by respiratory droplets and that the 
nasopharyngeal mucosa rather than impetiginous lesions, is the main reservoir of group 
A streptococci causing severe invasive disease in the population (Bessen et al., 1997; 
Fiorentino et al., 1997). Currently, the emm pattern was determinate for isolates of 184 
different emm types and since a given emm type usually has the same emm pattern it is 
possible to predict the emm pattern of an isolate based on its emm type (McMillan et al., 
2013a; McGregor et al., 2004). Overall, 21% of emm types are pattern A-C, 38%, 
pattern D and 37%, pattern E (McMillan et al., 2013a). The association of emm-patterns 
with site of infection was reinforced in a meta-analysis of 5439 isolates whereby emm 
pattern group was inferred from the emm type (Bessen et al., 2014). The results showed 
that overall pattern A-C strains represented 46.6% of pharyngitis isolates but only 8.2% 
of impetigo isolates. In contrast, emm pattern D strains represent 49.8% of impetigo 
isolates, but only 1.7% of pharyngitis isolates. Pattern E isolates account for almost 
equal fractions of throat and skin infections (51.7% and 42%, respectively).  
The study of other M proteins along the years has identified significant 
differences comparing with M6 structural protein model (pattern A-C) and currently, it 
was updated with three other representative M proteins, which were selected as 
prototypes for the structural characteristics of each emm pattern (M5, M80, and M77) 
(Figure 2) (McMillan et al., 2013a). In general, M proteins belonging to pattern A-C 
were the longest, followed by pattern D, and those of pattern E represented the shortest. 
The A repeats are more frequent amongst the pattern A-C and absent from the vast 
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majority of M proteins belonging to the pattern D and E groups. The B repeats are 
present in the majority of the pattern A-C and D but absent from most M proteins of the 
pattern E group. On the contrary, C repeated regions were present in all M proteins. 
Additionally, the non-helicoidal region in the amino-terminus was absent in 20% of the 
M proteins, including the M80 protein.  
 
 
Figure 2. Three representative M proteins (M5, M80, and M77) were selected as 
prototypes for the structural characteristics within each emm pattern group. M protein 
length and the size of the repeat and non-repeat regions are drawn to scale. Reproduced 
from (McMillan et al., 2013a). 
 
Distinct M proteins can be further differentiated into two groups (class I and class 
II) depending on their immunodeterminants in the conserved C repeat domain. While 
isolates with M proteins of class I expose a surface domain that reacts with antibodies 
against the C repeated region, M proteins of class II lack this domain and therefore no 
reaction is observed (Bessen et al., 1989; Bessen and Fischetti, 1990). This method of 
differentiation into the two classes is correlated with the expression of a streptococcal 
apoproteinase, named the serum opacity factor (SOF). SOF, is a surface protein that 
also has a secreted form that binds to fibronectin and enzymatically disrupts the 
structure of high-density lipoproteins in the blood (Courtney and Pownall, 2010). It is 
also the basis of a serological typing scheme that was used previously (discussed later). 
Thus, in general, streptococcal serotypes expressing class II M proteins are considered 
SOF positive and those expressing class I M proteins are considered SOF negative 
(Cunningham, 2000). Generally, class I/sof negative M proteins belong to the emm 
pattern A-C and D groups and class II/sof positive M proteins belong predominantly to 
emm pattern E group, although some exceptions have been noted (Bessen et al., 2014).   
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The emm type of an M protein is considered largely predictive of the structure of 
the full-length protein (McMillan et al., 2013a). Even so, there is size variation among 
M proteins of isolates of the same M/emm type, which was first reported in M6 isolates 
(Fischetti, 1989). It was reported that 81% of 80 different emm types showed intra-emm-
type differences in the size of M proteins. Nonetheless, within each one of these emm 
types, an average of 69% of isolates belonged to the most common size variant 
(McMillan et al., 2013a). Moreover, that intra-emm-type size variation is evenly 
distributed across the three emm pattern groups (McMillan et al., 2013a). Size variation 
has been attributed to intragenic recombination because it has been shown that 
spontaneous M6 protein size variants can occur in vitro by deletions resulting from 
homologous recombination events between intragenic tandem repeats (Smeesters et al., 
2010b; Fischetti, 1989). Normally, opsonic antibodies directed against the variable 
portion of the M protein will confer type-specific protective immunity (Bisno et al., 
2003). Therefore, this size variation could confer a selective advantage, because it could 
result in the change of their antigenic profile and therefore protect against host 
antibodies (Oehmcke et al., 2010). Thus, for certain M types, antibodies against the 
variable region confer strain-specific immunity but not necessarily serotype-specific 
immunity. In this way, protective immunity could be strain-specific rather type-specific 
(de Malmanche and Martin, 1994).  
In general, M proteins interact with numerous host ligands, which include 
fibronectin, albumin, plasminogen, fibrinogen, kininogen, factor H, factor H-like 
protein 1 (FHL-1), C4b binding protein (C4BP), IgA, IgG (1,2,3,4), and the 
keratinocyte membrane cofactor CD46 (Smeesters et al., 2010b). However, the specific 
interaction with the host ligands apparently depends on the M/emm type (Smeesters et 
al., 2010a). Probably, this specificity is even strain-specific due to the structural 
diversity within M proteins of the same M/emm serotype/type. In addition, it was 
observed that an M1 protein at low temperature (20°C) present a coiled-coil dimeric 
configuration, with high-affinity binding to fibrinogen in the B repeat domain, and an 
unfolded state, with no binding activity at 37°C (Nilson et al., 1995). Therefore, the 
environmental conditions could also influence the interactions between M protein and 
the host, preventing or promoting the infection (Smeesters et al., 2010b). In temperate 
countries the incidence of clinical pharyngitis increases during winter and it has been 
shown that pharyngeal temperatures could drop to as low as 26°C, a fact that could be 
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partly mediated by changes in the M protein (Rouadi et al., 1999; Smeesters et al., 
2010b). 
It is well established that the M protein plays a critical role in GAS resistance to 
phagocytic killing by inhibiting complement deposition on the bacterial surface (Bisno, 
1979; Courtney et al., 1997; Moses et al., 1997). This mechanism results from the M 
protein binding to complement-inhibitory proteins, including C4BP, factor H, and FHL-
1. C4BP is an inhibitor of the classical complement pathway and it binds to the amino-
terminal sequence of several M proteins (Johnsson et al., 1996; Johnsson et al., 1998). It 
was shown that C4BP retains its complement regulatory function when bound to M 
protein (Carlsson et al., 2003). Furthermore, the binding of C4BP at the amino terminus 
competes with serotype-specific antibodies for target sites (Berggard et al., 2001). 
Contrasting results are reported regarding the percentage of isolates that bind C4BP, 
which is probably due to the distinct composition of M serotypes in the collections 
tested. In one study, it was observed that most of the analyzed isolates were able to bind 
C4BP, accounting all sof positive isolates and 80% of sof negative isolates. Among the 
C4BP non-binding sof negative isolates, the majority belong to A-C pattern (Smeesters 
et al., 2010b). In another study, only 33% of the isolates analyzed were able to bind 
C4BP (Perez-Caballero et al., 2000).  
Factor H and FHL-1, which is a splice variant of factor H, are both inhibitors of 
the alternative pathway of complement. While factor H binds to C repeat region of M 
protein, FHL-1 binds to the amino terminus (Johnsson et al., 1998). Unlike FHL-1 and 
C4BP, factor H does not bind to the M protein under physiologic conditions (Perez-
Caballero et al., 2000), so the significance of this interaction for pathogenesis remains 
unclear. Considering C4BP, factor H, and FHL-1 together, it was reported that only 
43.5% out of 69 isolates have the capacity to bind at least one of the three complement 
regulators and that 16% were able to bind all three (Perez-Caballero et al., 2000).  
Another antiphagocytic mechanism is the binding of fibrinogen to the M protein 
which decreases complement deposition resulting from the classical complement 
pathway (Carlsson et al., 2005). The amino acid sequence of the fibrinogen binding 
motifs differs among M1 and M5 proteins, suggesting that these domains have evolved 
independently in different M-proteins (Ringdahl et al., 2000). Moreover, binding to 
fibrinogen does not always inhibit the activation of the classical pathway. While 
fibrinogen binding to M5 reduced the amount of classical pathway C3 convertase on the 
bacterial surface (Carlsson et al., 2005), fibrinogen binding to the M6 protein had little 
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or no effect on complement deposition or phagocytosis resistance (Horstmann et al., 
1992). Moreover, opsonization may not result in phagocytic ingestion. Additionally to 
the M protein, the hyaluronate capsule is also important in conferring resistance to 
opsonization and phagocytic killing. However, the importance of these two virulence 
factors is variably dependent of the strain (Dale et al., 1996).  
It was also observed that isolates with the affinity for fibrinogen do not bind 
C4BP and vice versa (Carlsson et al., 2005). Therefore it was proposed that all M 
proteins may share ability to recruit either fibrinogen or C4BP, which inhibit 
complement deposition via the classical pathway (Carlsson et al., 2005). Moreover, 
Mrp, which is a M-like protein, can also bind fibrinogen. In sof positive isolates, it is the 
Mrp that binds fibrinogen instead of the M protein (Courtney et al., 2006). Additionally, 
upon expression of either an M5 or an M22 protein in a heterologous background, 
although both proteins have a normal structure and a normal ability to bind complement 
inhibitors, neither confers resistance to phagocytosis (Kotarsky et al., 2000). These data 
reinforce the idea that the surface expression of the M protein alone may not be 
sufficient for GAS isolates to resist phagocytosis, highlighting the importance of other 
strain-specific factors (Kotarsky et al., 2000).  
The M protein can also be released from the cell surface possibly through the 
action of a secreted bacterial cysteine protease (discussed later) (Berge and Bjorck, 
1995). The released M1 protein-fibrinogen complexes interact with β2 integrins on the 
surface of neutrophils. As a result, these cells produce heparin-binding protein (HBP), 
which is a potent inflammatory mediator that induces vascular leakage (Herwald et al., 
2004). Streptococcal M1 protein can also interact with Toll-like receptor 2 on human 
peripheral monocytes, resulting in the expression of cytokines: interleukin (IL)-6, IL-1β 
and tumor necrosis factor α (Pahlman et al., 2006). This response is significantly 
increased in the presence of HBP (Pahlman et al., 2006). These M protein/fibrinogen 
complexes were identified in tissue biopsies from a patient with necrotizing fasciitis and 
STSS, supporting the importance of these complexes in severe streptococcal infections 
(Herwald et al., 2004). In addition, IL-6 is significantly upregulated in severe 
streptococcal infections such as sepsis (Holub et al., 2004). It was also shown that the 
soluble form of the M1 protein is a potent inducer of T cell proliferation and release of 
T-helper-1 type cytokines (Pahlman et al., 2008). These observations suggest that the M 
protein has a superantigen activity. However, this theory remains controversial with 
several studies reporting conflicting results (Oehmcke et al., 2010). 
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Human serum albumin binds to the C repeated domain of several distinct M 
proteins (Smeesters et al., 2010b). However, this interaction with the M1 protein is 
dependent on the presence of the flanking B and D repeats regions strengthening the 
coiled-coil structure of the C repeated region (Gubbe et al., 1997). It was reported that 
the binding of fibrinogen and albumin to B- and C-repeats, respectively, inhibits 
antibody binding under physiological conditions (Sandin et al., 2006). 
Several M proteins have also the ability to bind host plasminogen through their 
sub-N-terminal regions (Smeesters et al., 2010b). Upon cleavage, plasminogen in the 
plasma turns into plasmin. Plasmin has the ability to degrade fibrin clots, connective 
tissue, ECM components, and adhesion proteins (Walker et al., 2014). Human 
plasminogen can be activated by host factors as well by a GAS secreted virulence factor 
designated streptokinase (discussed later) (Ringdahl et al., 2000). In addition to the M 
protein, other GAS surface proteins also bind plasminogen, including several M-like 
proteins. It was observed an enhanced mortality in “humanized” transgenic mouse 
expressing human plasminogen infected with GAS. Moreover, the susceptibility of 
these mice to GAS infection was dependent on the expression of bacterial streptokinase 
(Sun et al., 2004). The host inflammatory response to bacterial infections possibly 
results in local thrombosis and microvascular occlusion. The formation of active 
plasmin on the bacterial surface may break the fibrinogen layer deposited by the host 
around the site of local infection allowing the spread of bacteria to deeper tissues (Sun 
et al., 2004). In agreement, for GAS strains that express a plasminogen binding M 
protein, targeted elimination of the plasminogen binding motif reduces the capacity of 
GAS to cause lethal infection in the humanized plasminogen mouse model (Walker et 
al., 2014). In addition, the plasminogen accumulation on the GAS surface prevents 
deposition of the opsonin C3b, impairing phagocytic uptake of GAS by neutrophils (Ly 
et al., 2014). The presence of plasmin activity on the GAS surface was also shown to 
promote degradation of the human antimicrobial peptide cathelicidin LL-37 (Hollands 
et al., 2012). Furthermore, plasminogen bound to the cell surface of GAS can act as a 
bridging molecule for bacterial interactions with host cells, for example contributing to 
keratinocyte invasion (Siemens et al., 2011) 
Several M proteins also have the ability to bind to immunoglobulins IgG and IgA 
(Smeesters et al., 2010b). IgA is predominantly found in mucosal secretions and is most 
effective at impairing bacterial adhesion (Walker et al., 2014). IgG is found in the 
bloodstream and injured tissues, facilitating the contact between the phagocytes and 
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bacteria via the Fc receptors on phagocytes (Walker et al., 2014). The consequences of 
these interactions between M protein and immunoglobulins are still not clear but 
probably contribute to resistance to phagocytosis (Smeesters et al., 2010b).  
M protein on the GAS surface can also bind to kininogen, which is a precursor of 
the vasoactive peptide hormone bradykinin (Ben Nasr et al., 1997). The cleavage of 
kininogen at the bacterial surface is associated with the release of bradykinin (Ben Nasr 
et al., 1997). Bradykinin is responsible for several proinflammatory reactions, namely 
induction of vasodilatation, vascular leakage, and chronic pain (Oehmcke et al., 2010). 
The role of this mechanism during infection is still not clear.  
Furthermore, the M protein impairs phagosome maturation by inhibiting the 
fusion of azurophilic granules within the phagosome, increasing the survival of certain 
GAS strains inside human neutrophils (Staali et al., 2006). Protein M1 was also shown 
to stimulate the formation of neutrophil extracellular traps (NETs). However, the same 
study showed that it also promotes resistance to the human cathelicidin antimicrobial 
peptide LL-37, an important effector of bacterial killing within such phagocyte 
extracellular traps (Lauth et al., 2009) 
The M protein is also among the multiple GAS adhesins that are involved in the 
initial interaction of GAS with the human host. It is suggested that binding of GAS to 
epithelial cells involves an interaction between M protein and host fibronectin as well 
with the keratinocyte membrane cofactor CD46 (Okada et al., 1995; Cue et al., 2001). 
Additionally, was also reported that most of the M proteins bind to glycosaminoglycans 
promoting the attachment of GAS to human epithelial cells and skin fibroblasts. The 
binding of M protein to fibronectin is apparently also related with the GAS ability to 
internalize into human epithelial lung cells (Oehmcke et al., 2010).   
   
5.2. Superantigens  
SAgs are major virulence factors that belong to a family of low-molecular-weight 
extracellular toxins (23.6-27.4 kDa) with a highly potent mitogenic activity due to their 
ability to trigger excessive stimulation of human T lymphocytes resulting in a massive 
production of proinflammatory cytokines (Proft and Fraser, 2016).   
To date, although there is some confusion with the nomenclature in the literature, 
eleven distinct GAS superantigens genes have been reported, including the 
streptococcal pyrogenic exotoxins (SpeA, SpeC, SpeG, SpeH, SpeI, SpeJ, SpeK, SpeL 
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and SpeM), the streptococcal superantigen (SSA) and streptococcal mitogenic exotoxin 
Z (SmeZ) (Proft and Fraser, 2016; Commons et al., 2014). Of these, three are 
chromosomally encoded (SpeG, SpeJ, and SmeZ), while the remaining eight are 
encoded in temperate phages (SpeA, SpeC, SpeG, SpeH, SpeI, SpeJ, SpeK, SpeL; 
SpeM, and SSA) (Proft and Fraser, 2016). All superantigens have a signal N-terminal 
sequence which is cleaved at the bacterial cell surface to allow secretion (Sriskandan et 
al., 2007). Originally, two additional superantigens were described. However, later it 
was noted that these two chromosomally encoded toxins named SpeB and SpeF were, in 
fact, a cysteine protease and a DNase, respectively (Gerlach et al., 2001; Kapur et al., 
1993).  
With the exception of smeZ, SAgs genes are well conserved and show only minor 
allelic variations although these may have important functional consequences. 
Currently, the known SAg variants are six speA alleles, three speC, six speG, two speH, 
two speI, three speJ, one speK, three speL, four speM, three ssa, and 56 smeZ (Proft and 
Fraser, 2016). This diversity could result in differences regarding the superantigenic 
activity and may also contribute to antigenic variation between alleles of the same toxin 
(Sriskandan et al., 2007). Curiously several smeZ genes contain nonsense mutations 
resulting in the expression of truncated and inactive forms of this toxin (Turner et al., 
2012).  
The mitogenic activity results from the ability of SAgs to simultaneously bind to 
major histocompatibility (MHC) class II molecules and to the variable β-chain of the T 
cell receptor (TcRVβ), thereby bringing MHC class II molecules and TCR together. In 
contrast to conventional peptides, the binding of SAgs to MHC class II occur outside 
the peptide-binding groove and does not require previous processing by antigen 
presenting cells. Thus, SAgs are able to bypass the conventional antigen presentation 
process, also resulting in the activation of T cells. However, the magnitude of T cell 
activation induced by superantigens exceeds by several logs that which can be obtained 
by conventional antigens (Sriskandan et al., 2007). 
SAgs bind to the variable region of the TcRVβ. Within the human T cell 
repertoire, there are less than 50 different TcR β-chains which are distributed among 25 
major Vβ types. Even so, each SAg binds to more than one specific Vβ region and 
therefore is estimated that a single SAg is capable of activating up to 25% of an 
individual´s T cell repertoire (Proft and Fraser, 2016; Reglinski and Sriskandan, 2014). 
The oligoclonal activation of T cells and antigen presenting cells results in a massive 
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release of proinflammatory cytokines, including IL-1β, tumor necrosis factor alpha 
(TNF-α), and T cell mediators, such as IL-2 (Proft and Fraser, 2016). The unrestrained 
release of these cytokines could result in the activation of complement, coagulation, and 
fibrinolytic cascades ending in hypotension and the widespread organ damage 
characteristic of STSS (Bisno et al., 2003).  
Regarding MHC class II, SAgs can bind to the invariant α-chain or the 
polymorphic β-chain. With the exception of SpeA and SSA, all other nine Streptococcal 
SAgs binds the polymorphic β-chain (Proft and Fraser, 2016). 
Recently, was been shown that SAgs can also bind CD28, which is a co-
stimulatory receptor constitutively expressed on T cells, which apparently are crucial for 
the superantigenic activity of at least SAgs that bind to the MHC class II α-chain (Proft 
and Fraser, 2016). In addition, SpeA and SpeC, SpeJ and SSA are capable of forming 
monomeric dimers. However, the physiological relevance of this dimerization remains 
to be elucidated (Proft and Fraser, 2016; Commons et al., 2014). 
Little is known about the regulation of Streptococcus pyogenes SAg production, 
but under typical laboratory growth conditions, only small amounts of SAgs are 
secreted. A significant upregulation is detected after infection, which is apparently 
related to host factors that are still unknown. The expression of speA increases 7 days 
after the subcutaneous inoculation into BALB/c mice and it remains high after 21 in 
vitro passages (Kazmi et al., 2001). The in vitro expression of speC is increased in 
culture with the presence of human pharyngeal cells (Broudy et al., 2001). Analysis 
using DNA microarrays showed a significant increase in speA, speG, speJ and smeZ 
transcripts of an M1 strain growing in human blood, compared to growth in medium 
(Graham et al., 2005). Additionally, microarrays showed that speA, speJ, and smeZ 
were highly expressed in distinct phases during infection of cynomolgus macaques. Of 
all GAS SAgs, SmeZ was reported to be at least 10 times more potent than any other in 
the ability to stimulate cytokine release by human T cells (Proft and Fraser, 2016).  
The presence of SAgs has been associated with the severity of GAS infections. 
The predominant serotypes/emm types recovered from STSS, frequently produce SpeA 
and SpeC (Talkington et al., 1993; Yu and Ferretti, 1989). It was also reported a strong 
correlation of M1 isolates carrying speA and speC with SSTS (Vlaminckx et al., 2003). 
Consistently, several studies observed that speA was more frequent in isolates recovered 
from invasive disease rather than in isolates from non-invasive disease (Cleary et al., 
1992; Kittang et al., 2011; Hauser et al., 1991; Friães et al., 2012). In contrast, there are 
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also some reports that showed no significant differences in the frequency of speA 
between invasive isolates and isolates from carriage or pharyngitis (Mylvaganam et al., 
2000; Hsueh et al., 1998; Descheemaeker et al., 2000). More rarely, SAg genes speK, 
ssa, speJ and speM have also been associated to invasive isolates (Ikebe et al., 2002; 
Murakami et al., 2002; Friães et al., 2012; Lintges et al., 2010).  
 
5.3. Hyaluronic acid capsule 
The majority of GAS isolates produce a capsule that consists of a hyaluronic acid 
polysaccharide, which is a linear, high-molecular-mass polymer of glucuronic-β-1,3-N-
acetylglucosamine. The capsule is produced by enzymes encoded in the highly 
conserved hasABC synthase operon and is upregulated in the presence of human blood. 
The first gene of the operon (hasA) encodes a membrane-associated hyaluronate 
synthase which is essential for capsule biosynthesis. On another hand, hasC is not 
essential for the capsule synthesis. In M1T1 isolates a second UDP-glucose 6-
dehydrogenase encoded by hasB2 is located outside the hasABC operon and can replace 
that encoded by hasB (Walker et al., 2014). The glucuronic-β-1,3-N-acetylglucosamine 
is structurally identical to the hyaluronic acid expressed on human cell surfaces and 
connective tissue, which can contribute for evasion of the host immune response 
through molecular mimicry (Cunningham, 2000). It was shown that the hyaluronic acid 
capsule facilitates adherence to the oropharyngeal epithelium by binding human CD44 
(Cywes et al., 2000). However, it was also reported that the upregulation of capsule 
synthesis reduces the capacity to bind to epithelial cell layers (Hollands et al., 2010). 
Although the exact role of capsule in adherence, colonization, and persistence remain 
controversial, there is much more consensus about the role of capsule in the following 
steps of infection. The mucoid phenotype of GAS colonies is attributed to the higher 
expression of capsule and strains with this phenotype are frequently isolated from 
patients with GAS invasive disease (Cole et al., 2011). Consistently, the capsule was 
shown to inhibit complement deposition, to promote resistance to opsonophagocytosis 
and to enhance GAS M1T1 survival within NETs by inhibition of human cathelicidin 
antimicrobial peptide LL-37 (Cole et al., 2011). It was also shown to be essential for 
full virulence in mouse subcutaneous and intraperitoneal models as well in a nonhuman 
primate model of GAS invasive disease (Ashbaugh et al., 1998; Wessels et al., 1991; 
Moses et al., 1997). In 2012, it was reported the circulation of M4 and M22 GAS strains 
lacking the hasABC operon and consistently none of these strains produced detectable 
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hyaluronic acid capsule. Even so, these strains were shown to proliferate ex vivo in 
human blood. The authors suggest that these strains may have alternative compensatory 
mechanisms to promote virulence (Flores et al., 2012). More recently, it was reported of 
a new highly successful acapsular emm89 clade that became rapidly dominant in 
multiple geographic regions including Portugal (Turner et al., 2015; Friães et al., 2015). 
These isolates present a variant of the nga promoter region, which is associated with 
increased production of the secreted cytolytic toxins NADase and Streptolysin O (SLO). 
Due to the high virulence of these isolates in a mouse model of soft-tissue infection, it 
was suggested that the capsule is dispensable if toxin levels are high (Zhu et al., 2015). 
On the other hand, in vitro studies indicate that isolates belonging to this clade may be 
at an advantage for environmental persistence and transmission, resulting in increased 
numbers rather than severity of infections (Turner et al., 2015). 
 
5.4. Pili 
In 2005, Mora et al. described four variant of long surface extended pilus-like 
structures in GAS strains of several serotypes (Mora et al., 2005). They also showed 
that these structures actually corresponded to the trypsin resistance T antigens described 
by Lancefield more than 60 years ago (Lancefield and Dole, 1946). The variability of 
the T antigens constituted the basis for the Lancefield serological T-typing system 
(discussed later). These pili, are heteropolymeric structures consisting of a backbone 
protein and either 1 or 2 ancillary proteins covalently joined and linked to the cell wall 
by a series of sortase mediated transpeptidase reactions (Mora et al., 2005).  
The pilus is encoded in a discrete 11-16Kb highly recombinogenic zone of the 
GAS chromosome named FCT region, based on the presence of fibronectin- and 
collagen-binding proteins as well as the T antigen (Bessen and Kalia, 2002). Currently, 
there are 9 different variants described of the pilus gene region, designated FCT types 1-
9 (Kratovac et al., 2007; Falugi et al., 2008). There is a hypothesis put forward that the 
gene products coded in FCT region contribute for tissue site preference for infection 
(Kratovac et al., 2007). The FCT typing combined with the ability to produce biofilm 
was also proposed as parameters in GAS epidemiological studies (Koller et al., 2010) 
Furthermore, there is evidence that immunization of mice with a combination of 
recombinant pilus proteins confer protection against mucosal challenge in a mouse 
model of infection (Mora et al., 2005). According to Falugi et al., a vaccine comprising 
a combination of 12 backbone variants would protect against more than 90% of the 
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circulating strains (Falugi et al., 2008). Moreover, some T types share sufficiently high 
similarity levels, thereby cross-protection could potentially occur, allowing the 
reduction of the number of backbone proteins required for obtaining a wide coverage 
(Dale et al., 2016).   
Several roles have been attributed to pili which are mainly associated with GAS 
adherence to host cells, colonization and biofilm formation (Manetti et al., 2007; Abbot 
et al., 2007).  These roles are attributed mainly to the activity of the ancillary protein 1 
(Cpa) of a FCT-1 pilus variant (Becherelli et al., 2012). Nagata et al., showed that the 
disruption of pilus assembly by sortase deletion resulted in a more aggressive phenotype 
in a dermonecrotic mouse infection model, suggesting that pilus expression could result 
in a less virulent phenotype (Nakata et al., 2009). The pilus-encoding genes in the FCT 
region are controlled mainly by RofA/Nra and MsmR, which are two stand-alone 
regulators encoded in the same locus (Nakata et al., 2005; Kreikemeyer et al., 2007). 
Moreover, it was reported a higher expression of the pilus backbone at 30°C compared 
with 37°C, which would be consistent with a more important role of pili in superficial 
skin infections (Nakata et al., 2009; Abbot et al., 2007). 
 
5.5. Streptococcal pyrogenic exotoxin B  
Streptococcal pyrogenic exotoxin B (SpeB) is a potent broad-spectrum cysteine 
protease secreted by GAS (Carroll and Musser, 2011). The speB gene is chromosomally 
located and even though it is found in almost all isolates, not all express a detectable 
SpeB activity (Chaussee et al., 1996; Talkington et al., 1993). The production of fully 
active, mature SpeB, is a complex multistage process involving a tight regulatory 
control including post-transcriptional and post-translational mechanisms that are 
influenced by at least 21 gene products (Carroll and Musser, 2011). Moreover, these 
mechanisms are also influenced by several environmental signals, including changes in 
pH and electrolytes (Loughman and Caparon, 2006). The transcription of speB occurs 
from two promoters and is directly regulated by RopB, CcpA, and probably by CovRS. 
Following transcription and translation, the SpeB protein is secreted as an inactive 42-
kDa zymogen, which is then autocatalytically processed through a series of at least 8 
intermediates to form the 28-kDa mature active protease (Chen et al., 2003; Carroll and 
Musser, 2011). Mature SpeB can cleave many GAS proteins, as well host proteins, with 
apparently opposing impacts in virulence (Table 1). The expression of SpeB has been 
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shown to contribute for the survival and proliferation at the site of localized skin 
infections (Svensson et al., 2000; Cole et al., 2006). It was also shown to contribute for 
persistence and growth of GAS in human saliva in vitro (Shelburne et al., 2005). 
However, the role of SpeB during infection is still not clearly understood. While several 
studies suggest that proteolytic action of SpeB contributes to virulence, others suggest 
that its downregulation is a critical step for the transition from localized to invasive 
disease. In agreement with the first hypothesis, it was reported that among 6775 clinical 
isolates, 84.3% presented a wild-type SpeB protease phenotype in vitro (Olsen et al., 
2015). SpeB was also suggested to confer protection against the antibacterial peptide 
LL-37 (Nyberg et al., 2004a; Johansson et al., 2008). Neutralization of SpeB was 
significantly lower in acute-phase sera of patients with STSS than in sera from patients 
with bacteremia or erysipelas (Eriksson et al., 1999). Similarly, it was also reported that 
the acute-phase serum of patients with GAS bacteremia had significantly lower 
neutralizing ability against SpeB than did sera from patients with uncomplicated 
tonsillitis (Norrby-Teglund et al., 1994). In addition, immunization of mice with SpeB 
or treatment with a protease inhibitor confers protection against lethal challenge (Bjorck 
et al., 1989; Kapur et al., 1994; Ulrich, 2008). In contrast with the previous results, an 
inverse relation between disease severity and expression of SpeB among M1T1 isolates 
recovered from invasive human infections has reported. Among STSS isolates, 41% 
produced little or no SpeB compared to only 14% of isolates recovered from less severe 
cases. Moreover, the cysteine protease activity among those isolates that expressed 
SpeB was significantly lower for STSS isolates than for isolates from less severe cases 
(Kansal et al., 2000). The downregulation of SpeB production has been considered 
mainly a consequence of spontaneous covRS mutations in M1 isolates (discussed later). 
In this way, several GAS virulence factors are preserved from proteolytic degradation 
by SpeB and therefore contribute for the transition from localized to invasive disease 
(Walker et al., 2007; Cole et al., 2006; Aziz et al., 2004b). 
 
Table1. Host and bacterial proteins cleaved by SpeB. Table reproduced from (Chiang-
Ni and Wu, 2008) 
Before SpeB 
cleavage  
After SpeB 
cleavage  
Potential effects  Reference:  
Host proteins     
Interleukin-1β 
precursor  
Active 
interleukin-1β 
Induces inflammation  (Kapur et al., 1993) 
Pro-matrix 
metalloprotease 
Active MMP 
(2,9) 
Enhances tissue damage and 
bacterial invasion  
(Burns et al., 1996; 
Tamura et al., 2004) 
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(pro-MM2, 9) 
Fibronectin  Fragmented  Participates in bacterial 
colonization and invasive 
infection  
(Kapur et al., 1993) 
Vitronectin  Degraded  Enhances tissue damage  (Kapur et al., 1993) 
Kininogen  Bradykinin Increases vascular 
permeability: induce fever 
and pain  
(Herwald et al., 1996) 
Immunoglobulin 
(IgA, IgM, IgD, 
IgE, IgG) 
Cleavage into Fc 
and FAb 
fragments  
Inhibits immunoglobulin-
mediated 
opsonophagocytosis 
(Eriksson and 
Norgren, 2003; Collin 
and Olsen, 2001; 
Collin et al., 2002) 
C3b Degraded Escapes phagocytosis (Terao et al., 2008) 
Plasminogen  Degraded Reduces plasmin activity on 
GAS surface  
(Cole et al., 2006) 
Bacterial 
Proteins  
   
Zymogen form 
of SpeB 
Active SpeB Degrades or cleaves of 
bacterial and host proteins  
(Liu and Elliott, 1965; 
Chen et al., 2003; 
Hauser and Schlievert, 
1990; Nomizu et al., 
2001) 
M protein Remove 24 amino 
acids from N-
terminus; released 
from bacterial 
surface  
Alters immunoglobulin 
binding properties; promote 
bacterial dissemination  
(Raeder et al., 1998; 
Berge and Bjorck, 
1995; Kansal et al., 
2003) 
Protein F1 Degraded Reduced bacterial 
internalization  
(Chaussee et al., 2000; 
Nyberg et al., 2004b) 
Endo S Degraded Loses IgG glycan-
hydrolyzing activity 
(Allhorn et al., 2008) 
SmeZ  Degraded Abolishes immune 
stimulatory activity  
(Nooh et al., 2006) 
Fba  Degraded Inhibit binding of FH and 
FHL-1 
(Wei et al., 2005) 
C5a peptidase  Released from 
bacterial surface  
Degrades chemotactic 
complement factor C5a 
(Berge and Bjorck, 
1995; Ji et al., 1997; Ji 
et al., 1996) 
Streptokinase  Degraded  Unknown (Johnston and 
Zabriskie, 1986; 
Svensson et al., 2002) 
Protein H Released from 
bacterial surface  
Promotes bacterial 
dissemination  
(Berge and Bjorck, 
1995) 
Sda1 Degraded  Decreases neutrophil 
extracellular trap clearance  
(Walker et al., 2007) 
 
5.6. Streptolysin O  
Streptolysin O (SLO) is a 69-kDa oxygen-labile secreted cytolysin which is 
inhibited by small amounts of cholesterol. Its activity is responsible for the 
characteristic GAS β-hemolysis under the surface of blood agar medium (Molloy et al., 
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2011). The screening of anti-streptolysin O (ASO) antibodies in serum of patients is one 
of the most common serological tests used to confirm an antecedent streptococcal 
infection. Curiously, infection of the skin does not always elicit a strong ASO response 
(Cunningham, 2000). SLO oligomerizes to form large pores in host cell membranes, 
therefore promoting resistance to phagocytic killing by compromising the integrity of 
host cell membranes and cause caspase-dependent apoptosis in neutrophils, 
macrophages, and epithelial cells (Walker et al., 2014). In addition to protecting GAS 
from phagocytic killing, expression of SLO also reduces the host inflammatory 
responses by reducing the production of TNFα and IL-β. Moreover, in M1 isolates, SLO 
has been shown to induce the aggregation between platelet and neutrophils, contributing 
to vascular occlusion and tissue damage. Several studies reported attenuated virulence 
of SLO mutants in mouse models of invasive disease, supporting the key role of this 
virulence factor during infection (Walker et al., 2014). In agreement, the expression of 
SLO is higher in GAS isolates recovered from severe invasive clinical cases rather than 
isolates of the same serotype recovered from non-invasive infections (Ato et al., 2008). 
 
5.7. Nicotinamide glycohydrolase 
Nicotinamide glycohydrolase (NADase) is a secreted protein that catalyses the 
hydrolysis of the nicotinamide-ribose bond of NAD
+
 resulting in nicotinamide and 
adenosine diphosphoribose (ADP-ribose). NADase is coexpressed with SLO, and 
penetrates into the cytoplasm of epithelial cells through SLO pores depleting 
intracellular energy stores (Madden et al., 2001). The toxic effect of NADase on 
keratinocytes in vitro is associated with cytotoxic effects and induction of apoptosis 
(Bricker et al., 2002). Due to a side reaction, NADase activity can also results in an 
alternative enzymatic product, named cyclic ADP-ribose (cADPR), which has been 
shown to act as a signaling molecule in eukaryotic cells, triggering Ca
2+
 entry or release 
from intracellular stores and may contribute to cytotoxic effects of SLO and NADase 
(Bricker et al., 2002). Furthermore, in a mouse model of GAS invasive disease, it was 
reported that isogenic mutants lacking NADse and SLO, were significantly attenuated 
in virulence compared with the WT parent, confirming that both proteins enhance GAS 
virulence in vivo (Bricker et al., 2005). 
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5.8. Streptolysin S 
Streptolysin S (SLS) is an oxygen-stable cytolytic toxin responsible for the 
characteristic zone of β-hemolysis surrounding the GAS colonies on the surface of 
blood agar medium (Molloy et al., 2011). SLS is encoded by the sag operon comprising 
nine genes from sagA to sagI and is secreted by virtually all GAS isolates. SLS 
expression enhances GAS resistance to phagocytosis through the formation of 
hydrophilic pores in the membrane of neutrophils. In addition to erythrocytes and 
neutrophils, SLS is also able to lyse lymphocytes, platelets and several other host cells 
(Walker et al., 2014). It was proposed that in invasive soft tissue infection SLS may 
significantly impair inflammatory cells locally and facilitate the spread of streptococci 
in tissue (Heath et al., 1999). Using mouse models of invasive GAS infection several 
studies reported that SLS-deficient mutants, belonging to different M serotypes are 
markedly less virulent than their isogenic parents (Betschel et al., 1998; Miyoshi-
Akiyama et al., 2005; Engleberg et al., 2004; Molloy et al., 2011). 
 
5.9. Streptokinase 
 Streptokinase (Ska) is a secreted plasminogen activator encoded by the ska gene. 
Ska is highly specific for human plasminogen, which upon cleavage originates activated 
plasmin, that has the ability to degrade fibrin clots, connective tissue, ECM 
components, and adhesion proteins, possibly contributing to the spread and 
dissemination of GAS as discussed before. Phylogenetic studies have shown that ska 
variants are distributed among two 2 main sequence clusters. Furthermore, while strains 
containing cluster 1 ska alleles display soluble plasminogen activation, in strains 
containing cluster 2 ska alleles, this feature could only be detected when plasminogen 
was prebound with fibrinogen (McArthur et al., 2008). The requirement of human 
fibrinogen additionally to Ska and plasminogen by some GAS isolates for the 
acquisition of plasmin activity is related with an indirect plasminogen binding pathway. 
This alternative pathway involves the formation of a trimolecular complex comprising 
streptokinase, plasminogen, and fibrinogen (Wang et al., 1995b; Wang et al., 1995a). 
Therefore the expression of fibrinogen binding proteins, such as several M proteins, 
PrtF1 and PrtF2 can also contribute to the accumulation of plasminogen on the GAS 
surface. Supporting the importance of the indirect pathway, it was reported, for a 
representative isolate, that the presence of fibrinogen and streptokinase resulted in a 
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significant increase in plasminogen binding. Moreover, this enhancement of 
plasminogen binding did not occur when streptokinase alone or fibrinogen alone was 
added (McKay et al., 2004). The same study reported that in the presence of 
streptokinase and fibrinogen, isolates from invasive infections bound more plasminogen 
than isolates from uncomplicated infections. 
 
5.10. Extracellular streptodornase D 
Streptodornase D, also named Sda1 or SdaD2 is a secreted DNase encoded in a 
prophage commonly found among M1T1 isolates (Aziz et al., 2004a). The expression 
of Sda1 was shown to protect GAS against neutrophil killing by degrading the DNA 
scaffold of NETs (Buchanan et al., 2006; Sumby et al., 2005a). In 2004, NETs were 
reported for the first time as DNA-structures secreted by host neutrophils structures 
containing microbicidal effectors such as histones, the granule proteases elastase and 
myeloperoxidase, and cathelicidin antimicrobial peptide LL-37 (Brinkmann et al., 
2004). Sda1 was also shown to suppressed both the TLR-9 mediated immune response 
and macrophage bactericidal activity (Uchiyama et al., 2012). 
 
5.11. Streptococcal inhibitor of complement  
Streptococcal inhibitor of complement (SIC), is a highly polymorphic 31kDa 
secreted protein that prevents the formation of the membrane attack complex through 
the binding and inactivation of complement C5b67 complex. Several roles were 
reported for SIC, including that it contributes to epithelial cell adherence and mucosal 
colonization. It was also shown to bind innate immune factors such as secretory 
leukocyte protease inhibitor, lysozyme, human α-defensin-1, and human cathelicidin 
antimicrobial peptide LL-37 (Walker et al., 2014). 
 
5.12. C5a peptidase 
C5a peptidase, also named SCPA, is a protease located on the cell surface that 
cleaves the polymorphonuclear leukocyte binding site of chemotactic peptide C5a. The 
cleavage of C5a abolishes its chemoattractant activity, impairing the recruitment of 
phagocytes to the site of GAS infection. Interestingly, another GAS surface protein 
(GAPH/PLR/SDH) binds to human C5a, which apparently facilitates the action of 
SCPA (Walker et al., 2014).   
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5.13. SpyCEP  
SpyCEP is cell-wall protease that cleaves and inactivates the host CXC 
chemokine IL-8 impairing neutrophil recruitment to the infection site. Is has been 
shown to increase GAS resistance to neutrophil killing and promote virulence in a 
murine model of systemic infection (Walker et al., 2014). Additionally, SpyCEP 
activity is associated with the severity of invasive disease (Turner et al., 2009).  
 
5.14. GRAB   
GRAB is a surface protein that binds to the α2-macroglobulin, which is a major 
proteinase inhibitor of human plasma. In the GAS surface, α2-macroglobulin entraps 
and inhibits GAS and host proteinases, protecting bacterial surface proteins and 
virulence factors from degradation. However, some proteinases, such as SpeB, remain 
proteolytically active against small peptides that can enter the α2-macroglobulin 
complex. Thereby, it was reported that α2-macroglobulin-SpeB complexes formed on 
the surface of GAS through protein GRAB confer protection from killing by LL-37 
(Nyberg et al., 2004a). 
 
6. HOST FACTORS AND SUSCEPTIBIBLITY TO INFECTION  
 
Several studies suggest that the susceptibility to GAS invasive disease is related to 
the genetic background of the host, in particular with HLA polymorphisms. These could 
explain why distinct individuals infected with high related isolates can develop very 
different manifestations (Chatellier et al., 2000). It was reported that specific HLA class 
II haplotypes conferred strong protection from severe systemic disease, whereas others 
increased the risk of severe disease. For example, it was observed that patients with the 
HLA-DRB1*1501/DQB1*0602 haplotype presented significantly reduced responses to 
streptococcal SAgs and therefore were less likely to develop severe systemic disease 
compared to individuals with higher risk or neutral haplotypes (Kotb et al., 2002). 
Additionally, other study showed that alleles, such as HLA-DR14/DR7/DQ5 are 
considered of high-risk, while alleles such as HLA-DR15/DQ6 not only strongly 
protected against severe invasive S. pyogenes disease but also resulted in significantly 
General Introduction 
 
33 
higher amounts of anti-inflammatory cytokines, such as IL-10, compared to pro-
inflammatory cytokines, like IFN-γ (Nooh et al., 2011). 
 
7. VIRULENCE REGULATION MECHANISMS 
 
Currently, 13 two-component regulatory systems are described and more than 100 
putative stand-alone transcriptional regulators were found in the available GAS 
genomes (Walker et al., 2014). Among these, the most studied include the two-
component regulatory systems CovRS and Ihr-Irr, and the stand-alone regulators RopB 
and Mga.  
The Ihk-Irr two-component regulatory system has been suggested to control genes 
involved in cell wall synthesis and resistance to oxidative stress. Its inactivation 
significantly attenuates streptococcal virulence in mouse models of soft tissue infection 
and bacteremia (Voyich et al., 2004). 
The Mga regulator activates the transcription of multiple virulence genes such as 
the M protein family (emm, mrp, arp, and enn), sof, and sic (Walker et al., 2014). Two 
divergent alleles were described (mga-1,mga-2) which were correlated with different 
tissues sites (Bessen et al., 2005). Given its role in controlling the expression of M 
protein, it was reported to be critical for multiple roles, such as biofilm formation, 
growth in human blood and resistance to phagocytosis (Hondorp et al., 2013).  
Moreover, its function is altered depending on sugar availability, by modulating the 
expression of several colonization factors (Hondorp et al., 2013). Furthermore, Mga 
mutants were attenuated in a model of GAS invasive skin disease (Hondorp et al., 
2013). 
Regarding the CovRS regulatory system and RopB, they will be described in 
more detail in the next sections. 
 
7.1. CovRS two component regulatory system 
The CovRS system is a two component regulatory system that belongs to the 
OmpR family and was initially named CsrRS because was first described as a regulator 
of capsule synthesis. When inactivated it results in a mucoid colony phenotype 
associated with the overexpression of hyaluronic acid capsule (Levin and Wessels, 
1998). Using DNA microarrays and quantitative RT-PCR, it was observed that CovR 
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influences directly or indirectly the transcription of between 10 to 15% of all 
chromosomal genes during in vitro growth, including several virulence factors (Sumby 
et al., 2006; Graham et al., 2002). Therefore, these proteins were renamed as control of 
virulence regulator (CovRS). It is presumed that the protein CovS acts as a membrane 
located histidine kinase, whose phosphorylation status is influenced by environmental 
signals, while CovR is the cytoplasmic DNA-binding response regulator that binds to 
specific promoters (Cole et al., 2011). Under normal growth conditions, CovS probably 
acts as a kinase phosphorylating CovR, primarily repressing the expression of a subset 
of genes encoding virulence factors. In contrast, under stress conditions, such as 
elevated temperature, acidic pH, high osmolarity, presence of LL-37 and iron starvation, 
CovS alters the phosphorylation state of CovR, resulting in the derepression of genes 
encoding virulence factors as well as genes encoding for proteins essential for growing 
under stress conditions (Dalton and Scott, 2004; Froehlich et al., 2009). CovRS 
regulation may also be influenced by environmental Mg
2+
 (Gryllos et al., 2003) and 
could also be related to the response to antibiotic stress (Sawai et al., 2007). Contrasting 
results have been reported regarding which are the exact virulence factors responsive to 
the effect of covS and covR mutations and their impact on virulence in mouse models. 
This could be partially explained by the interaction of CovRS with other transcriptional 
regulators, which creates complex regulation patterns that can vary between different 
strains (Aziz et al., 2010; Sugareva et al., 2010; Horstmann et al., 2014). Even so, the 
overall virulence factors reported by most studies that are negatively controlled by 
CovRS include the hyaluronic acid capsule, SLS, SLO, SIC, NADase, SpyCEP, DNase 
Sda1, C5a peptidase, and Ska, among others. In contrast, mutations in CovRS result in 
decreased expression of GRAB, and SpeB (Aziz et al., 2010; Hasegawa et al., 2010). It 
has been suggested that phosphorylated CovR represses the first genes while non-
phosphorylated CovR represses the second group (Trevino et al., 2009; Churchward, 
2007).    
In 2006, Sumby and co-workers using microarray analysis of nine isolates 
recovered from human infections observed two different transcriptomes, named by them 
as pharyngeal transcriptome profile (PTP) and invasive transcriptome profile (ITP). 
They also observed that ITP isolates could be recovered from mice infected 
subcutaneously with PTP. Complete genome analysis revealed that the only difference 
between both isolates was a single 7bp insertion within the covS gene (Sumby et al., 
2006). This frameshift mutation resulted in the production of a 202-amino acid 
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truncated CovS compared to the 500 amino acid from the WT. They also observed that 
isolates with an ITP were significantly more virulent than PTP in a mouse bacteremia 
model, whereas in a mouse model of soft-tissue infection PTP GAS were more virulent 
than ITP GAS as assessed by lesion volume. Furthermore, they observed that ITP 
isolates were better able to survive phagocytosis and killing by human 
polymorphonuclear leukocytes comparing with PTP isolates. Taken together, these 
results suggest that the mutation in covS was the trigger responsible for the transition 
from PTP to ITP transcriptome during invasive infection. Consistently, in 2001, 
Engleberg et al. had described the recovery of several mucoid isolates from 
experimental murine skin infections with spontaneous mutations in covRS and that these 
isolates yielded larger and more necrotic lesions (Engleberg et al., 2001). They also 
found these mutations among clinical isolates from invasive disease (Engleberg et al., 
2001). Previously, it had already been observed that the deletion of covR enhanced GAS 
virulence in mouse infection models (Levin and Wessels, 1998; Heath et al., 1999). 
Meanwhile, several studies have reported the presence of covRS mutations among 
human clinical isolates, and most of them have suggested that these mutations occur 
more frequently among isolates recovered from invasive infections (Lin et al., 2014; 
Hasegawa et al., 2010; Ikebe et al., 2010; Shea et al., 2011). Other studies, mostly 
based on murine infections models, also suggest that isolates of the highly invasive 
M1T1 clone have a higher ability to acquire covRS mutations than strains of other emm 
types (Mayfield et al., 2014; Maamary et al., 2010) 
Currently, the most accepted model to explain the presence of these mutations is 
that, after GAS adhesion and invasion of epithelial cells, the neutrophils recruited to the 
site of infection exert a strong selection for those isolates having spontaneous mutations 
within the covRS genes. The enhanced ability to resist neutrophil killing allows the 
dissemination of GAS covRS mutants, potentiating the transition from localized to 
systemic infection (Cole et al., 2011).  
The downregulation of SpeB expression has been considered, by the majority of 
studies with covRS mutants, a critical step for the transition from localized to invasive 
infection. Even though SpeB is required for the establishment of localized GAS 
infection, it was suggested that the loss of SpeB activity prevents the degradation of key 
host proteins and GAS virulence factors, such as Ska and M1 protein and allowing the 
sequestration of human plasmin protease activity on the cell surface (Cole et al., 2006). 
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The resulting accumulation of plasmin activity on the GAS surface may contribute to 
GAS systemic dissemination by degrading host tissue barriers (Cole et al., 2006). 
Additionally, it was reported that, while the loss of several individual virulence 
factors did not prevent GAS covRS switching in vivo, M1 protein, hyaluronic acid 
capsule, and DNase Sda1 are indispensable for the switching of phenotype (Cole et al., 
2010; Walker et al., 2007). The loss of SpeB also spares Sda1 from degradation 
improving GAS resistance against neutrophil extracellular traps (Sumby et al., 2005b; 
Aziz et al., 2004b; Buchanan et al., 2006; Walker et al., 2007). Taken together, capsule, 
M protein, and Sda1 enhance survival of M1T1 GAS within NETs, which could 
promote the in vivo selection of hypervirulent speB-negative covRS mutants (Cole et al., 
2010). 
 
7.2. Regulator of proteinase B 
Regulator of proteinase B (RopB), also named Rgg, controls directly the 
expression of SpeB by binding to speB promoter (Carroll and Musser, 2011; Shelburne 
et al., 2011). RopB is encoded by the ropB gene, which is located 940bp away from 
speB, in the opposite DNA strand (Neely et al., 2003). Additionally to SpeB, RopB 
significantly influences the expression of ≈25% of the GAS genome during the 
stationary growth phase, including genes that are involved in virulence, stress responses 
and interactions with the host (Carroll et al., 2011). Naturally occurring mutations in 
ropB have been shown to impair SpeB production (Hollands et al., 2008). In agreement 
with the controversial role of SpeB, contrasting results have been reported regarding the 
RopB role during the infectious process. While some studies reported that ropB 
mutations result in decreased GAS virulence in animal models of infection (Carroll et 
al., 2011; Olsen et al., 2012), others found that clinical isolates with ropB mutations 
recovered from SSTS have an enhanced lethality in mouse models (Ikebe et al., 2010). 
With the exception of the members of the speB operon, a strain-specific variation, inter 
and intra-serotypic was reported in the transcriptome of ropB mutants, which may 
explain the contrasting results (Dmitriev et al., 2008). 
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8. TYPING METHODS 
 
Typing methods are the basis of epidemiological studies with bacterial pathogens. 
Their use is intended to distinguish isolates, which may allow the identification of 
outbreaks, the determination of the infection source, monitoring vaccination programs, 
trace cross-transmission of nosocomial pathogens, and evaluate the effectiveness of 
control measures (Ranjbar et al., 2014). Additionally, typing methods can be used to 
control the geographical and temporal dissemination of clones with specific features. 
Currently, there are a vast set of GAS typing methods, which can be divided into 
phenotypic and genotypic methods (van Belkum et al., 2007). Several phenotypic 
methods are being replaced by genotypic methods, and some are no longer used.  
In the next section, a description of some typing methods is presented, including 
those with more relevance nowadays. 
   
8.1. Serotyping  
While attempting to understand the basis for protective immunity to GAS 
infection, serotypic diversity in GAS was first reported by Dr. Rebecca Lancefield, who 
developed the serotyping scheme based on the variability of the N-terminal region of 
the surface exposed M protein (Lancefield, 1962; Lancefield, 1928; Cunningham, 
2000). More than 80 different serotypes were identified, each requiring a specific 
serum. However, due to several technical difficulties, such as ambiguous results, the 
discovery of new M types, the existence of non-typeable isolates and the difficultly and 
the high cost of preparing high-tittered sera, this method was replaced by the currently 
widely used DNA sequencing method emm-typing (Cunningham, 2000; Beall et al., 
1996).  
Meanwhile, alternative serotyping methods were developed. One of them, that is 
no longer used, was based on a lipoproteinase named serum opacity factor (SOF). Its 
presence can be screened by the increased opacification of mammalian serum. 
Approximately half of GAS isolates produce SOF and there is a correlation between the 
M type and the antibodies against SOF, which are also type-specific (Cunningham, 
2000; Maxted et al., 1973). Genotypic sof sequence types were also defined based on 
the 5’ end of the sof gene and, although the sof sequence is a useful predictor of emm-
type, some exceptions have been noticed (Beall et al., 2000).  
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 A third serological typing scheme, that was widely used for GAS, was the T-
typing, which is based in the variability of the trypsin-resistant T antigens described by 
Lancefield more than 60 years ago (Lancefield and Dole, 1946). In 2005, these antigens 
were described as the backbone protein of long surface extended pilus structures in 
several GAS strains (Mora et al., 2005; Falugi et al., 2008). More specifically, 
immunoblot and agglutination assays revealed, with few exceptions, that the T type is 
determined by the variant of backbone protein (Mora et al., 2005; Falugi et al., 2008). 
In fact, it was proposed the use of backbone gene sequence typing (tee gene), analogous 
to emm typing, as a potential molecular tool that could substitute the serological T 
classification of GAS strains (Falugi et al., 2008).    
 
8.2. emm typing 
This method consists in the PCR amplification of the 5’ end of the emm gene 
corresponding to the hypervariable amino-terminal region of the M-protein. Then, the 
sequence of the PCR product is submitted to the CDC database 
[https://www2a.cdc.gov/ncidod/biotech/strepblast.asp (27/07/2018)], and an emm type 
number is attributed. For those that were M typeable, a strong correlation was observed 
between M and emm type. Currently, more than 250 emm-types have been identified. A 
unique emm-type is defined as having <92% sequence identity over the nucleotide 
sequence corresponding to the first 30 codons of the M protein (Beall et al., 1996). 
After the implementation of the sequence-based emm typing in 1996, this scheme has 
become the dominant typing scheme for GAS, and is used in virtually all contemporary 
epidemiological studies. Even so, epidemiological data from Portugal, showed that 
emm-typing should be complemented with other typing methods, for a more accurate 
identification of GAS clones (Carrico et al., 2006).   
 
8.3. emm-clusters 
Recently, a new typing method was described based on the portion of the emm 
gene encoding the entire surface-exposed region of the M proteins. This initial study 
analyzed 1086 GAS isolates collected from 31 countries representing 175 emm-types 
(Sanderson-Smith et al., 2014). The phylogenetic analysis identified two well-supported 
clades (X and Y) that were further subdivided into 48 emm-clusters. Thirty-two emm-
clusters contained a single M protein, while the remaining 16 emm-clusters possessed 
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multiple M proteins. Of the pattern E emm-types, 98% belong to clade X, whereas 92% 
of pattern A-C emm-types belong to clade Y. The emm-types belonging to pattern D 
were found in 3 different portions of the tree. The same study also assessed the binding 
activity of representative M proteins from each of the dominant emm-clusters to key 
host proteins known to interact with the M protein. These proteins included 
plasminogen, IgA, IgG, fibrinogen, albumin, and C4BP. It was found that M proteins 
assigned to an emm-cluster, in addition to a high sequence similarity also share 
functional properties (Sanderson-Smith et al., 2014). Similarly to emm-patterns, the 
emm-clusters can also be directly inferred from emm-typing information, given that the 
authors considered the emm-type is predictive of the whole M protein sequence (Table 
2) (McMillan et al., 2013a).  
 
Table 2. Distribution of emm-types per emm-cluster. Reproduced from (Sanderson-
Smith et al., 2014).  
emm-types emm-clusters 
4, 60, 78, 165 (st11014), 176 (st213)  E1 
13, 27, 50 (50/62), 66, 68, 76, 90, 92, 96, 104, 106, 110, 117, 166 
(st1207), 168 (st1389)  
E2 
 
9, 15, 25, 44 (44/61), 49, 58, 79, 82, 87, 103, 107, 113, 118, 144 
(stknb1), 180 (st2460), 183 (st2904), 209 (st6735), 219 (st9505), 231 
(stNS292)  
E3 
 
2, 8, 22, 28, 73, 77, 84, 88, 89, 102, 109, 112, 114, 124, 169 (st1731), 
175 (st212), 232 (stN554)  
E4 
 
34, 51, 134 (st2105), 137 (st465), 170 (st1815), 174 (st211), 205 
(st5282)  
E5 
11, 42, 48, 59, 63, 65 (65/69), 67, 75, 81, 85, 94, 99, 139 (st7323), 158 
(stxh1), 172 (st2037), 177 (st2147), 182 (st2861UK), 191 (st369)  
E6 
 
164 (st106M), 185 (st2917), 211 (st7406), 236 (sts104)  Single protein emm--
cluster clade X 
36, 54, 207 (st6030)  D1 
32, 71, 100, 115, 213 (st7700)  D2 
123, 217 (st809)  D3 
33, 41, 43, 52, 53, 56, 56.2 (st3850), 64, 70, 72, 80, 83, 86, 91, 93, 98, 
101, 108, 116, 119, 120, 121, 178 (st22), 186 (st2940), 192 (st3757), 
194 (st38), 208 (st62), 223 (stD432), 224 (stD631), 225 (stD633), 230 
(stNS1033), 242 (st2926)  
D4 
 
97, 157 (stn165), 184 (st2911)  D5 
46, 142 (st818)  A-C1 
30, 197 (st4119)  A-C2 
1, 163 (st413) 227 (stil103), 238 (1-2), 239 (1-4)  A-C3 
12, 39, 193 (st3765), 228 (stil62), 229 (stmd216)  A-C4 
3, 31, 133 (st1692)  A-C5 
5, 6, 14, 17, 18, 19, 23, 24, 26, 29, 37, 38 (38/40), 47, 57, 74, 105, 122, 
140 (st7395), 179 (st221), 218 (st854), 233 (stNS90), 234 (stpa57)  
Single protein emm -
cluster clade Y 
55, 95, 111, 215 (st804), 221 (stCK249), 222 (stCK401)  Single protein emm 
cluster outlier 
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8.4. SAG profiling  
Eight of the eleven SAgs reported to date are located in temperate phages 
(McMillan et al., 2013b). The exchange of mobile genetic elements (MGE), such as 
phages, has been considered a crucial contribution to the genetic diversity observed 
among GAS strains. Moreover, it has been suggested to be involved in the emergence of 
highly successful virulent clones (Lintges et al., 2010; Maamary et al., 2012; Maripuu 
et al., 2008). Due to the high polymorphism of some SAGs and the use of different 
primer sets by different groups, it has been difficult to compare the results from distinct 
studies (Commons et al., 2014). In 2012, a study with 480 isolates recovered throughout 
Portugal, was the first to report the use of a defined primer set that enabled the 
amplification of all known superantigen alleles at that time (Friães et al., 2013b). This 
study identified 49 different SAg profiles and found that SAg profile diversifies faster 
than other properties also used for molecular typing, namely emm type and MLST. 
Therefore, SAg profiling can be used to complement GAS characterization in 
epidemiology studies. Even so, it was observed a strong association between SAg 
profile and emm type, where the SAG profile is a better predictor of emm type than the 
reverse. This link between emm-type and SAg profile was previously been noted in 
several studies comprising isolates from different countries (Commons et al., 2008; Le 
Hello et al., 2010; Vlaminckx et al., 2003; Schmitz et al., 2003). 
 
8.5. Multilocus Sequence Typing  
MLST is a typing method based is the sequencing of 7 house-keeping genes used 
for several bacterial species. In GAS, these genes encode a glucose kinase (gki), a 
glutamine transport ATP-binding protein (gtr), a glutamate racemase (murI), a DNA 
mismatch repair (mutS), a transketolase (recP), a xanthine phosphoribosyltransferase 
(xpt), and a acetoacetyl-CoA thiolase (yqil) (Enright et al., 2001). Each variant of each 
gene corresponds to a specific allele number, and the combination of all seven to a 
specific sequence type (ST). The MLST sequence data are posted at 
https://pubmlst.org/spyogenes/ (27/07/2018) and currently, more than 900 ST are 
described. It has been considered a better method to infer evolutionary relationships 
between GAS isolates comparing to SAg profiling, because of the strong selection 
pressure to which virulence factors are subjected (McMillan et al., 2013b). 
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9. ANTIMICROBIAL THERAPY AND RESISTANCE MECANISMS 
 
Currently, GAS remains universally susceptible to penicillin with no confirmed 
reports of naturally occurring resistant isolates anywhere in the world. Therefore, 
penicillin is the antimicrobial of choice for the treatment of most GAS infections. 
Penicillin is a β-lactam antibiotic that binds to specific penicillin-binding proteins 
(PBPs) in the bacterial cell wall inhibiting the assembly of the peptidoglycan chains. 
Even so, therapeutic failures have been reported, which can lead to recurrent infections 
and persistent throat carriage. Internalization of GAS in epithelial cells has been 
suggested as one possible mechanism for these failures, given the poor ability of 
penicillin to penetrate epithelial cells. Biofilm production by GAS was also suggested to 
contribute for the escape to antimicrobials. Additionally, the production of β-lactamases 
by other species during infection may also protect GAS against penicillin treatment 
(Walker et al., 2014). 
 
9.1. Treatment of pharyngitis  
Although GAS pharyngitis is typically a self-limiting disease, treatment is 
recommended in symptomatic patients with a positive rapid antigen detection test 
(RADT) or a positive culture (Shulman et al., 2012). The treatment is intended to 
prevent progression to ARF, but also to thwart the symptoms, to decrease the 
transmission period and also to prevent the potential suppurative complications. 
Therefore, according to the clinical practise guidelines, penicillin or amoxicillin are the 
recommended drugs of choice. These choices are based on their narrow spectrum of 
activity, rare adverse reactions and modest cost (Shulman et al., 2012). Amoxicillin is 
frequently used in children, more than penicillin, due to the existence of suspension 
formulations with an acceptable taste. In penicillin-allergic individuals, the treatment 
should include a first generation cephalosporin, clindamycin, clarithromycin, or 
azithromycin. The use of a cephalosporin is only considered in patients that are not 
anaphylactically sensitive (Shulman et al., 2012). The treatment of GAS carriers is not 
generally recommended because they are unlikely to spread GAS pharyngitis to their 
close contacts and are at low risk for developing suppurative or non-suppurative 
complications (Shulman et al., 2012).  
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9.2. Treatment of impetigo  
The treatment of impetigo depends on the number of lesions, their location and 
the need to limit the spread of infection to others. Topical agents are preferred in an 
initial approach. Mupirocin is considered the best topical agent, although resistance has 
been described. Bacitracin and neomycin are less effective alternative choices (Stevens 
et al., 2005). Oral treatment is recommended in patients who have numerous lesions or 
who are not responding to topical agents. Nevertheless, it has to be taken into account 
that Staphylococcus aureus is also a common cause of several skin and soft tissue 
infections, ranging from impetigo to necrotizing fasciitis. Therefore, empirical choices 
of antimicrobials must include agents with activity against resistant strains including 
methicillin-resistant S. aureus (MRSA) and erythromycin-resistant GAS. Vancomycin, 
linezolid, clindamycin, daptomycin, doxycycline, minocycline, and trimethoprim-
sulfamethoxazole are possible choices (Stevens et al., 2005).  
 
9.3. Treatment of necrotizing fasciitis  
When the suspected diagnosis is necrotizing fasciitis, surgical exploration must be 
performed and debridement or fasciotomy is often needed. After GAS identification, the 
therapeutic scheme should be adjusted for intravenously administered penicillin G plus 
clindamycin for 10 to 14 days (Allen and Moore, 2010; Stevens et al., 2005). In two 
observational studies, adding clindamycin was demonstrated to be more effective that β-
lactam antibiotics alone (Zimbelman et al., 1999; Mulla et al., 2003). In a murine model 
of myositis, a similar observation was attributed to the “Eagle effect” characterized by 
the reduction in the expression of PBPs during the stationary growth phase (Stevens et 
al., 1988). However, the most relevant reason for using clindamycin has been its 
mechanism of action that by inhibiting protein synthesis may limit the production of 
several virulence factors, including SAg (Walker et al., 2014). Despite all these 
benefits, clindamycin should not be used as monotherapy because of the existence of 
clindamycin-resistant isolates (Allen and Moore, 2010).  
 
9.4. Mechanisms of action and antimicrobial resistance  
  Macrolides (erythromycin, azithromycin, and clarithromycin) inhibit bacterial 
protein synthesis by binding to the large subunit of the bacterial ribosome (50S) in the 
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upper portion of the peptide exit channel, which prevents translation, and also by 
blocking the assembly of the 50S subunit due to the interaction with its precursors (5S 
and 23S) (Douthwaite and Champney, 2001). Macrolide resistance in GAS comprises 
two major mechanisms: target site modification and efflux (Silva-Costa et al., 2015a). 
The modification of the target site is performed by a methyltransferase encoded by the 
erm genes (erythromycin ribosomal methylase) that methylates a single adenine in the 
23S rRNA preventing binding of the antimicrobial to the ribosome. This mechanism 
also confers resistance to lincosamides (clindamycin) and streptogramins B, and results 
in the characteristic MLSB phenotype, which can be expressed constitutively (cMLSB) 
or in an inducible manner (iMLSB). In iMLSB, the methyltransferase is translated only 
in the presence of macrolides. Currently, more that 20 classes of erm genes are known. 
However, erm(B) and erm(TR) are the most common among GAS with the MLSB 
phenotype. The second mechanism of efflux relies on membrane-spanning proteins 
encoded by the mef genes, of which mef(A) is the most common, which work as efflux 
pumps of 14- and 15- carbon ring macrolides to the outside the cell (Silva-Costa et al., 
2015a). Isolates with this mechanism alone presented the M phenotype, remaining 
sensitive to 16-member macrolides, lincosamides and streptogramins B.  
Contrasting results have been reported regarding the rates and trends of macrolide 
resistance worldwide. While some countries still report high resistance rates, such as 
China, Japan, and Korea, an overall decreasing trend has been noted in recent years, 
mostly in Europe. In some cases, no relation to macrolide consumption was been 
observed (Silva-Costa et al., 2015a). In agreement, a decreasing rate of erythromycin 
resistance was reported in Portugal among isolates recovered from pharyngitis from 
10% in 2007 to 1% in 2013, consistent with a continuous decline observed since 2000  
(Silva-Costa et al., 2015b). Among isolates recovered between 2006-2009 from 
invasive infections in Portugal, a resistance rate of 8% was reported (Friães et al., 
2013a).  
Tetracyclines inhibit bacterial protein synthesis by blocking the association of 
aminoacyl-tRNA with the bacterial ribosome (Chopra and Roberts, 2001). Tetracycline 
resistance has also been reported among GAS, mostly due to enzymes encoded by 
tet(M) and tet(O) genes that confer ribosome protection. They share homology with the 
elongation factors EF-Tu and EF-G, including their GTPase activity.  By competing to 
bind ribosomes, these proteins can lead to the displacement of tetracycline from the 
ribosome (Chopra and Roberts, 2001). Another resistance mechanism to tetracycline is 
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the presence of efflux pumps encoded by tet(K) and tet(L), although these mechanisms 
are much more uncommon (Roberts, 2005).  
Most of the genes conferring resistance to macrolides and tetracyclines are present 
in mobile genetic elements. Moreover, erm and mef genes are often collocated together. 
A well know linkage between erm(B) and tet(M) results from the insertion of ermB into 
conjugative transposons of the Tn916 family, which typically carry tet(M) (Brenciani et 
al., 2007). Numerous other combinations were also reported (Varaldo et al., 2009). 
Consistently, several studies found higher tetracycline resistance values among 
macrolide-resistant isolates, including in Portugal (Silva-Costa et al., 2015b). This 
linkage is the reason why both macrolide and tetracycline resistance are often screened 
together in several studies, even though tetracycline is not included in the therapeutic 
choices for the treatment of GAS infections.  
Fluoroquinolone resistance has also reported in GAS. While reduced 
susceptibility to fluoroquinolones is associated to point mutations in the quinolone 
resistance-determination region (QRDR) of the topoisomerase IV encoding gene parC, 
high-level resistance results from additional point mutations in gyrA that encodes a 
DNA gyrase (Hooper, 2002). These point mutations may be acquired by spontaneous 
mutations or via horizontal gene transfer (Pletz et al., 2006). In Portugal, a 4.9% of 
ciprofloxacin nonsusceptibility rate was reported in a sample comprising isolates from 
pharyngitis, skin and soft tissue and invasive infections and also from carriage (Pires et 
al., 2010). Moreover, this study also reported an association with emm6 isolates. In 
Spain, was reported an increasing trend in fluoroquinolone nonsusceptibility rates 
reaching 30.7% in 2007 (Montes et al., 2010).  
 
10. VACCINE CANDIDATES 
 
The history of S. pyogenes vaccine development dates back more than 90 years, 
however, currently there is no safe and effective vaccine to prevent S. pyogenes 
infections (Dale et al., 2016). This delay could be attributed the complexity of S. 
pyogenes infections, including the high number of isolates with different emm types, the 
variability of infections in distinct anatomic sites, and the geographic differences in the 
prevalence and burden of diseases. Besides all this, the economic hurdle is probably a 
major problem, considering that 95% of all serious S. pyogenes disease occurs in low 
and middle-income countries (Carapetis et al., 2005).  
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The natural infection with S .pyogenes results in protective immunity, explaining 
the higher incidence of infections among schoolchildren comparing with the incidence 
in adulthood. In 1959, Lancefield demonstrated that bactericidal type-specific M protein 
antibodies persisted in humans for years after infections. However, the antibody 
response to any given streptococcal infection was completely unpredictable because 
long persisting antibodies in some instances followed clinically mild infections, whereas 
severe infections might produce no response, or only one of low titer (Lancefield, 
1959). Years later, Fox et al., showed that the administration of purified M1 protein 
preparations subcutaneously to adult volunteers conferred protection against challenge 
with a virulent M1 strain when inoculated in the pharynx (Fox et al., 1973). Likewise, 
Poly et al., reach the same conclusion after administration by aerosol spray into the 
nares and oropharynx (Polly et al., 1975) 
The major concern in the development of S. pyogenes vaccines is related to the 
potential ability to trigger nonsuppurative autoimmune sequelae such as ARF, due to the 
presence of autoimmune epitopes. The studies of Massell et al. reported a link between 
a relatively crude M protein vaccine derived from hot acid extracts of type 3 
streptococci and at least two cases of acute rheumatic fever (Massell et al., 1968; 
Massell et al., 1969). Following studies revealed that intact M proteins not only contain 
protective epitopes but also contain cross-reactive epitopes with human tissue which 
occasionally resulted in the production of antibodies cross-reacting with human tissue 
(Cunningham, 2000). Additional studies have shown that the epitopes contained in the 
hypervariable, type-specific N-terminus of the M protein, evoke antibodies with the 
greatest bactericidal activity and that they are less likely to cross-react with host tissues 
(Dale et al., 2016). These observations led to the current and mostly accepted approach 
of including only N-terminal M peptides. Taking advantage of recombinant techniques, 
specific 5´ regions of the emm genes were linked together and the development of 
several vaccines containing distinct amounts of peptides was reported. Furthermore, 
these vaccines have been shown to evoke opsonic antibodies in animals, without 
evoking tissue cross-reactive antibodies. Two of these, the hexavalent and the 26-valent, 
reached clinical trials and were proven to be safe, well-tolerated, and to evoke 
bactericidal antibodies against the vaccine serotypes (Dale et al., 2016). However, due 
to the increasing data available, a new 30-valent vaccine was formulated based on 
epidemiological data from a North American pharyngitis study, the CDC´s ABC 
surveillance in the US, and the StrepEuro study of invasive S. pyogenes strains 
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(Shulman et al., 2009; Dale et al., 2011; Shulman et al., 2004; O'Loughlin et al., 2007; 
Luca-Harari et al., 2009). The serotypes included in this vaccine account for 98% of all 
cases of pharyngitis in the US and Canada, 90% of invasive disease in the US and 78% 
of invasive in Europe (Dale et al., 2011). In animal studies, the 30-valent vaccine 
evoked bactericidal antibodies against all vaccine serotypes of GAS (Dale et al., 2011). 
Curiously, the immunization with 30-valent vaccine also evoked bactericidal antibodies 
against several non-vaccine serotypes of S. pyogenes suggesting that the potential 
efficacy of this vaccine may extend beyond those serotypes represented in the vaccine 
(Dale et al., 2011; Dale et al., 2013). Overall, 83 different emm types have been tested 
in bactericidal assays, of which significant killing was observed in 73 (88%) of the 
isolates. Considering the non-vaccine types tested, 43 out of 53 (81%) were killed, with 
an average killing of 80% (Dale et al., 2016).   
Despite the potential presence of cross-reactive epitopes in the C-terminal region 
of M protein, to date, three main approaches based in this region were described for the 
development of a safe vaccine. However, no data from human trials were reported yet. 
These include the use of the entire C-terminal region of the M6 strain as a recombinant 
protein, the use of a 12 amino-acid minimal B-cell epitope from the C-repeated region 
(J8) as a synthetic peptide, and the use of B and T cell epitopes from the C-repeated 
region from an M5 strain as a synthetic peptide or recombinant protein (Dale et al., 
2016). 
Meanwhile, other protective antigens, alternatives to M protein-based vaccines, 
have been suggested, such as GAS carbohydrate, C5a peptidase, SOF, SpeB, SpeC, pili, 
SpyCEP, GRAB, among others (Dale et al., 2016).  However, these approaches are still 
in early stages of development. 
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AIMS OF THE THESIS 
 
According to WHO, GAS is considered one of the pathogens responsible for the 
highest rates of mortality with an estimated 500 000 deaths per year. Its ability to cause 
a wide variety of infections, differing according to tissue type and severity, associated 
with its autoimmune complications, is one of the most particular features of GAS.  
Surveillance studies evaluating the phenotypic and molecular characteristics of 
the isolates are the basis of all GAS research. Additionally to the overall prevalence and 
evaluation of antimicrobial resistance rates, these studies, through the use of typing 
methods, allow the identification of lineages, as well as their characteristics and their 
distribution among the different infections. Globally, this information highlighted that 
some lineages are more associated with certain types of infection. However, despite 
several theories, the specific characteristics responsible for a tissue preference or for an 
enhanced invasive potential of an isolate remain unknown. Among these theories, is the 
acquisition of spontaneous mutations in the CovRS regulator as a potential mechanism 
to increase the invasive potential. However, contrasting results have been reported 
regarding the prevalence of these mutations among invasive and non-invasive isolates. 
Therefore, we aimed to evaluate the prevalence of these mutations in isolates recovered 
from different infections and their distribution among different lineages. In order to 
address these questions, we sequenced the covRS operon in a collection of 191 isolates 
comprising isolates from distinct lineages recovered from invasive infections and 
pharyngitis. Since these mutations are associated with different expression patterns of 
several virulence factors, we also aimed to evaluate if this occurs in our isolates. Hence, 
we screened all isolates for the activity of SpeB, NADase, and SLS. The 
downregulation of speB, as a consequence of covRS mutations, has been considered the 
determinant step in the transition to an invasive phenotype. Additionally to CovRS, 
speB is also directly controlled by RopB. Similarity to CovRS, ropB mutations have 
been also recovered from humans infections, and therefore we also wanted to know 
their importance. For that, we sequenced the ropB gene of all isolates.  
  GAS invasive diseases are frequently considered as a complication of skin and 
soft tissue infections. However, in comparison with the amount of knowledge referring 
to invasive and pharyngitis isolates there is little information regarding isolates 
recovered from SSTI. Therefore we characterized, by multiple typing methods, 320 
isolates from purulent exudates recovered in Portugal and performed a comparison to 
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313 contemporary invasive isolates, which were previously characterized. Additionally, 
we aimed to know if there were differences in comparison with invasive and also 
pharyngitis isolates regarding the prevalence of mutations predicted to eliminate protein 
function in covRS and ropB genes and also regarding SpeB activity. With this purpose, 
we tested all 320 SSTI isolates for SpeB activity and in those without detectable activity 
we sequenced the covRS and ropB genes.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER II 
 
 
CONSEQUENCES OF THE VARIABILITY  
OF THE OF COVRS AND ROPB REGULATORS  
AMONG STREPTOCOCCUS PYOGENES  
CAUSING HUMAN INFECTIONS 
 
 
 
 
 
 
 
CovRS and RopB 
 
75 
This chapter is a reproduction of the following publication: 
 
Friães, A., C. Pato, J. Melo-Cristino and M. Ramirez. 2015. Consequences of the 
variability of the CovRS and RopB regulators among Streptococcus pyogenes causing 
human infections. Sci Rep. 5: 12057. 
 
The supplementary information referred throughout the text can be consulted in 
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Consequences of the variability of the of CovRS and RopB regulators 
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1
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SUMMARY  
 
To evaluate the importance of covRS and ropB mutations in invasive disease 
caused by Group A Streptococci (GAS), we determined the sequence of the covRS and 
ropB genes of 191 isolates from invasive infections and pharyngitis, comprising a 
diverse set of emm types and multilocus sequence types. The production of SpeB and 
the activity of NAD glycohydrolase (NADase) and streptolysin S (SLS) were evaluated. 
The results support the acquisition of null covS alleles (predicted to eliminate protein 
function), resulting in downregulation of SpeB and upregulation of NADase and SLS, 
as a mechanism possibly contributing to higher invasiveness. Among the isolates tested, 
this mechanism was found to be uncommon (10% of invasive isolates) and was not 
more prevalent among clones with enhanced invasiveness (including M1T1) but 
occurred in diverse genetic backgrounds. In lineages such as emm64, these changes did 
not result in upregulation of NADase and SLS, highlighting the diversity of regulatory 
pathways in GAS. Despite abrogating SpeB production, null alleles in ropB were not 
associated with invasive infection. The covRS and ropB genes are under stabilising 
selection and no expansion of isolates carrying null alleles has been observed, 
suggesting that the presence of these regulators is important for overall fitness. 
 
 
 
 
 
                                                          
1
 A facsimile of this publication is found at “APPENDIX I”. 
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INTRODUCTION 
 
Streptococcus pyogenes (Group A Streptococci, GAS) is a human pathogen that 
can asymptomatically colonize the oropharynx, but is also responsible for a variety of 
human diseases, ranging from uncomplicated superficial infections of the respiratory 
tract and skin, such as pharyngitis and impetigo, to severe invasive infections associated 
with high morbidity and mortality, like necrotizing fasciitis and streptococcal toxic 
shock syndrome (STSS) (Cunningham, 2000). 
The recognition of the ability of strains belonging to the highly invasive M1T1 
clone to acquire mutations in the covRS genes during skin and soft tissue infection in 
mice suggested that GAS could increase its capacity to invade deeper tissues by altering 
its regulatory networks in order to produce a switch to an invasive transcriptome profile 
(Engleberg et al., 2001; Sumby et al., 2006). The adjacent and cotranscribed genes covR 
and covS encode the two-component regulatory system CovRS (also known as CsrRS). 
The DNA-binding response regulator CovR acts mostly as a repressor of transcription 
upon phosphorylation by the sensor kinase/phosphatase CovS, which responds to stress 
factors, such as elevated temperatures, high saline concentrations, and decreased pH 
(Churchward, 2007). CovRS is estimated to directly or indirectly influence the 
expression of 10–15% of the GAS genome. Although it is also involved in the 
regulation of metabolic genes, it is mostly known for controlling the expression of a 
large number of genes encoding factors that promote GAS virulence and evasion of the 
host immune system (Graham et al., 2002; Horstmann et al., 2014). Most studies 
indicate that mutations impairing CovRS function result in the upregulation of genes 
encoding the hyaluronic acid capsule, streptolysins S and O, streptokinase, DNases, the 
interleukin-protease SpyCEP, and NAD-glycohydrolase (NADase), among others, and 
in the downregulation of proteins like the extracellular cysteine protease SpeB and the 
protein-G-related α 2-macroglobulin-binding protein GRAB (Hasegawa et al., 2010; 
Aziz et al., 2010). However, contrasting results have been reported regarding the effect 
of covRS mutations in some of those virulence factors, which may be partly explained 
by the interaction of CovRS with other transcriptional regulators, resulting in complex 
regulation patterns that can vary between different strains (Aziz et al., 2010; Sugareva 
et al., 2010). 
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Mutations in CovRS and in the stand-alone transcriptional regulator RopB have 
been identified in isolates recovered from human infections (Hasegawa et al., 2010; 
Carroll et al., 2011; Ikebe et al., 2010; Lin et al., 2014). RopB (also known as Rgg) is 
encoded by the ropB (rgg) gene, which is located 940 bp away from speB, in the 
opposite DNA strand, and directly binds the promoter of the latter gene to activate its 
transcription (Neely et al., 2003). In some strains, this regulator has been reported to 
affect the transcription of other virulence factors, including DNases, the hyaluronic acid 
capsule, NADase, streptokinase, streptolysins, and phage-encoded superantigens, 
among others (Carroll et al., 2011; Ikebe et al., 2010). 
The downregulation of SpeB, which is usually observed as a consequence of 
CovRS and RopB mutations, is considered to be a determining step in the transition to 
an invasive phenotype, since this potent protease degrades several extracellular GAS 
virulence factors that play an important role in the invasive process, including the M 
protein, the F1 protein, C5a peptidase, streptokinase, and SmeZ (Carroll and Musser, 
2011). In agreement, SpeB production has been inversely correlated with disease 
severity, in both human infections and murine models (Kansal et al., 2000; Ashbaugh et 
al., 1998). SpeB is initially synthesised and secreted as an inactive 42-kDa zymogen, 
which is then autocatalytically processed through a series of intermediates to form the 
28-kDa mature active protease. Each stage from transcription to mature SpeB involves 
tight regulatory controls, including post-transcriptional and post-translational 
mechanisms (Carroll and Musser, 2011). 
Some studies suggest that covRS and ropB mutations occur more frequently 
among isolates from invasive infections, while others found them in a similar proportion 
among non-invasive isolates (Lin et al., 2014; Hasegawa et al., 2010; Ikebe et al., 
2010). Contrasting observations have also been reported regarding the impact of 
alterations in these regulators on virulence using animal models, as well as on the 
expression of virulence factors like SpeB and the streptolysins (Engleberg et al., 2001; 
Sumby et al., 2006; Graham et al., 2002; Hasegawa et al., 2010; Aziz et al., 2010; Ikebe 
et al., 2010; Mayfield et al., 2014; Miller et al., 2001; Trevino et al., 2009; Ravins et 
al., 2000). Given these discrepancies and the fact that most of the studies have focused 
on particular emm types, especially emm1 and emm3, the importance of the acquisition 
of these mutations for the overall invasiveness and virulence of GAS strains is still not 
completely understood. 
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In order to address these questions, we sequenced the covRS and ropB genes in a 
collection of 191 GAS isolates presenting a high diversity of emm types and multilocus 
sequence types (STs), including the most prevalent clones causing pharyngitis and 
invasive infections in Portugal and in a majority of other countries from temperate 
climate regions (Friães et al., 2012; Shulman et al., 2004; Luca-Harari et al., 2009). The 
genetic diversity of the genes was evaluated, and the respective alleles were correlated 
with the activity of SpeB and of two other virulence factors whose expression has been 
suggested to be under the influence of CovRS and RopB, at least in some strains, 
namely the NADase and the streptolysin S (SLS) (Hasegawa et al., 2010; Ikebe et al., 
2010; Miller et al., 2001; Hollands et al., 2008).  
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RESULTS  
 
Genetic variation of the covR, covS and ropB genes.  
In the present work, the sequence of the covR, covS, and ropB genes was 
determined for a collection of 191 isolates (Supplementary Table S1) comprising one 
third of the isolates of each emm type present in a larger collection of strains recovered 
from pharyngitis and invasive infections in Portugal, which has been characterized 
elsewhere (Friães et al., 2012). In addition, all isolates of emm types 1 and 64 were 
included in this study, since these two emm types were shown to be significantly 
associated with invasive disease.  
The three genes presented a high allelic diversity in the studied GAS collection, 
with Simpson’s index of diversity (SID) values close to the ones obtained for emm type 
and ST (Table 2). The allelic diversity of the covR genes was lower than that of covS (P 
= 0.0140) and of the ST (P = 0.0137). Overall, isolates sharing the same emm type or 
ST frequently shared the same covR, covS, and ropB alleles (Supplementary Table S2). 
This association was stronger for covR, in line with the lower allelic diversity of this 
gene. These results indicate that the covR, covS, and ropB alleles present in a given 
isolate were essentially clonal properties, although some level of intra-clonal diversity 
was observed, particularly for covS and ropB. 
 
Table 2. Simpson’s index of diversity (SID) and corresponding 95% confidence 
intervals (CI95%) of the alleles of covR, covS, and ropB, the emm types, and the STs 
identified among the 191 GAS isolates analyzed in this study. 
 
 
Gene 
All isolates (n = 191) Invasive isolates (n = 87) Pharyngitis isolates (n = 
104) 
No. 
partitions 
SID [CI95%] No. 
partitions 
SID [CI95%] No. 
partitions 
SID [CI95%] 
covR 19 0.831 
[0.793-0.870] 
17 0.816 
 [0.752-0.880] 
13 0.839  
[0.794-0.885] 
covS 43 0.893 
 [0.861-0.925] 
31 0.870 
 [0.811-0.930] 
25 0.905  
[0.873-0.938] 
ropB 38 0.850  
[0.805-0.896] 
23 0.806  
[0.729-0.883] 
29 0.879  
[0.828-0.929] 
emm 
type 
26 0.877  
[0.844-0.910] 
20 0.833 
[0.769-0.898] 
20 0.900  
[0.868-0.932] 
ST 41 0.894 
 [0.861-0.927] 
27 0.860  
[0.798-0.922] 
32 0.910  
[0.876-0.945] 
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Together with the alleles previously deposited in GenBank, we identified a total 
of 54 alleles for covR, 121 for covS, and 78 for ropB (Table 1). One of the isolates in 
our study is devoid of the ropB gene due to a previously characterized deletion that also 
involves the speB gene (Friães et al., 2013). Alterations relative to the nucleotide 
sequence of the three genes in strain SF370 are depicted in Fig. 1. For each of the genes, 
more than half of the alleles result in alterations in the amino acid sequence, with ropB 
presenting the highest proportion of distinct amino acid sequences relative to the total 
number of alleles. However, all the Ka/Ks ratios were significantly lower than 1 (Table 
1), indicating that all three genes are under stabilising selection. Ka/Ks is the ratio of the 
number of nonsynonymous substitutions per nonsynonymous site to the number of 
synonymous substitutions per synonymous site. This measure is often used to evaluate 
deviations from neutral evolution. A value of Ka/Ks < < 1 indicates that the protein is 
under stabilising selection, i.e. selection favours alleles that do not change the amino 
acid sequence. In contrast, a value of Ka/Ks > > 1 is strong evidence for positive 
selection, indicating that selection drove changes to the protein (Hurst, 2002).  
 
Table 1. Type of amino acid alteration, nucleotide diversity, and Ka/Ks values 
associated with the covR, covS, and ropB alleles described in this study and those 
previously reported in GenBank. 
Gene No. alleles 
(this 
study) 
No. amino 
acid 
sequences 
(this study) 
No. 
alleles 
with 
indels 
No. alleles 
with nonsense 
mutations 
Nucleotide 
diversity 
Ka/Ks P 
value 
covR 54 (19) 32 (5) 1 2 0.0058 0.19 0.0032 
covS 121 (43) 83 (26) 28
a 
11 0.0043 0.14 0.0029 
ropB 78 (37
c
) 56 (21
c
) 7
b 
2 0.0055 0.23 0.0015 
a
 Three of the covS indels are in frame. 
b
 Two of the ropB indels are in frame, but one of these deletes a considerable portion of the 
protein (119 residues). 
c
 Excluding the isolate with a complete ropB deletion. 
 
Nucleotide diversity was also similar for the three genes, with differences in the 
total number of alleles basically reflecting the different sizes of the genes (687 bp for 
covR, 1503 bp for covS, and 843 bp for ropB). Null alleles were defined as those 
presenting changes predicted to result in a complete absence of protein function - 
including nonsense mutations, indels that result in frameshifts, large in-frame indels ( ≥ 
357 bp), and complete gene deletions. In spite of similar diversity, the covS gene 
presented more null alleles than covR (P = 0.0004). 
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Figure 1. Nucleotide alterations identified in the covR (A), covS (B), and ropB (C) 
alleles reported in this study and previously deposited in GenBank, relative to the alleles 
present in strain SF370 (AE004092). Each gene is indicated by a grey arrow and a 
nucleotide numbering scale is represented below each one. Each sequence variation is 
indicated in the respective nucleotide position by a letter corresponding to the variant 
nucleotide, or the sequence or number of base-pairs inserted (ins), deleted (del), or 
duplicated (dup). Synonymous nucleotide changes are represented in black; missense 
mutations and short in-frame indels (≤ 6 bp) are represented in blue; changes predicted 
to result in null alleles, including nonsense mutations, indels that generate frameshifts, 
and long in-frame indels (≥ 357 bp) are represented in red. 
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Mutations in covR, covS, and ropB, and association with emm type and 
invasiveness.  
For covR and ropB, the reference alleles (those present in SF370) were the most 
common among the 191 GAS isolates analysed in this study [n = 67 (35%), and n = 69 
(36%), respectively]. The SF370 covS allele was present in only five isolates, but 68 
isolates (36%) presented only synonymous nucleotide changes (15 alleles). Since our 
collection was enriched in emm1 isolates, the most common covS allele (covS-02, 28%) 
included a missense mutation characteristic of the M1T1 clone, namely I332V. Other 
missense mutations were also commonly identified in isolates of specific emm types, in 
both covS and ropB genes.  
In addition to the coding sequence of the genes, the region upstream of covR, 
which includes the covRS promoter, was also analysed for all isolates, but no nucleotide 
changes were found in the identified -35 and -10 regions, in the transcription start site, 
nor in the consensus sequences that have been identified as binding targets for CovR 
auto-repression (Gusa and Scott, 2005). 
The overall distribution of emm types differed significantly between the isolates 
carrying missense or null alleles of covR, covS, or ropB and those with no amino acid 
alterations (P < 0.0001). Null alleles were not associated with any particular emm type, 
occurring in isolates of seven different emm types for covS (SID = 0.909 [CI95% 0.822 
-0.996]) and of four different emm types in the case of ropB (SID = 0.867 [CI95% 
0.738–0.995]). Missense mutations in covS and ropB were significantly more prevalent 
in isolates of certain emm types due to the presence of clonal alleles in specific lineages, 
i.e. alleles carrying amino acid changes that occur in several isolates of that emm type 
(Supplementary Table S1). 
According to the SID values, the allele diversity of the three genes was similar for 
the subsets of isolates associated with pharyngitis and with invasive infections (Table 
2). The overall distribution of covS and ropB alleles was significantly different between 
the two subsets (P < 0.0001), but no specific covR, covS, or ropB allele presented a 
significant association with either infection type after correcting for the false discovery 
rate (FDR), except for ropB-23, which was significantly associated with invasive 
infections (P = 0.0109). This association is explained by the fact that ropB-23 was 
present in all emm64 isolates and not found in any other emm type (Supplementary 
Table S1), and emm64 was significantly associated with invasive infections in Portugal 
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(Friães et al., 2012). This allele presents only two synonymous nucleotide changes, 
which are not likely to be the cause of the high invasiveness of this lineage.  
The presence of an altered amino acid sequence in general was not associated with 
infection type for any of the genes. However, null covS alleles were significantly 
overrepresented among the invasive isolates (P = 0.0247) (Table 3), even though they 
were only present in nine of these isolates (10%). 
 
Table 3.  Number of isolates from invasive infections and pharyngitis presenting null 
and missense alleles in the covR, covS, and ropB genes. 
gene Allele type Invasive (n = 87) Pharyngitis (n = 104) 
covR 
Null 0 0 
Missense
 
2 2 
covS 
Null 9 2 
Missense 51 61 
ropB 
Null 3 3 
Missense 13 26 
covRS/ropB 
Null 12 5 
Missense 56 72 
 
SpeB production.  
In this study, the presence or absence of extracellular proteolytic activity was 
tested for all isolates using a spectrophotometric assay based on the degradation of 
azocasein by culture supernatants, as well as by a plate assay in which the strains were 
cultured in solid medium containing casein. To confirm that the proteolytic activity 
detected by these two methods was essentially due to SpeB, which has been described 
as the major extracellular protease of GAS (Chaussee et al., 1993), Western blot 
analysis using monoclonal anti-SpeB antibodies was performed in a subset of six 
isolates of emm types 1, 64 and 89. For each emm type, one protease-positive and one 
protease-negative isolate were randomly chosen. The presence of a 28-kDa band similar 
to the one detected for SF370 was considered as a positive result (Fig. 2). The Western 
blot results were concordant with those of the two proteolytic activity assays for this 
subset of isolates. The emm1 strains SF370 and MGAS5005 were used as controls in all 
assays. As expected, strain SF370, which encodes a functional CovRS, presented 
proteolytic activity in both assays and was positive for mature SpeB production by 
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Western blotting. In contrast, almost undetectable amounts of mature SpeB and no 
proteolytic activity were observed for MGAS5005, which harbours a frameshift 
mutation in covS (Fig. 2 and Fig. 3). Taken together, these results confirm that SpeB is 
the major protease of GAS, allowing us to use the total proteolytic activity as a proxy 
for SpeB activity. Western blot was also performed for all isolates in which the 
azocasein and casein-plate results were discordant (n = 31). In these cases, the Western 
blot result was considered as final. 
Of a total of 191 isolates, 153 (80%) presented SpeB activity, while for the 
remaining 38 (20%) no SpeB activity could be detected (Fig. 3 and Supplementary 
Table S1). All isolates with null alleles, either in covS or in ropB, were associated with 
an absence of SpeB activity (P < 0.0001 for both). In contrast, the prevalence of 
missense alleles among the SpeB-negative and SpeB-positive isolates was similar, 
except for non-clonal missense alleles in ropB (i.e. missense alleles that were not 
identified in other isolates of the same emm type in this study or in the GenBank 
database), which were associated with the absence of SpeB production (P = 0.0008). 
Only two SpeB-negative isolates presented alleles encoding the reference amino acid 
sequence in all three genes. The absence of SpeB activity in isolates carrying non-null 
alleles in the three genes could be due to alterations in the speB gene, its promoter, or in 
other mechanisms involved in the post-transcriptional or post-translational regulation of 
SpeB (Carroll and Musser, 2011).  
There was no significant association between the SpeB activity of the isolates and 
infection type. The overall distribution of emm types differed significantly between 
SpeB-producing isolates and those without protease activity (P = 0.0030), but after FDR 
correction, only emm types 89 and 6 were significantly associated with the absence of 
SpeB (P = 0.0354 for both). 
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Figure 2. Representative Western blot result for detection of mature SpeB (28 kDa) 
expression by GAS isolates. The blot shown was cropped to the region of interest.  
 
NADase activity.  
In this work, the NADase activity of the isolates was measured by an endpoint 
titre method based on the degradation of β -NAD by culture supernatants, which results 
in a reduction of the fluorescence emitted by the reduced form of β -NAD. GAS emm1 
strains SF370 and MGAS5005 were used as controls of the assay. As expected, SF370 
presented a low NADase activity (NADase ≤ 3), while MGAS5005 was found to have 
the highest NADase activity level measured (NADase = 192) (Fig. 3). The high 
NADase activity of the latter strain can be attributed to the null covS allele, as well as to 
a different NADase locus from the one carried by old emm1 strains such as SF370 
(Sumby et al., 2005). 
 The gene encoding the GAS NADase, known as spn or nga, presents multiple 
variants and has been shown to be diverging into NADase-active and -inactive subtypes, 
which are correlated with emm patterns and tissue tropism (Riddle et al., 2010). 
Therefore, variations in the levels of NADase activity exhibited by distinct GAS 
lineages, which may encode different nga alleles, are expected and were observed 
among the isolates analysed in this study (Fig. 3 and Supplementary Table S1). Despite 
this lineage-specific variation, it was possible to identify a significant association 
between the highest activity values, namely NADase = 96 and NADase = 192, and the 
presence of null alleles in covS (P = 0.0005), while covR and ropB changes did not 
significantly contribute to an increased NADase activity. In agreement, all the strains 
carrying covS null alleles expressed higher levels of NADase activity than the majority 
of the isolates of the same emm type, except for two emm64 isolates (Fig. 3). The 
absence of NADase activity could be an intrinsic characteristic of this lineage, 
regardless of the CovRS alleles, due to alterations in the nga gene, its promoter, or other 
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regulatory pathways. It is also possible that nga is not part of the CovRS regulon in the 
emm64 clone. Both inter- and intra-serotype differences in the regulatory activity of 
CovRS have been proposed (Sugareva et al., 2010). 
Despite the association between high levels of NADase activity and covS null 
mutations, it was not possible to detect any significant association between the level of 
NADase activity and invasive disease. 
 
Streptolysin S activity. 
The SLS activity of the isolates was evaluated by an endpoint titre method based 
on the amount of released haemoglobin from sheep erythrocytes during incubation with 
culture supernatants. Although the majority of the isolates (n = 179, 94%) presented an 
SLS activity ≤ 3, it was possible to identify multiple isolates with increased SLS activity 
and that also carried alterations in CovRS (Fig. 3). Accordingly, the SLS activity 
determined for the reference strains SF370 (SLS ≤ 3) and MGAS5005 (SLS = 12) were 
consistent with a de-repression of the sag operon in the latter due to the null allele in 
covS, and a significant association between activity values of SLS = 12 and SLS = 48 
and covS null alleles was observed (P = 0.0003 and 0.0040, respectively). In fact, all 
isolates with an SLS ≥ 12 presented null alleles in covS (Fig. 3 and Supplementary 
Table S1). Four isolates carrying null alleles and belonging to emm types 6, 44, and 64 
did not exhibit an increased SLS activity. The coherent low NADase and SLS activity 
among emm64 isolates independent of the CovRS alleles is consistent with a potentially 
different CovRS regulon in these isolates. Among emm6 and emm44 isolates, it is 
possible that the sag operon, which encodes SLS activity, is not regulated by CovRS. 
Alternatively, SLS activity may not be significantly increased in these isolates due to 
mutations in the sag operon, which have been infrequently reported among S. pyogenes 
isolates (Yoshino et al., 2010). 
It was not possible to detect any significant associations of SLS activity levels 
with the presence or absence of changes in covR and ropB, nor with infection type. 
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Figure 3. SpeB production and NADase and SLS activity determined for the 191 
isolates analyzed in this study, according to emm type. The emm types represented by < 
5 isolates are grouped into “Others” and include emm 9, 11, 18, 29, 43, 53, 58, 74, 77, 
78, 87, 94, 102 and 113. The results of reference strains SF370 and MGAS5005 are also 
presented. 
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DISCUSSION 
 
Variations at the level of the regulatory networks governing GAS gene expression 
may constitute key elements differentiating strains with a high invasive ability from 
those that carry the same virulence genes, but cause mild infections or asymptomatically 
colonise the host. Mutations impairing the function of the two-component system 
CovRS and the stand-alone regulator RopB could play this role and have been shown to 
be important in animal models of infection, mostly using representatives of the M1T1 
clone (Engleberg et al., 2001; Sumby et al., 2006; Ikebe et al., 2010; Mayfield et al., 
2014). However, the actual impact of these mechanisms in invasive human GAS 
infections remains unclear. 
In the characterised collection, all three genes (covR, covS, and ropB) presented a 
high genetic diversity and the allele distribution was closely associated with emm type 
and ST. Some studies, mostly based on murine infection models, suggest that isolates of 
the highly invasive M1T1 clone have a higher ability to acquire covRS mutations than 
strains of other emm types (Mayfield et al., 2014; Maamary et al., 2010). However, in 
our study mutations in the covR, covS, and ropB genes were not more prevalent in 
emm1 or any other emm type. We conclude that among the GAS population causing 
human infections, the acquisition of mutations in any of the three genes can occur in 
isolates of diverse lineages, in agreement with data from Japan and Taiwan (Ikebe et al., 
2010; Lin et al., 2014). We also did not find a higher prevalence of covRS mutations in 
isolates carrying the DNase gene sda1 (data not shown), although it has been suggested 
that the presence of the phage encoding this gene exerts a selective pressure that favours 
the acquisition of covRS mutations, at least in the M1T1 genetic background (Walker et 
al., 2007). 
Null covS alleles were found to have a significant association with invasive 
infections, while the missense alleles in covS and all null and missense alleles in covR 
and ropB were not differently distributed among isolates from pharyngitis and from 
invasive disease. According to these results, only the null alleles in covS would 
contribute to the transition to invasive infection. In addition, the fact that null alleles are 
significantly more common in covS than in covR supports the hypothesis that during the 
infection process, the acquisition of mutations that impair signalling through CovS, 
while keeping CovR functional and possibly responsive to phosphorylation by other 
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kinases, such as SP-STK, may favour the progression to invasive infection (Trevino et 
al., 2009; Agarwal et al., 2011). However, this mechanism of transition to an invasive 
phenotype seems to be uncommon, since it was found in a minority of invasive isolates 
(10%). 
The absence of expansion of isolates carrying null alleles in any of the three 
analysed genes and the fact that they are all under stabilising selection suggests that 
although mutations compromising the activity of these regulators may favour the 
progression to invasive disease, they are not beneficial to the overall fitness of S. 
pyogenes. Strains carrying covRS null alleles presented decreased ability to survive in 
human saliva and to persist in the murine nasopharynx, leading to the proposal that 
these strains would have an impaired colonisation and transmission capacity (Trevino et 
al., 2009; Alam et al., 2013). In a murine skin and soft tissue infection model, infection 
with a mixed population containing both the wild-type strain and a derivative covRS 
mutant resulted in higher virulence than infection with either strain alone, highlighting 
the importance of the presence of isolates carrying a functional CovRS (Engleberg et 
al., 2001). Therefore, in spite of promoting a switch to a phenotype that favours the 
survival of GAS in deeper tissues, the loss of CovS may affect the success of the initial 
stages of infection (Aziz et al., 2010). 
In order to evaluate the phenotypic impact of mutations in the covRS and ropB 
genes, we determined the activity of three extracellular proteins that are known to be 
involved in GAS pathogenesis and to be under the direct or indirect influence of these 
regulators, namely SpeB, NADase, and SLS. A functional RopB is considered an 
absolute requirement for speB transcription (Neely et al., 2003), while the influence of 
covS mutations in speB expression is more controversial (Engleberg et al., 2001; 
Graham et al., 2002; Hasegawa et al., 2010; Aziz et al., 2010; Mayfield et al., 2014; 
Miller et al., 2001; Trevino et al., 2009; Maamary et al., 2010). Our results support a 
role of both CovRS and RopB in the expression of SpeB, since null alleles in both covS 
and ropB were associated with the absence of SpeB production. Overall, the absence of 
SpeB activity was significantly more common among emm types 6 and 89, both 
frequently reported among invasive infections, especially emm89, which is one of the 
leading emm types among invasive isolates in several European countries (Luca-Harari 
et al., 2009). However, the emm types that have been found to be significantly 
overrepresented among invasive infections in Portugal, namely emm1 and emm64 
(Friães et al., 2012), were not associated with an increased proportion of SpeB-negative 
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isolates. In agreement, the absence of SpeB activity was not associated with invasive 
infection, indicating that, in spite of preserving several virulence factors that are 
regarded as important for the invasive process, the abrogation of SpeB activity cannot 
explain by itself the higher ability of certain clones to cause invasive disease. 
Several studies report a significant influence of RopB on the expression of 
virulence factors other than SpeB, including NADase and SLS, either directly or due to 
the regulation of SpeB or the interaction with other transcriptional regulators (Carroll et 
al., 2011; Ikebe et al., 2010; Hollands et al., 2008). However, it has been demonstrated 
that the RopB regulon is highly variable, even among strains of the same emm type and 
that the core regulon is limited to the speB and spi genes (Dmitriev et al., 2008). Our 
results are in agreement with this observation, since changes in ropB were not 
significantly associated with altered NADase or SLS activities. This suggests that, 
despite the influence that the regulator may have in the expression of these proteins in 
particular lineages, in the overall GAS population and under the growth conditions used 
in this study, RopB does not contribute significantly to the expression of the nga and 
sag operons. In contrast, covS null alleles were significantly associated with an 
increased activity of both NADase and SLS, which is consistent with a repression of the 
corresponding operons by phosphorylated CovR, as demonstrated for the sag promoter 
(Miller et al., 2001). However, exceptions were noted in isolates of specific emm types, 
including emm64, supporting the existence of differences in the CovRS regulon of 
distinct GAS lineages (Sugareva et al., 2010). Although both NADase and SLS have 
been shown to contribute to GAS cytotoxicity and virulence (Bricker et al., 2002; 
Molloy et al., 2011), their individual activities were not correlated with the type of 
infection caused by the isolates. 
The association of missense alleles with invasiveness and with the activities of the 
studied virulence factors is harder to evaluate. Most of the alleles corresponding to 
amino acid changes in CovS and RopB occurred in multiple (often all) isolates of the 
same emm type, indicating that these are clonal mutations and probably do not represent 
the mechanism described for GAS in which mutations leading to a hypervirulent 
phenotype are acquired during infection (Engleberg et al., 2001; Sumby et al., 2006). 
Missense changes can have distinct effects on protein function depending on the nature 
of the amino acid replacement and the region where they occur. It is not possible to 
know from the current data if an altered phenotype in isolates carrying missense alleles 
is due to amino acid changes in these regulators or to some other characteristic of that 
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specific lineage. Possibly reflecting this, the prevalence of missense alleles in ropB, 
covR, and covS could not be associated with the phenotypes tested. When considering 
only the non-clonal missense alleles, an association with SpeB-negative isolates, but not 
with invasive disease, was observed in the case of ropB. Non-clonal missense alleles in 
covRS were not associated with any particular phenotype regarding the tested virulence 
factors, nor with disease presentation. 
Null covS alleles are associated with invasive isolates and present phenotypes 
consistent with the ablation of this regulatory system. However, none of the phenotypes 
is itself associated with invasiveness, indicating that other factors under covRS 
regulation may be responsible for this higher virulence. In agreement, impairment of 
RopB function, known to result in SpeB downregulation, is not associated with 
invasiveness. The data presented supports the abrogation of CovS function as a 
mechanism contributing to the pathogenesis of invasive GAS infections, although this is 
not specifically associated with lineages identified as having enhanced invasiveness, but 
occurred in isolates of diverse emm types and STs. This mechanism is uncommon and 
the acquisition of such changes, despite being beneficial in the specific context of 
invasive disease, may incur an overall fitness cost for GAS, preventing their fixation in 
the population. 
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MATERIALS AND METHODS 
 
Bacterial strains and culture conditions.  
GAS isolates used in this study (104 recovered from pharyngeal exudates of 
patients with pharyngitis and 87 associated with invasive disease, recovered from 
normally sterile sites) are listed in Supplementary Table S1 online. The strains were 
randomly selected among a collection of 480 non-duplicate isolates recovered from 
human infections between 2000 and 2005 that have been previously characterized 
(Friães et al., 2012), so as to include one third of the isolates of each emm type present 
in the collection with n ≥ 3, as well as all isolates of emm types 1 and 64. Strains SF370 
(CECT 5109, obtained from Colección Española de Cultivos Tipo) and MGAS5005 
(BAA-947, obtained from American Type Culture Collection) were used as controls. 
Strains were grown at 37 °C in Todd Hewitt broth (THB) (BD, Sparks, MD, USA) or in 
Tryptone Soya Agar (Oxoid, Basingstoke, UK) supplemented with 5% defibrinated 
sheep blood. 
 
Molecular typing.  
In addition to the molecular characterisation of the isolates that had been 
previously performed (Friães et al., 2012), multilocus sequence typing analysis was 
completed for all isolates. 
 
Gene sequencing and analysis.  
Genomic DNA of the isolates was extracted using cetyl trimethylammonium 
bromide (CTAB) (Ausubel, 1999). All PCR and sequencing primers used in this study 
are listed in Supplementary Table S3. The sequences obtained for each isolate were 
assembled and compared with the corresponding regions of the genome of strain SF370 
(GenBank AE004092), considered to be the reference wild-type alleles.  
Geneious R7 (Biomatters, Auckland, New Zealand) was used to search the 
GenBank database (accessed on April 7th 2014) using BLAST for all previously 
deposited sequences of covR, covS, and ropB of S. pyogenes, and align them with the 
trimmed sequences of the isolates analysed in this study, using the MUSCLE algorithm 
with default settings.  
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The subset of non-duplicate alleles without indels was used to calculate the ratio 
of the number of nonsynonymous substitutions per nonsynonymous site to the number 
of synonymous substitutions per synonymous site (Ka/Ks), and the respective Z test for 
stabilizing selection, using MEGA5, with the Mega-Kumar method (Kimura 2-
paramether). Values of P < 0.05 were considered statistically significant. Nucleotide 
diversity was calculated using DnaSP v.5.10.1. 
 
Determination of protease activity.  
Azocasein assay. SpeB protease activity in stationary phase GAS culture supernatants 
was determined using an adapted azocaseinolytic assay already modified for the 96-well 
plate format (Collin and Olsen, 2000; Cole et al., 2010). Briefly, 24 h-cultures of each 
strain were diluted 1:10 in fresh THB and grown for 18 h, in 96-well plates. Bacteria-
free supernatants were obtained by centrifugation at 3220 × g for 10 min, and 
transferred to a new microtitre plate. An equal volume of activation buffer (0.1 M 
sodium acetate [pH 5], 1 mM EDTA, 20 mM dithiothreitol) was added and the plate 
was incubated for 1 h at 40 °C. After activation, 2% azocasein (Sigma-Aldrich, St. 
Louis, MO, USA) (w/v in activation buffer) was added and incubated for 6 h at 40 °C. 
Samples were then precipitated with 2.5 volumes of 6% trichloroacetic acid and 
centrifuged at 15000 × g for 5 min. The optical density at 450 nm of the resulting 
supernatants was determined. The corresponding proteolytic activities were calculated 
using a calibration curve performed for each plate with known concentrations of 
proteinase K (Roche Diagnostics). Three independent assays were performed for each 
strain. The presence of proteolytic activity was considered positive when at least two of 
the three assays showed a value ≥0.0025 U. 
 
Casein-plate assay. GAS expression of extracellular cysteine protease was determined 
by a plate assay as previously described (Ashbaugh et al., 1998). Briefly, single GAS 
colonies were stab-inoculated into plates of medium containing 0.5-strength Columbia 
broth (BD), 3% w/v skim milk (BD), and 1% w/v agar (Oxoid). Protease-expressing 
strains produced a translucent zone surrounding the site of inoculation after 24-h 
incubation at 37 °C. Three independent assays were performed for each strain. The 
presence of proteolytic activity was considered positive when at least two of the three 
assays presented a translucent zone of size similar to the one of strain SF370. 
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SpeB Western blot analysis.  
For Western blot analysis, bacterial cultures were grown to late stationary phase 
(18 h) and centrifuged at 3200 × g for 15 min. Sterile-filtered supernatants were 
separated by electrophoresis on a 12% SDS-PAGE gel and transferred to a 
nitrocellulose membrane (Whatman, Dassel, Germany) using a Mini Trans-Blot (Bio-
Rad, Hercules, CA, USA). Immunodetection was performed by chemiluminescence 
using monoclonal anti-SpeB antibody (Toxin Technology, Serasota, FL, USA) and goat 
anti-rabbit IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology, 
Dallas, TX, USA). Detection was performed with ECL detection reagents (Thermo 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. 
 
Determination of NADase activity.  
The NADase activity of each strain was determined by an endpoint titre method 
based on previously published assays (Bricker et al., 2002). Briefly, bacteria-free 
supernatants of stationary-phase cultures of GAS strains were obtained as described for 
the azocasein assay and serially diluted (three-fold for the first dilution and two-fold for 
the second dilution onwards, up to 1/384) in β -NAD (Sigma-Aldrich) dissolved in PBS 
for a final concentration of 0.67 mM, in black 96-well plates (transparent bottom) 
(Greiner Bio-One, Frickenhausen, Germany). Wells containing sterile THB serially 
diluted in PBS and in β -NAD/PBS were used as controls, for each plate. After 
incubation for 1 h at 37°C in the dark, an equal volume of NaOH was added, for a final 
concentration of 2 N, and the plates were incubated for 1 h at room temperature, in the 
dark. Fluorescence was measured with excitation at 340 nm and emission detection at 
460 nm. For each strain, the NADase activity was expressed as the inverse of the 
highest dilution prior to a greater or equal to two-fold increase in the fluorescence value. 
This method has a limit of detection of 3, and strains for which a two-fold increase was 
not observed and with values similar to the THB + β -NAD control were considered to 
have a NADase activity of ≤3. A minimum of three independent assays were performed 
for each strain, and the majority rule was used to determine the final NADase activity. 
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Determination of streptolysin (SLS) activity.  
The streptolysin activity of each strain was determined by an endpoint titre 
method adapted from a previously published assay (Ravins et al., 2000). Briefly, 
bacteria-free supernatants of stationary-phase cultures of GAS strains were obtained as 
described for the azocasein assay. The supernatants (or sterile THB for control of 
spontaneous haemolysis - blank) were serially diluted in PBS in microplate wells (three-
fold for the first dilution and two-fold for the second dilution onwards, up to 1/192), and 
an equal volume of a 2.5% (v/v) suspension of defibrinated sheep erythrocytes was 
added. Two complete haemolysis controls were included in each plate, by incubating 
the erythrocytes suspension with 1% Triton X-100 (positive controls). The blank for 
these wells consisted only of PBS and the erythrocyte suspension. After incubation at 
37 °C for 1 h, erythrocytes were pelleted and the absorbance at 570 nm of the 
supernatants was measured. For each well, the percentage of haemolysis relative to the 
positive control was calculated as follows: 
 
The streptolysin activity was expressed as the inverse of the highest dilution prior 
to a ≥ two-fold decrease in the percentage of haemolysis. This method has a limit of 
detection of 3, and strains for which a two-fold decrease was not observed were 
considered to have a streptolysin activity of ≤ 3. A minimum of three independent 
assays were performed for each strain, and the majority rule was used to determine the 
final streptolysin activity. In four strains, two with functional covRS alleles (SF370 and 
SH0959A in Supplementary Table S1) and another two, of the same emm types, with 
null covS alleles and increased NADase activity (SH1025A and SH0421A in 
Supplementary Table S1), streptolysin assays were also performed in the presence of 
33.3 μ g/ml of trypan blue (Sigma-Aldrich) or of 16.7 μ g/ ml cholesterol (Sigma-
Aldrich). In all four strains, the results were not significantly changed by the presence of 
cholesterol, while trypan blue completely inhibited haemolysis, indicating that 
streptolysin O does not contribute to the haemolytic activity determined under these 
conditions, in agreement with previous reports (Ravins et al., 2000). 
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Statistical analysis.  
The allelic diversity of the covR, covS, and ropB genes in the studied collection of 
GAS isolates was evaluated using the Simpson’s index of diversity (SID) and 
corresponding 95% confidence intervals (CI95%) (Carrico et al., 2006). The overall 
association between covR, covS, or ropB alleles and the emm type and ST was evaluated 
with the Adjusted Wallace coefficient with corresponding CI95% (Pinto et al., 2008). 
 Unless otherwise specified, the statistical significance of pairwise associations 
was evaluated by calculating the respective odds ratios (when applicable) and the two-
tailed Fisher’s exact test, correcting the P values for multiple testing through the FDR 
linear procedure (Benjamini, 1995). 
 
Additional Information: 
Accession codes: All new covRS and ropB sequences identified in this study were 
deposited in GenBank (accession numbers KM985476 to KM985497 and  KP101294 to 
KP101323). 
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SUPPLEMENTARY DATA 
 
Table S1. Isolation source, molecular typing data, results of covRS and ropB 
sequencing, and results of SpeB, NADase, and SLS activity obtained for the 191 GAS 
isolates studied. http://dx.doi.org/10.6084/m9.figshare.1328335 (27/07/2018) 
 
Table S2. Adjusted Wallace values (95% confidence intervals) of the emm type and the 
ST towards the covR, covS, and ropB alleles among the 191 GAS isolates analyzed in 
this study. 
 covR covS ropB 
emm type 
0.978  
(0.962-0.994) 
0.834  
(0.741-0.928) 
0.806  
(0.723-0.888) 
ST 
0.988  
(0.974-1.000) 
0.854  
(0.753-0.955) 
0.824  
(0.735-0.913) 
 
 
Table S3. Primers used for the amplification and sequencing of the covRS and ropB 
genes. 
Primer Name Sequence (5’→3’) 
covRS-1 TAACCTCGAAGAAAGTATTGTGG 
covRS-4 CAACACGCTCAAAGGTAGTAAAG 
covRS-5 GTTTGCCAGTCACTGAAAGG 
covRS-6 GGATTTTCAGAGATATTAC 
covRS-7 AATCAGTGTAAAGGCAGAG 
ropB-F GATAAAACTATCGCATCTGGC 
ropB-R CCTGGAGCTGTTGAGATAAAC 
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SUMMARY  
 
Although skin and soft tissue infections (SSTI) are the most common focal 
infections associated with invasive disease caused by Streptococcus pyogenes 
(Lancefield Group A streptococci - GAS), there is scarce information on the 
characteristics of isolates recovered from SSTI in temperate-climate regions. In this 
study, 320 GAS isolated from SSTI in Portugal were characterized by multiple typing 
methods and tested for antimicrobial susceptibility and SpeB activity, and compared to 
313 contemporary isolates from invasive infections (iGAS). The covRS and ropB genes 
of isolates with no detectable SpeB activity were sequenced. The antimicrobial 
susceptibility profile was similar to that of iGAS, presenting a decreasing trend in 
macrolide resistance. However, the clonal composition of SSTI was significantly 
different from that of iGAS. Overall, iGAS were associated with emm1, emm3 and 
emm64, while SSTI were associated with emm89, the dominant emm type among SSTI 
(19%). Within emm89, SSTI were only significantly associated with isolates lacking the 
hasABC locus, suggesting that the recently emerged emm89 clade 3 may have an 
increased potential to cause SSTI. Reflecting these associations between emm type and 
disease presentation, there were also differences in the distribution of emm clusters, 
sequence types, and superantigen gene profiles between SSTI and iGAS. According to 
the predicted ability of each emm cluster to interact with host proteins, iGAS were 
associated with the ability to bind fibrinogen and albumin, whereas SSTI isolates were 
associated with the ability to bind C4BP and IgG. SpeB activity was absent in 79 
isolates (25%), in line with the proportion previously observed among iGAS. Null covS 
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and ropB alleles (predicted to eliminate protein function) were detected in 10 (3%) and 
12 (4%) isolates, respectively, corresponding to an underrepresentation of mutations 
impairing CovRS function in SSTI relative to iGAS. Overall, these results indicate that 
the isolates responsible for SSTI are genetically distinct from those recovered from 
normally sterile sites, supporting a role for mutations impairing CovRS activity 
specifically in invasive infection and suggesting that this role relies on a differential 
regulation of other virulence factors besides SpeB. 
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INTRODUCTION 
 
Streptococcus pyogenes (group A streptococcus, GAS) is responsible for a variety 
of human infections ranging from mild and frequent diseases, such as pharyngitis and 
cutaneous infections, to more severe and rare invasive infections including sepsis, 
necrotizing fasciitis and streptococcal toxic shock syndrome (Walker et al., 2014). In 
2005, the estimated global incidence of invasive GAS infections (iGAS) was 663,000 
new cases, resulting in 163,000 deaths, while  at least 111 million children under 15 
years suffered from pyoderma, mostly in developing countries, and pharyngitis 
incidence was estimated at over 616 million cases (Carapetis et al., 2005). Even though 
mild infections are usually self-limited, they may play a crucial role in transmission. 
Furthermore, the nasopharyngeal mucosa and the skin can also be asymptomatically 
colonized representing primary reservoirs of GAS (Cunningham, 2000).  
The gold-standard typing methodology of GAS is emm typing, which relies on the 
variability of the amino acid sequence of the N-terminal portion of S. pyogenes major 
virulence factor: the M protein (McMillan et al., 2013). The sequence of the 5’ variable 
region of the emm gene encoding the M protein determines the emm type, of which 
there are more than 250 distinct variants (https://www.cdc.gov/streplab/m-proteingene-
typing.html). However, emm typing is based on the sequence of only approximately 10-
15% of the complete emm gene. Recently a new classification was proposed based on 
emm clusters established by phylogenetic analysis of the entire sequence of the emm 
gene of 175 different emm types (Sanderson-Smith et al., 2014). Each cluster contains 
isolates with closely related M proteins that share binding motifs to host proteins and 
other structural properties. Since isolates with the same emm type encode nearly 
identical M proteins, the emm cluster can be inferred from the emm type.  
Associations between certain emm types and specific disease presentations have 
been established. Of particular importance is the association of iGAS with a 
contemporary emm1 clone, frequently designated as M1T1, which has persisted for 
decades as the major cause of invasive disease in most developed countries (Friães et 
al., 2012; Luca-Harari et al., 2009; O'Loughlin et al., 2007; Aziz and Kotb, 2008). 
Recently, the emergence of a specific emm89 clade (clade 3) that rapidly outcompeted 
the previously circulating emm89 strains was reported in multiple countries and 
associated with an increase in the prevalence of emm89 among GAS infections (Turner 
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et al., 2015; Zhu et al., 2015; Friães et al., 2015a). Isolates from clade 3 are 
characterized by the absence of the hasABC locus encoding the hyaluronic acid capsule 
of GAS, and by a variant nga-ifs-slo locus, similar to the one present in M1T1 strains, 
which is associated with increased expression of NAD-glycohydrolase (NADase) and 
streptolysin O (SLO) (Turner et al., 2015; Zhu et al., 2015). 
Despite the success of emm typing, some studies have suggested it is not enough 
to identify GAS clones and that it must be complemented with other typing methods 
such as multilocus sequence typing (MLST), superantigen (SAg) gene profiling 
(Carrico et al., 2006; Friães et al., 2013b), and, more recently, whole genome 
sequencing (Carrico et al., 2013). However, variability in key virulence factors and 
regulators within clones defined by these typing methods may have important 
consequences for the virulence of a particular isolate.  
A mouse model of skin and soft tissue infection (SSTI) showed that mutations in 
the covRS two component system were a key step for the transition from a localized to a 
systemic infection (Sumby et al., 2006). Consistently, several studies reported covRS 
mutations in isolates recovered from human infections (Engleberg et al., 2001; 
Hasegawa et al., 2010; Ikebe et al., 2010; Lin et al., 2014; Friães et al., 2015b). In these 
isolates the downregulation of SpeB expression, a potent extracellular cysteine protease, 
is thought to be fundamental towards the switch to a hipervirulent phenotype (Aziz et 
al., 2004; Kansal et al., 2010). Transcription of speB is also under direct control of 
RopB (Carroll and Musser, 2011), and naturally occurring mutations in ropB were also 
shown to impair SpeB production (Hollands et al., 2008; Carroll et al., 2011). We 
reported previously that mutations resulting in the truncation of CovS, which 
presumably impaired its function, were significantly overrepresented among iGAS in 
Portugal. However these were only present in 10% of invasive isolates, not explaining 
why most isolates caused invasive infections. Additionally, among all studied isolates, 
which included invasive and pharyngeal isolates, 20% had no detectable SpeB activity 
but no significant association was detected between the presence or absence of SpeB 
activity and the type of infection (Friães et al., 2015b). 
In order to cause a wide spectrum of disease, GAS has to be able to adapt to 
different environments in the host and despite decades of research there is still no 
consensus regarding which molecular or phenotypic properties are responsible for an 
enhanced invasive potential of certain lineages. Although the nasopharyngeal mucosa is 
usually considered as the main source of isolates causing iGAS in developed countries 
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(Fiorentino et al., 1997), SSTI are commonly reported as the predominant foci 
associated with invasive disease (Lamagni et al., 2008). This raises the possibility that 
strains adapted to infect the skin have an increased ability to invade and survive in 
deeper tissues. However, there is scarce data about the characteristics of GAS isolates 
responsible for SSTI, especially in developed, temperate climate regions. Most of the 
studies from these regions report the characteristics of SSTI isolates together with GAS 
from other non-invasive sites (mostly pharyngeal swabs) when comparing invasive and 
non-invasive disease (Rivera et al., 2006; Ekelund et al., 2005; Descheemaeker et al., 
2000). A few others specify the molecular characteristics of the SSTI isolates subset, 
but are limited in the number of isolates or are restricted to short time periods (Tamayo 
et al., 2014; Vahakuopus et al., 2012; Mijac et al., 2010; Kittang et al., 2008). In this 
study we characterized 320 isolates from SSTI recovered in Portugal during 2003-2009 
for their susceptibility to a panel of antimicrobials, emm type, SAg profile, and MLST. 
The genes conferring resistance to selected antimicrobials were also investigated. In 
addition, all 320 isolates were tested for SpeB activity and in those without detectable 
activity we sequenced the covRS and ropB genes to document any mutations. The SSTI 
isolates presented substantial differences relative to a collection of iGAS isolates 
recovered in the same period in Portugal regarding both the clonal composition and the 
prevalence of mutations impairing CovRS function. 
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METHODS 
 
Bacterial isolates  
For this study, 24 hospital laboratories distributed throughout Portugal were asked 
to send us, on a voluntary basis, all GAS isolated from SSTI between January 2003 and 
December 2009. The study was approved by the Institutional Review Board of the 
Centro Académico de Medicina de Lisboa. These were considered surveillance 
activities and were exempt from informed consent. All methods were performed in 
accordance with the relevant guidelines and regulations. The data and isolates were de-
identified so that these were irretrievably unlinked to an identifiable person. 
Participation was low in the first two years (n = 17 in 2003, n = 8 in 2004), but 
subsequently increased (average n = 59 / year, range 48-77) (Dataset available at 
10.6084/m9.figshare.6736313). Overall, 320 non-duplicate GAS isolates from SSTI 
were recovered and included in the study: 306 from skin and soft tissue exudates (pus) 
and 14 from skin and soft tissue biopsies. Identification of isolates was performed by 
colony morphology, β-hemolysis on blood agar, and the presence of the characteristic 
Lancefield group A antigen (OXOID, Basingstoke, UK). In addition, 313 non-duplicate 
iGAS isolates recovered in the same hospitals and time period, which had been partially 
characterized previously (Friães et al., 2007; Friães et al., 2013a), were also included. 
Strain SF370 was obtained from Colección Española de Cultivos Tipo (CECT5109). 
Strains were grown at 37ºC in Todd Hewitt broth (THB) (BD, Sparks, MD, USA) or in 
Tryptone Soya Agar (Oxoid, Basingstoke, UK) supplemented with 5% defibrinated 
sheep blood.  
 
Antimicrobial susceptibility testing and genetic determinants  
Susceptibility tests were performed by disk diffusion according to the guidelines 
of the Clinical and Laboratory Standards Institute (CLSI) for penicillin, vancomycin, 
erythromycin, levofloxacin, tetracycline, chloramphenicol, clindamycin and linezolid 
(Oxoid, Basingstoke, UK). E-test strips (BioMérieux, Marcy l’Etoile, France) were used 
for MIC determination in cases of intermediate susceptibility and to confirm resistance 
when ≤ 5 isolates were resistant to a particular antimicrobial. Determination of 
macrolide resistant phenotype was performed as previously described (Melo-Cristino 
and Fernandes, 1999). A multiplex PCR reaction for erm(B), erm(A) and mef genes was 
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used on macrolide resistant isolates to identify the resistance conferring genes (Figueira-
Coelho et al., 2004). The mef positive isolates were further analyzed in order to 
distinguish between mef(A) and mef(E) (Silva-Costa et al., 2008). The tetracycline 
resistance genotype was determined for resistant isolates by a multiplex PCR for the 
genes tet(K), tet(L), tet(M) and tet(O) (Trzcinski et al., 2000). 
. 
Molecular typing 
The emm typing was performed according to the protocols and recommendations 
of the Center for Disease Control and Prevention (CDC) 
(https://www.cdc.gov/streplab/protocol-emm-type.html). 
The presence of 11 SAg genes (speA, speC, speG, speH, speI, speJ, speK, speL, 
speM, smeZ and ssa) was tested by two multiplex PCR reactions using the amplification 
of speB and speF gene fragments as positive controls (Friães et al., 2013b). Absence of 
a PCR product for speB and speF was confirmed by Southern blotting as previously 
described (Friães et al., 2013b). 
MLST analysis was performed for all SSTI isolates (n = 320), as well as for the 
iGAS isolates that had not been previously typed by MLST (n = 152/313) (Friães et al., 
2012; Friães et al., 2007; Friães et al., 2013a).  Allele and sequence type (ST) 
identification was done using the S. pyogenes MLST database 
(https://pubmlst.org/spyogenes/). 
The sequence of the covRS and ropB loci of all isolates that presented no 
proteolytic activity (see below) was determined as previously described (Friães et al., 
2015b). For each isolate, the sequences were assembled and compared with the 
corresponding regions of the genome of strain SF370 (GenBankAE004092), considered 
as the reference wild-type alleles. Isolates were considered to carry null alleles if the 
changes found were predicted to result in absence of a functional protein due to 
nonsense mutations or frameshifts. All new covRS and ropB sequences identified in this 
study were deposited in GenBank (accession numbers MH537795-MH537849). 
 
Determination of proteolytic activity and SpeB expression  
All isolates were screened for detectable SpeB activity using a plate assay, as 
previously described (Friães et al., 2015b). Briefly, single GAS colonies were stab-
inoculated into fresh plates of medium containing 0.5-strength Columbia broth (BD), 
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3% w/v skim milk (BD, Sparks, MD, USA), and 1% w/v agar (Oxoid). A strain was 
considered to show proteolytic activity when it presented a translucent zone of size 
similar to the one of strain SF370 after 24h incubation at 37ºC, in three independent 
assays. On the contrary, a strain was considered not to show proteolytic activity if it did 
not produce a translucent halo in any of the three assays. For strains in which the results 
of the three assays were inconclusive or not consistent, detection of SpeB by Western 
blot was performed as described previously (Friães et al., 2015b) and this was 
considered the final result.  
 
Statistical analysis 
Simpson’s index of Diversity (SID) with respective 95% confidence intervals 
(CI95%) was used for the analysis of the typing methodologies and to evaluate the allelic 
diversity of the covR, covS and ropB genes found in this study (Carrico et al., 2006). 
Two–tailed Fisher’s exact test and odds ratios were used to identify significant pairwise 
associations. P-values for multiple tests were corrected using the FDR linear procedure 
(Benjamini, 1995). The Cochran-Armitage test was used to evaluate trends. A P-value < 
0.05 was considered significant for all tests.  
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RESULTS 
 
Antimicrobial susceptibility and genotypic determinants of resistance 
 All 320 SSTI isolates analyzed (Dataset) were susceptible to penicillin, 
vancomycin, and linezolid. Two isolates were non-susceptible to levofloxacin (MIC = 6 
mg/mL and 3 mg/mL, both emm89). One was resistant to chloramphenicol (emm147).  
Macrolide resistance was detected in 33 SSTI isolates (10%) of 12 different emm 
types (Dataset), with a significant decreasing trend during the years of the study (p < 
0.001) (Supplementary Figure 1). The majority of these isolates presented the cMLSB 
phenotype and carried the erm(B) gene (n = 22). The remaining macrolide resistant 
isolates (n = 11) exhibited the M phenotype and carried the mef(A) gene, with the 
exception of one isolate that was positive for the mef(E) gene.  
Tetracycline resistance was detected in 47 SSTI isolates (15%) comprising 25 
emm types (Dataset) with no significant temporal trend (Supplementary Figure 1). The 
majority of these isolates (n = 42) presented only the tet(M) gene, while three isolates 
carried both tet(M) and tet(L) and two isolates presented solely the tet(O) gene. 
Resistance to tetracycline and macrolides was simultaneously detected in 12 isolates, of 
which 9 presented the cMLSB phenotype.   
 
emm typing  
A total of 51 different emm types were identified among SSTI isolates (Table 1). 
Isolates with emm89 were the most frequently recovered (n = 62, 19%), followed by 
emm1 (n = 55, 17%), together accounting for 36% of all SSTI isolates (Figure 1). 
Considering emm types with ≥ 10 isolates, no significant changes in time were detected 
during 2003-2009 after FDR correction (data not shown).  
The emm types were distributed into 15 emm clusters (Table 1 and Figure 1). The 
majority of SSTI isolates belong to emm clusters from clade X (n = 189, 59%). No 
significant changes in prevalence of any cluster were detected in the study years (data 
not shown). 
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Table 1. Simpson’s Index of Diversity (SID) and respective 95% confidence intervals 
for emm type, emm cluster, superantigen (SAg) profile, and sequence type (ST) among 
skin and soft tissue infections (SSTI) and invasive infections (iGAS) in Portugal during 
2003-2009. 
   emm type emm cluster SAg profile ST 
SSTI 
(n = 320) 
No. partitions 51 15
a
 50 70 
SID 
(CI95%) 
0.916 
(0.899-0.933) 
0.838 
(0.813-0.862) 
0.934 
(0.922-0.946) 
0.945 
(0.933-0.958) 
iGAS 
(n = 313) 
No. partitions 37 16
a
 37 52 
SID  
(CI95%) 
0.891  
(0.870-0.912) 
0.852  
(0.832-0.873) 
0.908  
(0.891-0.926) 
0.911 
(0.890-0.933) 
a
 Isolates with no emm cluster (SSTI: n = 3, emm type 127, 147 and 167; iGAS: n = 3, emm 
types 196, 199 and stG1750) were not considered for SID determination. 
 
 
 
Figure 1. Distribution of isolates recovered from skin and soft tissue infections (SSTI) 
and invasive infections (iGAS) according to emm cluster and emm type. Only emm 
clusters with a total of ≥ 10 isolates in both infection types are represented. Numbers 
inside the bars represent the emm types included in each cluster. Black bars include 
emm types with < 3 isolates [SSTI, E4: emm77 (n = 2), emm73, emm102, and emm109 
(each n = 1); E3: emm209 (n = 2), emm82, emm103, and emm168 (each n = 1); D4: 
emm70, and emm223 (each n = 2), emm33, emm43, emm80, emm83, emm93, and 
emm225 (each n = 1); E6: emm65, emm81, and emm94 (each n = 1). iGAS, E4: emm77 
(n = 2), emm2, and emm84 (each n = 1); A-C3: emm227 (n = 1); E3: emm9, emm58, and 
emm103 (each n = 2), emm118 (n = 1); D4: emm53 (n = 2), emm43 (n = 1); E6: emm75, 
and emm81 (each n = 1)]. *p ≤ 0.01. 
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When comparing with iGAS isolates recovered in the same period, significant 
differences were detected in the overall distribution of emm types (p = 0.007), as well as 
in the prevalence of specific emm types (Supplementary Figure 2), although the SIDs 
were not significantly different (Table 1, p = 0.064). Twenty-three emm types 
accounting for 27 isolates were identified exclusively among SSTI, while seven emm 
types accounting for nine isolates were found only in iGAS. While emm1, emm3 and 
emm64 were significantly overrepresented among iGAS (p = 0.009, p = 0.010 and p = 
0.011, respectively), emm89 was significantly overrepresented among SSTI (p = 0.006). 
However, when stratifying the emm89 isolates as to the presence or absence of the 
hasABC locus, only the isolates lacking the locus were associated with SSTI (p = 
0.006). All these differences were still significant after FDR correction.  
These differences of emm types were reflected in the distribution of emm clusters 
among SSTI and iGAS isolates (Figure 1). While iGAS isolates were significantly 
associated with emm clusters A-C3 (comprising almost exclusively emm1 isolates) and 
A-C5 (comprising exclusively emm3 isolates) (p = 0.007 and p = 0.010, respectively), 
SSTI isolates were significantly associated with emm cluster E4 (dominated by emm89) 
(p = 0.004). 
The emm cluster typing system can be used for predicting the ability of the strains 
to bind different host proteins based on the binding properties of the respective M 
proteins (Supplementary Table 1) (Sanderson-Smith et al., 2014). When comparing 
SSTI and iGAS isolates, the ability to bind C4BP and IgG was associated with SSTI 
isolates (p < 0.001 and p = 0.008, respectively), whereas the invasive isolates were 
associated with the ability to bind fibrinogen and albumin (both p < 0.001), all 
significant after FDR. 
 
MLST  
The studied SSTI isolates comprised 70 different STs, presenting a higher 
diversity than the invasive isolates recovered in the same period (p = 0.006) (Table 1 
and Table 2). A total of 20 new STs were found among the SSTI and iGAS isolates 
typed in this study (ST817-ST836), including two new alleles for gtr (108; 109), three 
for murI (105-107), two for mutS (88; 89), two for recP (125-126), two for xpt (102; 
103), and three for yqil (119-121). 
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Table 2. Distribution of sequence types (ST) among emm types identified in skin and 
soft tissue infections (SSTI) and invasive infections (iGAS) in Portugal during 2003-
2009. 
emm type ST (no. of isolates) 
SSTI (n = 320) iGAS (n = 313) 
1 28(52); 643(1); 830(2) 28(77); 618(1); 643(3) 
89 101(37); 408(15); 824(10) 101(18); 408(14); 824(3) 
6 382(13); 411(7) 382(15); 411(9) 
3 15(8); 315(5) 15(19); 315(4); 406(6) 
28 52(17) 52(20); 458(1); 821(1) 
4 38(2); 39(15) 39(18); 771(1); 823(2) 
12 36(10); 467(1) 36(18); 551(1) 
44 25(13); 178(2); 429(1); 555(2) 25(8); 178(1); 555(2) 
64 164(3) 124(1); 164(12) 
87 62(9) 62(7) 
11 403(6) 403(5); 562(1) 
22 46(6); 389(1) 46(4) 
5 99(4) 99(6) 
Others
a 
 
2(1); 3(2); 5(1);10 (1); 24(2); 50(2); 
55(8); 60(1); 63(2); 75(3); 
89(1);120(1); 130(3); 150(3); 161(7); 
164 (1);166 (1); 167(1); 184(1); 
200(1); 253(3); 331(2); 340(2); 
341(1); 409(1); 565 (2); 569(1); 
573(1); 642(3); 701(1); 718(1); 754 
(1); 817(1); 819 (1); 820 (1); 822(1); 
826(3); 825(1); 827(1); 828(1); 
829(1); 831(1); 833(1); 834(1); 
835(1); 836(1) 
3(1); 11(2); 28(2); 50(1); 53(1); 
55(1); 63(2); 75 (2); 95(1); 99(1); 
120(1); 150(1); 184(1); 201(2); 
258(1); 402(1); 409 (3); 410(2); 
619(1); 679(3); 769(1); 816 (1); 
818(1), 832(1); 833(1) 
a “Others” include emm-types with n<10 isolates considering both SSTI and invasive isolates. 
Those include emm-types: 2; 9; 18; 19; 33; 43; 48; 50; 53; 58; 65; 68 70; 71; 73; 74; 75; 76; 77; 
78; 80; 81; 82; 83; 84; 90; 93; 94; 102; 103; 109; 113; 118; 209; 223 127; 147; 164; 167; 168; 
179; 196; 199; 225; 227 and stG1750. 
 
The overall distribution of STs differed significantly between SSTI and iGAS (p 
<0.001). Some STs were associated with certain infection types, in agreement with the 
associations of the corresponding dominant emm types with infection type (emm1 for 
ST28, emm3 for ST15, emm64 for ST164, and emm89 for ST101). However, these 
differences were not statistically supported after FDR correction (Supplementary Figure 
3). 
No significant differences were detected when comparing the ST diversity 
between isolates with the same emm type recovered from each type of infection (Table 
2). 
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SAg profiling  
Overall, chromosomally encoded smeZ and speG genes were the most frequently 
detected among SSTI isolates, being present in 307 (96%) and 301 (94%) isolates, 
respectively (Table 3 and Supplementary Figure 4(A)). PCR-amplification of speB and 
speF was not possible for one isolate, and the absence of both genes was confirmed by 
Southern blot (data not shown). The presence of the genes speA and speK was 
significantly associated with invasive isolates (p = 0.001 and 0.017, respectively), while 
speL and speM were significantly associated with isolates from SSTI (p = 0.002 and p < 
0.001, respectively) (Supplementary Figure 4(A)).  
A total of 50 distinct SAg profiles were identified among the SSTI isolates (Table 
1 and Table 3). The SAg profiles of SSTI isolates were more diverse than those of 
invasive isolates (p = 0.016) (Table 1). Reflecting the association between emm type 
and infection, SAg profiles 8 and 10, which correspond mostly to emm3 and emm1, 
respectively, were associated with iGAS (p = 0.005 and 0.003, respectively), while SAg 
profile 29, mostly found among emm89, was associated with SSTI (p = 0.010) 
(Supplementary Figure 4(B)).   
Table 3. Superantigen (SAg) profiles identified in isolates recovered from skin and soft 
tissue infections (SSTI) in Portugal during 2003-2009.  
SAg 
profilea speA speC speG speH speI speJ speK speL speM ssa smeZ 
emm type 
 (No. of isolates) 
2 + + + - - - + - - - + 6(17); 74(1) 
3 + + + - - + - - - - + 1(11); 87(1) 
4 + + + - - - - + + - + 18(3); 22(1) 
5 + + + - - - - - - - + 
5(2); 11(1); 18(1); 
122(1) 
8 + - + - - - + - - + + 3(11) 
9 + - + - - - + - - - + 6(1) 
10 + - + - - + - - - - + 1(43); 71(1) 
11 + - + - - - - - - - + 43(1); 82(1) 
12 - + + + + + - - - + + 44(2) 
13 - + + + + - - - - + + 22(1) 
15 - + + + - + + - - - + 28(1) 
16 - + + + + - - - - - + 11(4); 16(6); 48(4) 
18 - + + - - + + - - + + 87(1) 
19 - + + - - - + - - + + 22(2) 
20 - + + - - + - - - + + 84(4) 
21 - + + - - - - - - + + 22(2) 
23 - + - - - - - - - + + 4(16) 
24 - + + - - + + - - - + 28(8) 
26 - + + - - - + - - - + 89(3) 
27 - + + - - + - - - - + 
28(8); 68(1); 70(2); 
89(15); 90(1) 
28 - + + - - - - + + - + 75(1) 
29 - + + - - - - - - - + 
5(2); 11(1); 48(3); 
50(1); 77(1); 78(4); 
89(35); 118(1); 127(1) 
31 - + + - - - - + + - - 2(7) 
CHAPTER III 
122 
32 - - + + + + - - - + + 44(12) 
33 - - + + + - - - - - + 12(5); 73(1); 76(2) 
35 - - + + - - - - - - + 75(1); 94(1) 
38 - - + - - + - - - + + 44(1);87(1); 223(1) 
39 - - + - - - - + + + + 53(1); 75(2) 
40 - - + - - - - - - + + 90(3); 22(1) 
41 - - - - - - - - - + + 4(1) 
43 - - + - - - + - - - + 65(1); 209(1) 
44 - - + - - + - - - - + 
102(1); 103(1); 
118(2); 223(1) 
45 - - + - - - - + + - + 80(1) 
46 - - + - - - - - - - + 
53(2); 58(1); 64(3); 
75(1); 89(9); 118(1); 
147(1); 167(1); 168(1) 
47 - - - - - - - - - - + 77(1) 
48 - - + - - - - + + - - 2(1) 
51 + + + + + - + - - - + 6(2) 
52 + + + - - - + - - + + 22(1) 
53 + - + - - - - - - + + 3(2) 
54 - + + + + + - - - - + 87(1) 
56 - - + + - + - - - - - 44(3) 
60 + - + + + + - - - - + 71(2) 
61 + - + - - + + - - - + 1(1) 
64 - + + + + - - + + - + 93(1) 
66 - + + - - - - - + - + 58(3) 
67 - - + + - + - - - + + 33(1) 
68 - - + + + - - - - - - 209(1) 
69 - - + + - - - - - - - 81(1) 
70 - - + - - + + - - - + 87(1) 
71 - + + - - + - + + - + 83(1) 
a
 The numbering of the SAg profiles follows the one adapted previously (Friães et al., 2013b; Friães et 
al., 2013a; Silva-Costa et al., 2014) 
 
SpeB protease activity and sequence of covRS and ropB 
We previously showed that the total proteolytic activity could be used as a proxy 
for SpeB activity and that all isolates with null alleles, either in covS or in ropB, lacked 
SpeB activity (Friães et al., 2015b).  
Among the 320 SSTI isolates, 79 (25%) had no detectable SpeB activity 
(Dataset). These isolates represented 22 different emm types and 28 STs. 
Among the isolates with no SpeB activity, 15 distinct covR alleles were identified, 
resulting in only two different amino acid sequences, while 34 and 47 different alleles 
were detected for covS and ropB, corresponding to 22 and 37 distinct amino acid 
sequences, respectively (Figure 2). In two isolates no PCR product was amplified using 
the ropB specific primers, indicating a possible deletion involving the ropB gene, as 
previously described in other GAS isolates (Friães et al., 2013b). In one of these 
isolates, the absence of PCR amplification of the speB and speF genes, both located in 
the same locus than ropB, supports the occurrence of a large deletion encompassing the 
entire ropB gene, as well as speB and speF.  
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No null alleles were detected in covR, while null covS alleles were detected in 10 
isolates. Since none of the SpeB-positive isolates is expected to have null covS alleles, 
these would correspond to 3% of all isolates recovered from SSTI. These null covS 
alleles were present in isolates of six different emm types and seven STs (Dataset), and 
there were no associations with specific emm types or STs. Two isolates presented in-
frame indels (45 bp deletion and 3 bp insertion). Since both isolates also have a null 
ropB allele which could explain the downregulation of SpeB, the consequences of these 
indels in CovS protein function are not clear and therefore they were not considered null 
alleles.  
A total of 12 isolates presented null ropB alleles (including the two isolates with a 
ropB deletion), representing 4% of all SSTI isolates, and 15% of the isolates with no 
detectable SpeB.  
Overall, a total of 22 SSTI isolates (29%) presented a null allele in at least one of 
the three genes. Forty-four SpeB-negative SSTI isolates carry amino acid changes in 
covRS or ropB whose impact on SpeB expression is difficult to predict (Friães et al., 
2015b). The remaining 13 isolates with no detectable SpeB showed the same amino 
acid sequence as the reference strain for all sequenced genes (emm71, n = 1; emm80, n 
= 1; emm87, n = 1; emm89, n = 8; emm109, n = 1; emm122, n = 1). In these isolates the 
absence of SpeB probably resulted from changes other than the impairment of CovRS 
or RopB function, possibly due to mutations in one of the at least 19 other genes whose 
products have been shown to influence the production of an enzimatically active SpeB 
(Carroll and Musser, 2011). No emm type was associated with the absence of detectable 
SpeB activity and the only ST (ST382 representing 65% of all emm6 isolates) 
associated with a lack of SpeB activity (p = 0.004) presented no null alleles at any of the 
sequenced loci. However, isolates of this ST harbor multiple amino acid substitutions in 
both covS and ropB genes that could contribute to the speB-negative phenotype.  
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Figure 2. Nucleotide alterations identified in the covR (A), covS (B), and ropB (C)  
alleles among skin and soft tissue isolates with no detectable SpeB (n = 79), relative to 
the alleles present in strain SF370 (AE004092). Each gene is indicated by a grey  arrow 
with the respective numbering scale below. Each sequence variation is indicated in the 
respective nucleotide position by a letter corresponding to the variant nucleotide, or the 
sequence or number of base-pairs inserted (ins), deleted (del), or duplicated (dup). 
Synonymous changes are represented in black; missense mutations and in-frame indels 
are represented in blue. Changes predicted to result in null alleles, including nonsense 
mutations and indels that generate frameshifts are represented in red. One exception is 
represented by “*” corresponding to an isolate with an early deletion of 4 bp in ropB 
which is more probable to result in the alteration of the start codon rather than a 
premature stop codon and therefore was not considered as a null mutation.   
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DISCUSSION 
 
Antimicrobial resistance among SSTI isolates was not significantly different from 
that found among contemporary iGAS and pharyngitis isolates, with the decreasing 
resistance to macrolides in SSTI mirroring declines in resistance previously described 
among isolates causing these other infections (Friães et al., 2013a; Silva-Costa et al., 
2015).  
A high diversity of emm types was found among the studied isolates. Although 
most of the emm types were identified among both iGAS and SSTI isolates, there were 
clear differences in the overall emm and clonal distribution between the two infections. 
The emm types 1 and 64 associated to iGAS were also previously found to be 
overrepresented among iGAS relative to pharyngitis (Friães et al., 2012), confirming 
the enhanced capacity of these lineages to cause invasive disease. The emm1 isolates 
have remained a major cause of iGAS in Portugal in recent years (Friães et al., 2013a), 
in line with the worldwide dissemination of the M1T1 clone (Luca-Harari et al., 2009; 
O'Loughlin et al., 2007; Aziz and Kotb, 2008). On the other hand, emm64 decreased 
markedly as a cause of iGAS in Portugal in recent years (Friães et al., 2013a) and was 
not associated with iGAS elsewhere, indicating that its importance as a cause of 
invasive disease was short-lived. The association between emm3 and iGAS is not 
unexpected, since emm3 has been reported as a major cause of invasive disease in 
Portugal and other countries, although the comparison with pharyngitis isolates did not 
identify this emm type (Luca-Harari et al., 2009; Friães et al., 2013a; Beres et al., 
2004).  
The association between emm89 and SSTI has been previously reported in 
Northern Spain, but with no information regarding the specific clades involved 
(Tamayo et al., 2014). In Portugal, only emm89 isolates lacking the hasABC locus, 
presumed to belong to the recently emerged clade 3 (Zhu et al., 2015; Friães et al., 
2015a), were significantly associated with SSTI. This observation is in line with an 
increase in the prevalence of emm89 among SSTI in Portugal, but not in iGAS or 
pharyngitis, associated with the emergence of this acapsular clade (Friães et al., 2015a). 
Our data thus raises the possibility that the genome remodeling underlying the 
emergence of emm89 clade 3 may have led to a particular propensity to cause SSTI, 
although this clade also quickly replaced the previously circulating emm89 clades in all 
infection types. This association with SSTI could be due to an increased capacity to 
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colonize the skin, as well as to an improved ability to overcome the major host defense 
mechanisms present in skin and soft tissue or to produce cytotoxic effects at these sites. 
Increased transmissibility and persistence has been suggested for clade 3-associated 
strains based on enhanced capacity to adhere to uncoated plastic (Turner et al., 2015), 
while the increased expression of NADase and SLO by clade 3 has been associated with 
virulence in a mouse model of necrotizing fasciitis (Zhu et al., 2015). However, further 
investigation is needed to clarify the role of these phenotypes in the specific association 
of emm89 clade 3 with SSTI. 
These associations between emm type and disease presentation were reflected on 
the different prevalence of the respective STs and SAg profiles between iGAS and 
SSTI, in agreement with the high congruence previously observed between these three 
typing methods (Carrico et al., 2006; Friães et al., 2013b). The observed association of 
emm clusters A-C3 and A-C5 with iGAS, as well as that of cluster E4 with SSTI also 
reflects the association of the respective emm types with the types of infection. 
According to the predicted ability of the different M proteins to interact with host 
factors  (Sanderson-Smith et al., 2014), invasive isolates would be associated with the 
ability to bind fibrinogen and albumin. The ability to bind fibrinogen was proposed as a 
mechanism to decrease complementation deposition resulting from the activation of the 
classical pathway (Carlsson et al., 2005). A similar function is believed to be performed 
by C4BP (Carlsson et al., 2003), whose binding was associated with SSTI isolates. The 
reasons why complement inhibition could be achieved through fibrinogen in iGAS and 
C4BP recruitment in SSTI remain elusive. Most emm clusters include proteins able to 
bind albumin, with the exception of cluster E4 (Sanderson-Smith et al., 2014). The 
association of cluster E4 with SSTI resulted in the overrepresentation of albumin 
binding among iGAS. Although albumin binding was shown to mask epitopes in the C-
repeated region of the M protein (Sandin et al., 2006), deletion of this region did not 
impair virulence in a mouse intraperitoneal infection model (Waldemarsson et al., 
2009), not providing clues as to why this could be important in the context of iGAS. 
The ability to bind to human IgG was associated with SSTI isolates. Immunoglobulin 
binding was shown to hinder opsonophagocytosis, even in the absence of a specific 
immune response (Carlsson et al., 2003). One can imagine such defense mechanism 
could be useful to bacteria in the context of both SSTI and iGAS and the reasons for the 
observed differences deserve further scrutiny. Only 5% of the SSTI isolates were 
predicted to bind plasminogen, although this was recently shown to facilitate 
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keratinocyte invasion (Siemens et al., 2011) and could thus be beneficial in the context 
of SSTI. 
The acquisition of mutations in the two-component regulatory system CovRS is 
regarded as an important mechanism promoting the transition to an invasive phenotype 
among GAS isolates. Current data suggests that upon infection with a wild type strain, 
covRS mutants arise at the focal infection site, from which mixed populations are 
recovered, and are subsequently selected for during transition to deeper, normally sterile 
sites (Sumby et al., 2006; Mayfield et al., 2014). In our previous work, we observed that 
null covS alleles were significantly overrepresented among iGAS (10%) relative to 
pharyngeal isolates (2%) (Friães et al., 2015b). The data reported here reveals an 
underrepresentation of covS null alleles in SSTI (3%) relative to iGAS isolates (p = 
0.009), but no significant difference relative to pharyngeal isolates (2%). Since our 
isolates were obtained from a single colony from each patient, there was a sampling of 
possibly mixed populations, which could introduce a bias or at least underestimate the 
ongoing selection of covRS impaired variants. Still we do not believe this compromises 
our conclusions since the colonies were randomly picked without particular care to 
select any of the variants. Our results therefore indicate that mutations impairing CovRS 
are a hallmark of iGAS isolates, although they still represent a minority of iGAS (Friães 
et al., 2015b). The lower prevalence of covS null alleles among pharyngeal and SSTI 
isolates supports the importance of a functional CovRS in the initial stages of non-
invasive infection, both in skin and in the upper respiratory tract (Hollands et al., 2010; 
Alam et al., 2013). As reported for pharyngeal and invasive isolates (Friães et al., 
2015b), covRS and ropB mutations occurred in SSTI isolates of diverse lineages and 
were not a particular characteristic of any specific clone. In contrast to covS, the 
proportion of ropB null alleles among SSTI isolates (4%) was similar to that found 
among both pharyngeal and invasive isolates (3%), indicating that mutations abrogating 
RopB activity occur in a low fraction of GAS isolates, regardless of the type of 
infection they cause. 
The abrogation of SpeB activity is usually regarded as one of the most important 
features of CovRS mutants contributing to the invasive phenotype, since this abrogation 
spares multiple virulence factors involved in invasive disease pathogenesis and evasion 
of host immunity (Carroll and Musser, 2011). The proportion of isolates lacking SpeB 
among our SSTI collection (25%) was similar to that found previously among iGAS 
(24%) and higher, but not significantly, than that found among pharyngitis isolates  in 
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Portugal (16%, p = 0.081) (Friães et al., 2015b). Only one ST was associated with a 
lack of SpeB expression (ST382) and both this ST and the emm type it expresses 
(emm6) were evenly distributed in both SSTI and iGAS. These results suggest that, in 
addition to SpeB downregulation, the differential regulation of other virulence genes 
induced by impairment of CovRS is also critical for an enhanced invasive capacity of 
the isolates. In agreement with this suggestion, a mouse model of SSTI showed that 
covRS mutants produced larger necrotic regions than speB mutants (Engleberg et al., 
2004).  
A limitation of this study is the lack of information regarding the specific 
infection caused by the isolates, as well as the clinical evolution and outcome of each 
infection. SSTI include a wide range of superficial and deep infections which vary 
greatly in severity. It was therefore not possible to evaluate possible correlations 
between the clones identified in SSTI and the severity of the respective infections. This 
could bias the comparison between SSTI and iGAS, leading to a possible 
underestimation of the differences between the two types of infection. However, even in 
these conditions we still identified significant differences between the two subsets of 
isolates regarding both clonal composition and presence of null covS alleles, which are 
in agreement with our previous observations from the comparison between pharyngeal 
and iGAS isolates (Friães et al., 2012; Friães et al., 2015b).       
GAS isolates causing SSTI in Portugal are a temporally stable and genetically 
diverse population. Still, the 30 valent M protein-based vaccine, which was shown to 
evoke cross-opsonic antibodies against non-vaccine serotypes (Dale et al., 2011), could 
potentially cover up to 95% of SSTI in Portugal. Although SSTI are the main primary 
foci associated with invasive disease (Lamagni et al., 2008), SSTI isolates, inasmuch as 
pharyngeal isolates (Friães et al., 2012), present a clearly different clonal composition 
from contemporary iGAS isolates. It is less clear how the differences in the presumed 
interaction with host proteins and exotoxin profiles brought about by those clonal 
differences could explain the distinct disease presentations. Despite the different 
prevalence of multiple emm types between SSTI and iGAS, within each emm type the 
same MLST defined lineages and the same SAg profiles could be found in both 
infection types. This indicates that any intra-emm type genetic differences between the 
two populations must be explored at a more detailed level, such as by whole-genome 
sequencing. Our current data therefore indicates that among the GAS clones causing 
infection in the Portuguese population, some have an increased capacity to invade 
Skin and Soft Tissue Infections 
129 
deeper tissues and cause severe infections, while others seem to be particularly 
successful at establishing SSTI or pharyngeal infections. The proportion of SSTI 
isolates with no detectable SpeB activity was modest and similar to that found 
previously in Portugal among iGAS and pharyngitis isolates, indicating that the 
selective pressure to eliminate SpeB is also not a primary factor in SSTI. However, we 
confirmed an association between mutations abrogating CovRS function and iGAS, 
suggesting that increased expression of other virulence factors, such as the hyaluronic 
acid capsule, streptolysins or NAD-glycohydrolase, rather than SpeB downregulation, 
may be under selection in the context of iGAS. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
130 
ACKNOWLEDGMENTS 
 
Members of the Portuguese Group for the Study of Streptococcal Infections are: 
Teresa Vaz, Marília Gião, Rui Ferreira (Centro Hospitalar do Barlavento Algarvio); 
Ana Cristina Silva, Hermínia Costa, Maria Fátima Silva, Maria Amélia Afonso (Centro 
Hospitalar de Entre Douro e Vouga); Ana Domingos, Gina Marrão, José Grossinho 
(Centro Hospitalar de Leiria); Paulo Lopes, Angelina Lameirão, Gabriela Abreu; 
Aurélia Selaru (Centro Hospitalar de Vila Nova de Gaia/Espinho); Hermínia Marques, 
Margarida Tomáz, Paula Mota (Centro Hospitalar do Alto Ave); Maria Helena Ramos, 
Ana Paula Castro (Centro Hospitalar do Porto); Fernando Fonseca (Centro Hospitalar 
da Póvoa do Varzim/Vila do Conde); Nuno Canhoto, Teresa Afonso (Hospital Central 
do Funchal); Teresa Pina, Helena Peres, Odete Chantre, João Marques, Cristina 
Marcelo, Isabel Peres, Isabel Lourenço, Margarida Pinto (Centro Hospitalar de Lisboa 
Central); Lurdes Monteiro, Luís Marques Lito (Centro Hospitalar Lisboa Norte); 
Cristina Toscano, Maria Ana Pessanha (Centro Hospitalar Lisboa Ocidental); Elmano 
Ramalheira, Raquel Diaz, Sónia Ferreira, Inês Cravo Roxo (Centro Hospitalar do Baixo 
Vouga); Ana Paula Castro (Hospital de Vila Real); Graça Ribeiro, Rui Tomé, Celeste 
Pontes, Luísa Boaventura, Catarina Chaves, Teresa Reis (Hospitais da Universidade de 
Coimbra); Ana Buschy Fonseca (Hospital de Cascais); Manuela Ribeiro, Helena 
Gonçalves (Hospital de São João, Porto); Alberta Faustino, Adelaide Alves, Maria 
Cármen Iglesias (Hospital de Braga); Ilse Fontes, Paulo Martinho (Hospital de Santa 
Luzia, Elvas); Maria Luísa Gonçalves, Olga Neto (Hospital dos SAMS, Lisboa); Luísa 
Sancho (Hospital Dr. Fernando da Fonseca, Amadora/Sintra); Adriana Coutinho 
(Hospital do Espírito Santo, Évora); José Diogo, Ana Rodrigues (Hospital Garcia de 
Orta, Almada); Maria Antónia Read, Valquíria Alves, Margarida Monteiro (Hospital 
Pedro Hispano, Matosinhos); Rosa Bento (Unidade Local de Saúde do Baixo Alentejo, 
Beja). 
 
Funding 
This work was partially supported by LISBOA-01-0145-FEDER-007391, project 
cofunded by FEDER, through POR Lisboa 2020 - Programa Operacional Regional de 
Lisboa, PORTUGAL 2020, and Fundação para a Ciência e a Tecnologia. CP was 
Skin and Soft Tissue Infections 
131 
supported by a grant from Fundação para a Ciência e Tecnologia 
(SFRH/BD/81329/2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
132 
SUPPLEMENTARY DATA   
 
 
 
 
Supplementary Table 1- Host protein binding profile prediction for each cluster 
(Sanderson-Smith et al., 2014) and distribution of isolates according the type of 
infection. 
 
a 
Results from iGAS emm typing were reported previously (Friães et al., 2007; Friães et al., 2012; Friães 
et al., 2013a). 
b
 When < 80% isolates were tested for each emm cluster the property is classified as uncertain (UC). 
emm cluster SSTI/iGAS
a 
Plasminogen IgA IgG Fibrinogen Albumin C4BP 
E4 99/65 No UC
b 
Yes No No UC
b 
A-C3 55/82 No No Yes Yes Yes No 
E3 43/28 No UC
b 
Yes No Yes Yes 
E1 21/24 No Yes Yes No Yes Yes 
M6 20/24 No No No No UC
b 
UC
b 
A-C5 13/29 No No No Yes Yes No 
D4 16/16 Yes UC
b 
No No UC
b 
No 
A-C4 11/19 No No No Yes Yes No 
E6 21/8 No Yes Yes No Yes Yes 
M5 4/6 No No No Yes, UC
b 
UC
b 
E2 5/3 No No Yes No Yes No 
M18 4/2 No No No No UC
b 
UC
b 
D2 3/0 No No No No UC
b 
UC
b 
M74 1/1 No No No Yes UC
b 
UC
b 
M19 0/1 No No No Yes Yes No 
M122 1/0 No No No No UC
b 
UC
b 
M164 0/1 No No No No UC
b 
UC
b 
M179 0/1 No No No Yes UC
b 
UC
b 
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Supplementary Figure 1. Prevalence of tetracycline resistance, erythromycin 
resistance, and macrolide resistance phenotypes among GAS isolates recovered from 
skin and soft tissue infections (SSTI) in Portugal during 2003-2009. M, resistance to 
erythromycin and susceptibility to clindamycin; cMLSB, constitutive resistance to 
erythromycin and clindamycin. 
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Supplementary Figure 2. Distribution of emm types among isolates recovered from 
skin and soft tissue infections (SSTI) and invasive infections (iGAS) in Portugal during 
2003-2009. “Others” include emm types with a total of <10 isolates in both infection 
types [SSTI: emm2 (n = 8), emm48 (n = 7), emm75 (n = 5), emm18, emm58, emm78, 
and emm118 (each n = 4), emm9, emm53, and emm71 (each n = 3), emm70, emm76, 
emm77, emm209, and emm223 (each n = 2), emm33, emm43, emm50, emm65, emm68, 
emm73, emm74, emm80, emm81, emm82, emm83, emm90, emm93, emm94, emm102, 
emm103, emm109, emm122, emm127, emm147, emm167, emm168, and emm225 (each 
n = 1); iGAS: emm78 and emm113 (each  n = 3), emm9, emm18, emm53, emm58, 
emm77, emm90, and emm103 (each n = 2), emm2, emm19, emm43, emm74, emm75, 
emm76, emm81, emm84, emm118, emm164, emm179, emm196, emm199, emm227, and 
stG1750 (each n = 1)].*p ≤ 0.01. 
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Supplementary Figure 3. Distribution of sequence types (ST) among skin and soft 
tissue infections (SSTI) and invasive infections (iGAS) in Portugal during 2003-2009. 
“Others” include STs with a total of <10 isolates in both infection types [SSTI: ST55 (n 
= 8), ST161 (n = 7), ST315 (n = 5), ST75, ST130, ST150, ST253, ST642, and ST826 
(each n = 3), ST3, ST24, ST38, ST50, ST63, ST178, ST331, ST340, ST555, ST565, and 
ST830 (each n = 2), ST2, ST5, ST10, ST60, ST89, ST120, ST166, ST167, ST184, 
ST200, ST341, ST389, ST409, ST429, ST467, ST569, ST573, ST643, ST701, ST718, 
ST754, ST817, ST819, ST820, ST822, ST825, ST827, ST828, ST829, ST831, ST833, 
ST834, ST835, and ST836 (each n = 1); iGAS: ST406 (n = 6), ST315 (n = 4), ST409, 
ST643 and ST679 (each n = 3), ST11, ST63, ST75, ST201, ST410, ST555, and ST823 
(each n = 2), ST3, ST50, ST53, ST55, ST95, ST120, ST124, ST150, ST178, ST184, 
ST258, ST402, ST458, ST551, ST562, ST618, ST619, ST769, ST771, ST816, ST818, 
ST821, ST832, and ST833 (each n = 1)]. *p < 0.05  **p < 0.01. These p-values did not 
support statistical significance after FDR correction. 
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Supplementary Figure 4. Distribution of individual superantigen (SAg) genes (A) and 
SAg profiles (B) among isolates recovered from skin and soft tissue infections (SSTI) 
and invasive infections (iGAS) in Portugal during 2003-2009. “Others” include SAg 
profiles with a total of <10 isolates in both infection types [SSTI: SAg profiles 31 (n = 
7), 44 (n = 5), 4, 20, and 40 (each n = 4), 26, 38, 39, 56, and 66 (each n = 3), 11, 12, 19, 
21, 35, 43, 47, 51, 53, and 60 (each n = 2), 9, 13, 15, 18, 28, 41, 45, 48, 52, 54, 61, 64, 
67, 68, 69, 70, and 71 (each n = 1); iGAS: SAg profiles 20 (n = 5), 44 (n = 4), 26 (n = 
3), 17, 19, 30, 38, 45, 52, 54, and 56 (each n = 2), 1, 11, 12, 31, 34, 40, 43, 49, 50, 51, 
53, 55, and  57 (each n = 1)]. *p < 0.05  **p < 0.01. 
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Streptoccocus pyogenes is responsible for a wide variety of human infections 
ranging from mild superficial infections of the respiratory tract and skin, such as 
pharyngitis and impetigo, to potentially fatal invasive infection such as necrotizing 
fasciitis and streptococcal toxic shock syndrome (Cunningham, 2000). In order to cause 
this wide spectrum of diseases, GAS has to be able to adapt to the different 
environments in the host and despite decades of research, there is still no consensus 
regarding what are the genotypic or phenotypic properties responsible for an enhanced 
invasive potential of certain isolates. Moreover, most studies in attempting to find the 
answer to this question compare subsets of invasive isolates with subsets of non-
invasive isolates recovered from several non-invasive sites, including from skin and 
more frequently from pharyngeal swabs. However, since the characteristics of SSTI 
isolates are reported together with GAS from other non-invasive sites, there is a lack of 
data regarding the characteristics of GAS isolates specifically responsible for SSTI. 
 
In the present thesis, we sequenced the covRS and ropB genes of 191 GAS 
isolates, including isolates from pharyngitis and invasive infections with a high 
diversity of emm types and STs that were previously characterized (Friães et al., 2012). 
We also screened all isolates for the presence of SpeB activity and quantified their 
NADase and SLS activity. 
In the second part, we characterized a total of 320 isolates from SSTI recovered in 
Portugal and performed the comparison with invasive isolates recovered during the 
same period which had been characterized elsewhere (Friães et al., 2007; Friães et al., 
2013a). All SSTI isolates were tested for SpeB activity and for those without detectable 
SpeB activity we also determined the sequence of the covRS and ropB genes. 
 
Importance of CovRS and RopB spontaneous mutations among pharyngitis, 
invasive and SSTI isolates. 
In 2006, Sumby et al., using a microarray analysis of 9 M1 isolates including six 
from patients with pharyngitis and three from invasive disease, found mainly two 
different transcriptomes named pharyngeal transcriptome profile (PTP) and invasive 
transcriptome profile (ITP). They also observed that isolates with and ITP were 
recovered from mice infected subcutaneously with PTP isolates and that these isolates 
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were more able to resist killing by human polymorphonuclear leukocytes. Moreover 
using complete genome sequencing, the only difference between an ITP isolate from its 
PTP precursor was a 7bp frameshift mutation in the covS gene, which results in the 
production of a truncated 202-amino acid CovS (Sumby et al., 2006). The operon where 
covS is found encodes the two-component regulatory system CovRS, which is estimated 
to directly or indirectly influence the expression of 10-15% of the GAS genome 
(Graham et al., 2002; Sumby et al., 2006). In agreement with these results, others 
studies have also reported the presence of mutations impairing covRS function in 
isolates recovered from murine infections as well in patient isolates recovered mostly 
from invasive infections (Engleberg et al., 2001; Ikebe et al., 2010; Mayfield et al., 
2014; Kansal et al., 2010). Some of these studies, using mainly M1T1 isolates, also 
indicate that isolates with these mutations show an enhanced virulence in murine 
models of infection (Engleberg et al., 2001; Ikebe et al., 2010; Mayfield et al., 2014). 
Taken together, the previous results led to the hypothesis that spontaneous mutations in 
the covRS operon during SSTI results in a phenotypic switch that could explain the 
increased capacity of certain isolates to invade deeper tissues by changing their 
regulatory networks. 
However, contrasting results have been reported, namely regarding which are the 
consequences of spontaneous CovRS mutations on mouse models of infection and more 
specifically on the expression of several virulence factors, such as SpeB and 
streptolysins. We reported that covS null alleles were significantly associated with an 
increased activity of both NADase and SLS, and with the absence of SpeB production. 
These results are in agreement with previous studies reporting that the acquisition of 
null covS alleles actually results in the downregulation of SpeB and upregulation of 
NADase and SLS (Hasegawa et al., 2010; Aziz et al., 2010). However, we found a few 
exceptions in specific emm types, namely two emm64 isolates with null covS alleles 
that, in contrast with other isolates with null covS alleles, did not express higher levels 
of NADase activity nor of SLS activity. We suggest that these results could be due to 
intrinsic characteristics of this lineage, such as alterations in the nga gene, its promoter, 
or other regulatory pathways. Moreover two isolates with null covS alleles belonging to 
emm type 6 and 44, respectively, also did not exhibit an increased SLS activity 
suggesting that these isolates also show a potential different CovRS regulon in which 
the sag operon is not controlled by CovRS for example. The existence of mutations in 
the sag operon of these isolates is also a possibility. The use of isolates with distinct 
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emm types (and hence representing different genetic lineages), could be one reason, 
besides to the type and localization of the mutation, for the conflicting data between 
studies regarding the impact of covRS mutations in virulence. In agreement, with their 
diversity of phenotypic behaviours, it was shown that different in vivo induced covR 
mutations can result in markedly different transcriptomes (Trevino et al., 2009). 
Additionally, some studies highlight the interaction of CovRS with other transcriptional 
regulators, resulting in complex regulation patterns that can vary between different emm 
types and even between strains of the same emm type (Aziz et al., 2010; Sugareva et al., 
2010; Horstmann et al., 2014).  
Naturally occurring mutations in the standalone transcriptional regulator RopB 
have also been reported, and similarly to CovRS, with contrasting results regarding their 
impact in virulence in mouse models and in the expression of several virulence factors. 
The exception is SpeB, for which a functional RopB is considered an absolute 
requirement (Carroll et al., 2011; Ikebe et al., 2010; Hollands et al., 2008; Neely et al., 
2003). In our studies, all isolates with null ropB alleles had no detectable SpeB activity, 
in agreement with its role as a direct regulator of SpeB (Neely et al., 2003). 
Additionally, null ropB alleles were not associated with altered NADase or SLS 
activity, suggesting that RopB does not contribute significantly to the expression of the 
nga and sag operons. These results disagree with previous studies that reported an 
enhanced expression of several virulence factors attributed to ropB mutations (Carroll et 
al., 2011; Ikebe et al., 2010). However, it was shown that RopB regulation can be 
highly variable even among strains of the same emm type, what can explain these 
differences (Dmitriev et al., 2008).  
Mutations in covRS have been previously identified in clinical isolates. However 
while some studies suggest that covRS and ropB mutations occur more frequently 
among isolates from invasive infections, others found them in a similar proportion 
among non-invasive isolates (Hasegawa et al., 2010; Ikebe et al., 2010; Lin et al., 
2014). In addition, some studies that used mainly murine models suggest that isolates of 
the highly invasive M1T1 clone are more prone to acquire covRS mutations than strains 
of other emm types (Mayfield et al., 2014; Maamary et al., 2010). Considering our 
results, null covS alleles were found to have a significant association with invasive 
infections in comparison with both pharyngitis and SSTI isolates suggesting that these 
mutations can contribute for a higher invasive potential of these isolates. Even so, these 
mutations were present in only 10% of invasive isolates and were not associated to any 
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specific emm type, not even with those previously associated with invasive infections, 
but occurred in isolates of diverse lineages which is in agreement with reports from 
Japan and Taiwan (Ikebe et al., 2010; Lin et al., 2014). 
Regarding null ropB alleles, they were not differently distributed among isolates 
recovered from any of the type of infection, suggesting they are not related with the 
higher ability of some isolates to cause infection.   
In our isolates, no null covR mutations were detected in any of the infections, 
which is in agreement with the hypothesis that during the infection process, the 
acquisition of mutations that impair signalling through CovS and keep CovR functional 
and possibly responsive to phosphorylation by other kinases, such as SP-STK, may 
contribute for the progression to invasive infection (Trevino et al., 2009; Agarwal et al., 
2011). 
The loss of SpeB activity due to spontaneous covRS mutations have been 
considered the main event for explaining the increased virulence observed in some 
studies. This led to the hypothesis that M1T1 isolates are under selective pressure to 
decrease SpeB protease activity during infection. It was reported that the absence of 
SpeB allows the sequestration of human plasmin protease activity on the GAS surface, 
which may contribute to GAS systemic dissemination. The absence of SpeB also 
prevents the degradation of several GAS virulence factors, including M1 protein and 
Sda1, contributing for survival to neutrophil killing and degradation of NETs (Cole et 
al., 2006; Walker et al., 2007; Aziz et al., 2004). In agreement, an inverse relationship 
between disease severity and expression of SpeB among M1T1 isolates recovered from 
invasive infections was reported. Among isolates recover from SSTS, 41% produced 
little or no SpeB compared to only 14% of isolates recovered from non-severe cases. 
Moreover, the protease activity among those isolates that expressed SpeB was 
significantly lower for STSS isolates than for isolates from non-severe cases (Kansal et 
al., 2000). In our results, the majority of isolates produce detectable SpeB activity. 
Moreover, the proportion of isolates lacking SpeB expression among our SSTI 
collection (25%) was similar to that found among iGAS (24%) and higher but not 
significantly to that found among pharyngitis isolates (16%). Additionally, the absence 
of SpeB was not associated with invasive infection neither with emm types previously 
associated with invasive infection such as emm1 and emm64. These results are in 
agreement with a recent study that observed that among 6775 isolates, 84.3% of the 
strains have a wild-type SpeB phenotype. Furthermore, they also did not detect any 
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difference in the frequency of the SpeB-deficient phenotype between strains recovered 
from invasive infections and those recovered from pharyngitis (Olsen et al., 2015). The 
authors suggest that, contrary to the idea that the downregulation of SpeB promotes 
virulence, SpeB expression is actually a key contributor to pathogenesis. To support 
their results, the authors cite some of the following studies: it was observed that 
systemic infection in murine models of infection GAS requires an intact RopB and an 
efficient SpeB production (Hollands et al., 2008); consistently, isolates with ropB 
polymorphisms that lack SpeB activity killed significantly fewer mice and cause smaller 
lesions with less tissue destruction (Olsen et al., 2012; Carroll et al., 2011); speB 
mutants are less virulent in mouse models in comparison of their wt strains (Lukomski 
et al., 1997; Kuo et al., 1998; Lukomski et al., 1999); SpeB decreases biofilm formation 
in vitro what was associated with larger lesions in mice (Connolly et al., 2011);  SpeB 
inactivates the human cathelicidin LL-37 in vitro; the SpeB activity was also shown to 
contribute to escape from IgG mediated phagocytosis increasing GAS ability to survive 
in immune blood (Eriksson and Norgren, 2003); acute-phase serum of patients with 
GAS bacteremia had significantly lower neutralizing ability against SpeB than did sera 
from patients with uncomplicated tonsillitis (Norrby-Teglund et al., 1994); similarly, 
neutralization of SpeB was significantly lower in acute-phase sera of patients with 
STSS than in sera from persons with bacteremia or erysipelas (Eriksson et al., 1999); 
immunization of mice with SpeB or treatment with a protease inhibitor confers 
protection against lethal challenge or reduced the size of the skin lesions (Bjorck et al., 
1989; Kapur et al., 1994; Ulrich, 2008; Connolly et al., 2011).   
Despite isolates with covRS mutations possessing an apparent selective advantage 
in invasive infection due to improved neutrophil resistance and propensity for bacterial 
dissemination, we concluded through Ka/Ks determination that covS, covR and ropB 
genes are under stabilizing selection. This means that selection favours alleles that do 
not change the amino acid sequence. One explanation for why isolates with these 
mutations have not become prevalent in the community is the presence of an overall 
fitness cost specific to nasopharyngeal infection or colonization that can affect the initial 
stages of infections that then progress to more serious manifestations (Alam et al., 
2013). It was reported that ΔcovRS is detrimental to long term infection of the 
nasopharynx and to the transmission (Alam et al., 2013). Consistently, covS mutants 
showed a reduced capacity to bind to epithelial cell layers as a consequence of increased 
capsule expression and also a reduced capacity to bind fibronectin and to form biofilms 
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on plastic and epithelial cell layers. A defect in skin adherence of the covS mutant strain 
was also demonstrated in a murine model in vivo, suggesting that the fitness cost could 
also be incurred in skin additionally to the nasopharynx (Hollands et al., 2010). This 
theory of an associated fitness cost is also supported by a reported inverse correlation 
between the ability to adhere to host cells and GAS virulence (Miyoshi-Akiyama et al., 
2009). Furthermore, it was shown that GAS isolates with mutations in covS lack 
competitiveness in human saliva relative to the wt (Trevino et al., 2009). This 
phenotype could also be related with the levels of SpeB production, since it was 
demonstrated that SpeB contributes to persistence and growth in human saliva in vitro 
in M1 GAS (Shelburne et al., 2005). Moreover, the presence of SpeB is required for the 
establishment of localized skin infections (Cole et al., 2006). It was reported that in a 
murine skin and soft tissue infection model the inoculation of a mixture of the wild-type 
strain and its covRS mutant resulted in more necrotic lesions than did either strain at 
twice the inoculum, which suggests that these variants may exhibit pathogenic synergy 
(Engleberg et al., 2001), highlighting the complex interactions between these two 
phenotypes in vivo.  
Even though we have found a significant association of null covS alleles with 
invasive isolates we did not observe any further association between the 
presence/absence of detectable SpeB activity, the activity of NADase or SLS with 
invasiveness. These results suggest that other factors under CovRS regulation may also 
be critical for an enhanced invasive capacity of the isolates. Actually, in agreement with 
our suggestion, inoculation of CovRS mutants in a mouse model of SSTI yielded larger 
necrotic regions that SpeB mutants (Engleberg et al., 2004), but the nature of these 
possible enhancers of pathogenicity remains undefined.  
It has to be taken into consideration that our isolates were obtained from a single 
colony from each patient. According to Sumby et al., regardless of the transcriptional 
profile of the original infecting strain (ITP or PTP), all GAS isolated from the spleens of 
infected animals were mucoid (ITP_covSmut) and, although all GAS isolated from the 
skin lesions of mice infected with the ITP strain were also mucoid, colonies grown from 
the skin lesions of PTP-infected mice were a mixture of nonmucoid parental and 
mucoid variant strains at approximately 1:1 ratio (Sumby et al., 2006). Considering that 
a similar mechanism could occur in SSTI in humans, we could possibly have introduced 
a bias by sampling a colony of a possibly mixed population.  Even so, since we picked 
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each colony without particular care to select any of the variants we do not believe that 
this fact compromises our conclusions.  
Moreover, 4.8% of isolates among pharyngitis and invasive isolates with no SpeB 
activity had wt alleles in all 3 genes. Among skin and soft tissue isolates, this rate was 
higher but not significantly (15.8%). The generation of the final SpeB product is a 
complex, multistage process, dependent on at least 21 gene products, therefore a 
mutation in any one of them could lead to isolates with no detectable SpeB activity 
(Olsen et al., 2015). The higher value among SSTI could be due to the higher diversity 
of the sample. While among pharyngitis and invasive isolates, the sample was chosen to 
include one third of the isolates of each emm type present in the collection with n≥3 as 
well all emm types 1 and 64, all isolates from SSTI infection recovered during 2003 and 
2009 were screened for SpeB activity. It could also be related with the methodology that 
we used for screening of the SpeB activity. While among pharyngitis and invasive 
isolates we used two methods (azocasein and casein assay) combined with WB, for 
SSTI only the casein assay was used in combination with WB. Transcription and 
posttranscriptional processing of SpeB is influenced by various environmental signals 
(Olsen et al., 2015), including host factors that are not well defined and can contribute 
to significant differences between in vivo and in vitro observations. This is highlighted 
by Sumby et al., for the case of isolate MGAS5005 (ITP), that we also used as our 
negative control, that despite minimal SpeB expression in vitro (Sumby et al., 2006), it 
was reported that this strain produces extensive amounts of SpeB when grown ex vivo in 
human saliva (Shelburne et al., 2005).  
  
Characterization of SSTI isolates. 
 Most of the information regarding GAS isolates responsible for SSTI isolates are 
from studies that compare isolates from invasive and non-invasive isolates (Montes et 
al., 2011; Ekelund et al., 2005; Rivera et al., 2006; Lintges et al., 2010; Wajima et al., 
2008). Generally, invasive isolates are described as isolates collected from sterile sites 
such as blood, cerebrospinal fluid, ascitic fluid and synovial fluid (Friães et al., 2013a). 
All the rest are considered non-invasive isolates including isolates recovered from 
pharyngitis, otitis, vaginitis and also from SSTI. Therefore, it is difficult to distinguish 
the composition of isolates from each source separately. Even within SSTI caused by 
GAS there are several entities, ranging from mild to severe. In our study, isolates were 
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recovered from purulent exudates and unfortunately, we do not have information 
regarding the specific syndrome caused by the isolates, the clinical evolution, and 
outcome of each infection. We consider this to be a major limitation of our studies 
because it prevents us from evaluating further correlations between specific clones in 
SSTI and the severity of their respective infections. 
Macrolide resistance was detected in 10.3% of SSTI isolates and showing a 
decreasing trend similar to that found among contemporary invasive and pharyngitis 
isolates in Portugal (Silva-Costa et al., 2015a). Moreover, these values are very similar 
to those reported for invasive isolates in Portugal between 2006 and 2009 (8%), (Friães 
et al., 2013a), suggesting similar values of macrolide resistance rates among isolates 
responsible different types of infection. Penicillin is the antimicrobial of choice for the 
treatment of GAS infections since naturally occurring resistant isolates were never 
reported (Walker et al., 2014). Even so, in cases of patients with previously documented 
sensitivity reactions to β-lactams, macrolides are an important alternative that could be 
used. Moreover, in cases of severe invasive infections the use of a combination of 
clindamycin with β-lactam is recommended (Stevens et al., 2005; Allen and Moore, 
2010). In agreement with the results from Portugal, a decreasing trend in macrolide 
resistance was reported in several countries particularly in Europe, namely in the 
southern countries, such as Spain, Greece, and Italy (Silva-Costa et al., 2015a). 
Fluctuations in macrolide resistance rates are commonly associated with macrolide 
consumption. However, in some countries, including Portugal and Spain, the reported 
decreasing trend is not associated to lower macrolide consumption, suggesting that 
others factors that need to be further investigated may influence macrolide resistance 
(Silva-Costa et al., 2015a).  
Among our 33 SSTI macrolide-resistant isolates, the majority presented the 
cMLSB phenotype (n=22), while 11 isolates presented the M phenotype. Due to these 
lower numbers and also due to the difference in the total number of isolates between the 
years of the study it is hard to evaluate the fluctuations of phenotypes. Even so, with the 
use of Cochran-Armitage statistical test to both phenotypes considering the 33 
macrolide-resistant isolates as total, both phenotypes show a significant decreasing 
trend even with FDR, which was more significant for M isolates (p=0.001 for M 
isolates and P=0.006 for cMLSB). Macrolide resistance was detected in isolates 
comprising 12 different emm types. Isolates displaying a cMLSB phenotype were 
distributed among 5 different emm types [SID (CI95%)=0.662 (0.491-0.834)], while 
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isolates with an M phenotype were distributed among 8 different emm types [SID 
(CI95%)=0.927(0.833-1.000)]. Additionally, all isolates with cMLSB phenotype were 
positive for the presence of the ermB gene while all isolates with an M phenotype were 
positive for the presence of the mefA gene, with the exception of one isolate that 
presented the mefE gene. These results are also in agreement with the most common 
genetic elements found in M and cMLSB isolates among pharyngeal and invasive 
isolates in Portugal (Friães et al., 2013a; Silva-Costa et al., 2015b).  
Tetracycline resistance was found in 15% among SSTI isolates with no significant 
temporal trend. This result is also in agreement with the resistant rates described in 
invasive isolates between 2006-2009 (10.5%) (Friães et al., 2013a).  
The comparison of our SSTI isolates with invasive isolates recovered from the 
same period previously characterized in our lab (Friães et al., 2007; Friães et al., 
2013a), revealed significant differences regarding the emm type composition. While 
emm1, emm3, and emm64 isolates were significantly associated with invasive 
infections, emm89 isolates were significantly associated with SSTI infections and also 
the most prevalent among these. In a previous study from our lab with isolates 
recovered during 2000-2005, emm types 1 and 64 were considered as markers of 
invasiveness relative to pharyngeal isolates (Friães et al., 2012). Worldwide, emm1 
isolates are the most common isolates recovered from invasive infections and have been 
widely associated with resurgence of invasive infections since the 1980s (Aziz and 
Kotb, 2008; Steer et al., 2009; Smeesters et al., 2009; Luca-Harari et al., 2009; Henriet 
et al., 2010; Imohl et al., 2010; Olafsdottir et al., 2014) including in Portugal (Friães et 
al., 2007; Friães et al., 2013a). On the contrary, the number of emm64 isolates 
recovered from invasive infections has decreased markedly in Portugal in the period 
2006-2009, indicating that this clone did not persist (Friães et al., 2013a). The emm3 
isolates are also frequently associated to invasive infections, both in a large European 
study, as well in Portugal, where it was the third most frequent emm type recovered 
from invasive infection (Luca-Harari et al., 2009; Friães et al., 2013a). 
Regarding the emm89 isolates, a previous association with SSTI has been reported 
in Spain (Tamayo et al., 2014). These isolates have also been reported associated with 
invasive infections (Darenberg et al., 2007). Considering the distinct clades among 
emm89 isolates, only those lacking the hasABC locus were associated with SSTI. These 
isolates are presumed to belong to the recently emerged acapsular clade 3 that 
additionally to the absence of capsule also present an nga-ifs-slo locus variant 
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associated with the increased expression of NADase and SLO (Friães et al., 2015; Zhu 
et al., 2015). We also observed that the increase in the prevalence of emm89 among 
SSTI isolates was associated with the emergence of this clade, in contrast to isolates 
recovered from pharyngitis and invasive infections (Friães et al., 2015). Even so, this 
clade quickly replaced the previously circulating emm89 clades in all infection types. 
These results lead us to suggest that this clade has a higher propensity to cause SSTI. 
This could be due to several mechanisms such as, increased capacity to colonize the 
skin, an improved ability to overcome the major host defence mechanisms or the ability 
to produce cytotoxic effects at these sites. In fact, it was reported that clade 3 associated 
strains have an enhanced ability to adhere to plastic suggesting that these isolates may 
have an advantage in environmental persistence and transmission (Turner et al., 2015). 
On the contrary, it was also reported that there was increased virulence in an acapsular 
strain with the variant 3 of the nga promoter in a mouse model of necrotizing fasciitis 
(Zhu et al., 2015). Therefore, additional surveillance and further investigation is crucial 
to define the relevance of this new emm89 acapsular clade in different types of 
infection.  
In 2014, emm-clustering was described as a new typing method based on the 
portion of emm genes encoding the entire surface-exposed region of the M proteins 
(Sanderson-Smith et al., 2014). According to the authors, the M protein types assigned 
to an individual emm-cluster have high sequence similarity sharing functional 
properties, including the ability to bind to an array of host proteins. The authors also 
suggest that emm-clusters and emm-patterns can be directly inferred from the emm type 
because emm-type is considered to be predictive of the whole protein sequence 
(McMillan et al., 2013). Therefore, it is possible through emm-typing to predict the 
interaction of M protein with host proteins. We found that among our isolates, the emm-
clusters and the possible interactions with host proteins reflected the differences 
between emm-types. While invasive isolates were significantly associated with emm-
clusters A-C3 and A-C5, SSTI isolates were significantly associated to the emm-cluster 
E4. These differences can be explained by emm-clusters A-C3 and A-C5 grouping 
exclusively isolates of emm type 1 and 3, respectively, and emm-cluster E4 being 
dominated by emm89 which is associated with SSTI.  
After the attribution of a potential “binding profile” to each emm-cluster we 
observed that the ability to bind fibrinogen and albumin were associated to invasive 
isolates whereas the ability to bind C4BP and IgG were significantly associated to SSTI 
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isolates. Curiously, binding of protein M to either fibrinogen or C4BP were shown to 
reduce opsonophagocytosis due to inhibition of complement deposition on the bacterial 
surface (Carlsson et al., 2003; Carlsson et al., 2005). Thus it was proposed that all M 
proteins may share the ability to bind to fibrinogen or C4BP (Carlsson et al., 2005). 
However, the reasons why complement inhibition is achieved through fibrinogen in 
iGAS and C4BP recruitment in SSTI remain elusive. One possible reason is the released 
M1 protein-fibrinogen complexes due to the action of SpeB. These complexes were 
shown to interact with β2 integrins on the surface of neutrophils, resulting in the 
production of heparin-binding protein (HBP), which has been suggested to be a potent 
inflammatory mediator that induce vascular leakage which could promote invasiveness 
(Herwald et al., 2004). However, additionally to the M protein, other proteins also 
present on the GAS surface can bind fibrinogen (Courtney et al., 2006). Moreover, 
binding to fibrinogen does not always inhibit the activation of the classical pathway and 
it has been related to the presence of other virulence factors which could also contribute 
to the invasive potential of the isolates (Dale et al., 1996; Carlsson et al., 2005; 
Horstmann et al., 1992; Kotarsky et al., 2000). 
The association of cluster E4 with SSTI resulted in the overrepresentation of 
albumin binding among iGAS because most emm-clusters include proteins able to bind 
albumin, with the exception of cluster E4, which was associated to SSTI (Sanderson-
Smith et al., 2014) It was suggested that the binding of fibrinogen and albumin to B- 
and C-repeats, respectively, inhibit antibody binding under physiological conditions 
(Sandin et al., 2006). However, mutant strains lacking the conserved C-repeats were 
only slightly attenuated in a mouse intraperitoneal infection model (Waldemarsson et 
al., 2009). Therefore, the importance of the ability of iGAS to bind albumin remains to 
be explored.   
 The binding ability to human immunoglobulin IgG was found to be significant 
among SSTI isolates. Immunoglobulin binding was shown to hinder 
opsonophagocytosis even in the absence of a specific immune response (Carlsson et al., 
2003). However, the potential additionally benefits contributing to its 
overrepresentations among SSTI remain to be clarified.   
Only 5% of the SSTI isolates were predicted to bind plasminogen and no 
differences were observed compared with invasive isolates. Several roles have been 
proposed regarding de deposition of plasminogen on the cell surface which has been 
related with streptokinase and SpeB and therefore with covRS mutations. So, 
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considering that covRS mutations contribute to invasiveness, it could be expected that 
more invasive isolates would bind to plasminogen in comparison to SSTI. However, 
several other cell surface proteins can bind plasminogen and we are only predicting the 
binding ability of the M protein. Moreover, plasminogen binding was also shown to 
facilitate keratinocyte invasion (Siemens et al., 2011) which could be important in the 
context of SSTI. 
Regarding the distribution of isolates among emm-patterns, while SSTI isolates 
were associated with emm-pattern E, invasive isolates were associated with emm-pattern 
A-C (both p < 0.001). We would expect that our SSTI isolates, which were recovered 
from skin, would belong mainly to emm-pattern D (“skin specialist”). Instead, the 
majority presented an emm-pattern E, considered “the generalist” (Bessen et al., 1997). 
Possible explanations for this result include: that the GAS population responsible for 
SSTI has actually changed since the time the associations between emm-patterns and 
disease presentation were proposed or it could reflect differences between impetigo and 
other skin infections, given that the emm-pattern associations were established using 
only impetigo isolates.  
Taking into account the antigens present in the new 30-valent M protein-based 
vaccine, 86% (n=274) of the SSTI infections and 89% (n=279) of invasive infections 
could have been prevented. Considering also the non-vaccine emm types against which 
it was demonstrated that the 30-valent vaccine evokes cross-opsonic antibodies, the 
potential coverage rises to 95% among SSTI isolates and invasive isolates (Sanderson-
Smith et al., 2014; Dale et al., 2011; Dale et al., 2013). This vaccine would be 
particularly important in developing countries, in order to prevent the non-supputarive 
complications of GAS, such as ARF and RHD. In developed countries, given the 
universal susceptibility of GAS to penicillin, this vaccine would be important to reduce 
the frequency of invasive infections that continue to cause significant morbidly and 
mortality despite appropriate and effective antimicrobial therapy. However, these are 
rare events so vaccination may be questioned in economic grounds.    
 The screening of SAgs genes revealed significant differences between isolates 
from both sources. While the presence of SAg gene speA and speK was significantly 
associated with invasive isolates, speL and speM were significantly associated with 
isolates from SSTI. Consistent with our results, several studies reported the association 
of speA with iGAS (Friães et al., 2012; Lintges et al., 2010; Creti et al., 2005; Montes et 
al., 2011). However, in the studies where a comparison was performed, the majority of 
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non-invasive isolates are often recovered from pharyngitis. The fact that we observed an 
association of speA with iGAS relative to SSTI supports a role for SpeA specifically in 
invasive infection. The association of speK (formerly speL) with invasive disease was 
mainly due to the presence of speK in the majority of emm3 isolates. This association 
was previously reported (for the protein formerly known as SpeL) (Ikebe et al., 2002). 
The significant association of speL and speM with non-invasive isolates was also 
reported in other studies (Friães et al., 2012; Haukness et al., 2002).  
Currently, there are evidences that emm typing is not sufficient to identify GAS 
clones and that it must be complemented with other typing methods such as MLST and 
SAg profiling for further discrimination of genetic lineages within each emm type 
(Maripuu et al., 2008; Carrico et al., 2006; Friães et al., 2013b; Lintges et al., 2010; 
Meisal et al., 2010). Not surprisingly, due to the close link between emm type and SAg 
profile, the significant differences found between invasive and SSTI isolates reflect the 
differences found in emm-types. Therefore, SAg profiles 8 and 10, which correspond 
mostly to emm3 and emm1, respectively, were associated with invasive infection, while 
SAg profile 29, mostly found among emm89, was associated with SSTI infection. 
In contrast to previous results regarding SAg profiles in invasive isolates in 
Portugal (Friães et al., 2013a), in this study, no diversification of SAg profiles was 
observed in any of the most frequent emm types among SSTI isolates. These results 
suggest that isolates responsible for skin and soft tissue infections are probably under a 
weaker selective pressure than invasive isolates. Similarly, regarding MLST, no 
diversification in STs was observed in invasive nor in SSTI isolates.  
Despite the significant differences of prevalence of multiples emm types between 
SSTI and iGAS, we did not detect any significant distinct STs or SAgs profiles within 
each of the most prevalent emm types according to the type of infection, nor were there 
significant differences in diversity within isolates of each emm type between SSTI and 
iGAS, that could explain the ability to cause different infections.  
 
Concluding remarks and future work. 
Overall we found an association of null covS alleles with invasive isolates when 
comparing both with isolates recovered from pharyngitis and from SSTI. We also 
found, with few exceptions, that these isolates showed no SpeB activity and an 
upregulation of NADase and SLS, which supports the abrogation of CovS function as a 
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mechanism that favors the progression to invasive disease. Even so, these mutations 
were only found in a minority of invasive isolates (10%), which could partially be 
explained by an associated fitness cost resulting in impaired colonization and 
transmission. Additionally, SpeB activity was detected in most of the isolates tested and 
their proportion was similar in different types of infection, suggesting that others 
virulence factors under covRS regulation may be responsible for the higher virulence of 
iGAS isolates. Therefore, further studies evaluating and comparing the expression of 
virulence factors under the control of covRS, from invasive and non-invasive isolates, as 
well as of their activity will be key to explore which features confer a higher invasive 
potential to an isolate. Regarding isolates responsible for SSTI in Portugal they are a 
genetically diverse population and although this is the main primary focus associated to 
invasive disease, significant differences in the prevalence of the emm types were 
detected when compared with contemporary isolates recovered from invasive infection. 
However, considering isolates with the same emm type recovered from both sites we 
found the same MLST defined lineages and the same SAg profiles, not providing any 
clues about what distinguishes these isolates. Therefore more methods, such as whole 
genome sequence, must be used in order to detect genetic differences intra-emm type 
that could explain the tissue tropism of each isolate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
General Discussion 
159 
REFERENCES  
 
Agarwal, S., P. Pancholi and V. Pancholi. 2011. Role of serine/threonine phosphatase 
(SP-STP) in Streptococcus pyogenes physiology and virulence. J Biol Chem. 
286: 41368-41380. 
Alam, F. M., C. E. Turner, K. Smith, S. Wiles and S. Sriskandan. 2013. Inactivation of 
the CovR/S Virulence Regulator Impairs Infection in an Improved Murine 
Model of Streptococcus pyogenes Naso-Pharyngeal Infection. PLoS One. 8: 
e61655. 
Allen, U. and D. Moore. 2010. Invasive group A streptococcal disease: Management 
and chemoprophylaxis. Can J Infect Dis Med Microbiol. 21: 115-118. 
Aziz, R. K., R. Kansal, B. J. Aronow, W. L. Taylor, S. L. Rowe, M. Kubal, G. S. 
Chhatwal, M. J. Walker and M. Kotb. 2010. Microevolution of group A 
streptococci in vivo: capturing regulatory networks engaged in 
sociomicrobiology, niche adaptation, and hypervirulence. PLoS One. 5: e9798. 
Aziz, R. K. and M. Kotb. 2008. Rise and persistence of global M1T1 clone of 
Streptococcus pyogenes. Emerg Infect Dis. 14: 1511-1517. 
Aziz, R. K., M. J. Pabst, A. Jeng, R. Kansal, D. E. Low, V. Nizet and M. Kotb. 2004. 
Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to 
prevent proteolytic degradation of multiple virulence factors by SpeB. Mol 
Microbiol. 51: 123-134. 
Bessen, D. E., T. R. Fiorentino and S. K. Hollingshead. 1997. Molecular markers for 
throat and skin isolates of group A streptococci. Adv Exp Med Biol. 418: 537-
543. 
Bjorck, L., P. Akesson, M. Bohus, J. Trojnar, M. Abrahamson, I. Olafsson and A. 
Grubb. 1989. Bacterial growth blocked by a synthetic peptide based on the 
structure of a human proteinase inhibitor. Nature. 337: 385-386. 
Carlsson, F., K. Berggard, M. Stalhammar-Carlemalm and G. Lindahl. 2003. Evasion of 
phagocytosis through cooperation between two ligand-binding regions in 
Streptococcus pyogenes M protein. J Exp Med. 198: 1057-1068. 
Carlsson, F., C. Sandin and G. Lindahl. 2005. Human fibrinogen bound to 
Streptococcus pyogenes M protein inhibits complement deposition via the 
classical pathway. Mol Microbiol. 56: 28-39. 
Carrico, J. A., C. Silva-Costa, J. Melo-Cristino, F. R. Pinto, H. de Lencastre, J. S. 
Almeida and M. Ramirez. 2006. Illustration of a common framework for 
relating multiple typing methods by application to macrolide-resistant 
Streptococcus pyogenes. J Clin Microbiol. 44: 2524-2532. 
Carroll, R. K., S. A. Shelburne, 3rd, R. J. Olsen, B. Suber, P. Sahasrabhojane, M. 
Kumaraswami, S. B. Beres, P. R. Shea, A. R. Flores and J. M. Musser. 2011. 
Naturally occurring single amino acid replacements in a regulatory protein alter 
CHAPTER IV 
160 
streptococcal gene expression and virulence in mice. J Clin Invest. 121: 1956-
1968. 
Cole, J. N., J. D. McArthur, F. C. McKay, M. L. Sanderson-Smith, A. J. Cork, M. 
Ranson, M. Rohde, A. Itzek, H. Sun, D. Ginsburg, M. Kotb, V. Nizet, G. S. 
Chhatwal and M. J. Walker. 2006. Trigger for group A streptococcal M1T1 
invasive disease. FASEB J. 20: 1745-1747. 
Connolly, K. L., A. L. Roberts, R. C. Holder and S. D. Reid. 2011. Dispersal of Group 
A streptococcal biofilms by the cysteine protease SpeB leads to increased 
disease severity in a murine model. PLoS One. 6: e18984. 
Courtney, H. S., D. L. Hasty and J. B. Dale. 2006. Anti-phagocytic mechanisms of 
Streptococcus pyogenes: binding of fibrinogen to M-related protein. Mol 
Microbiol. 59: 936-947. 
Creti, R., G. Gherardi, M. Imperi, C. von Hunolstein, L. Baldassarri, M. Pataracchia, G. 
Alfarone, F. Cardona, G. Dicuonzo and G. Orefici. 2005. Association of group 
A streptococcal emm types with virulence traits and macrolide-resistance genes 
is independent of the source of isolation. J Med Microbiol. 54: 913-917. 
Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. Clin 
Microbiol Rev. 13: 470-511. 
Dale, J. B., T. A. Penfound, E. Y. Chiang and W. J. Walton. 2011. New 30-valent M 
protein-based vaccine evokes cross-opsonic antibodies against non-vaccine 
serotypes of group A streptococci. Vaccine. 29: 8175-8178. 
Dale, J. B., T. A. Penfound, B. Tamboura, S. O. Sow, J. P. Nataro, M. Tapia and K. L. 
Kotloff. 2013. Potential coverage of a multivalent M protein-based group A 
streptococcal vaccine. Vaccine. 31: 1576-1581. 
Dale, J. B., R. G. Washburn, M. B. Marques and M. R. Wessels. 1996. Hyaluronate 
capsule and surface M protein in resistance to opsonization of group A 
streptococci. Infect Immun. 64: 1495-1501. 
Darenberg, J., B. Luca-Harari, A. Jasir, A. Sandgren, H. Pettersson, C. Schalen, M. 
Norgren, V. Romanus, A. Norrby-Teglund and B. H. Normark. 2007. Molecular 
and clinical characteristics of invasive group A streptococcal infection in 
Sweden. Clin Infect Dis. 45: 450-458. 
Dmitriev, A. V., E. J. McDowell and M. S. Chaussee. 2008. Inter- and intraserotypic 
variation in the Streptococcus pyogenes Rgg regulon. FEMS Microbiol Lett. 
284: 43-51. 
Ekelund, K., J. Darenberg, A. Norrby-Teglund, S. Hoffmann, D. Bang, P. Skinhoj and 
H. B. Konradsen. 2005. Variations in emm type among group A streptococcal 
isolates causing invasive or noninvasive infections in a nationwide study. J Clin 
Microbiol. 43: 3101-3109. 
Engleberg, N. C., A. Heath, A. Miller, C. Rivera and V. J. DiRita. 2001. Spontaneous 
mutations in the CsrRS two-component regulatory system of Streptococcus 
pyogenes result in enhanced virulence in a murine model of skin and soft tissue 
infection. J Infect Dis. 183: 1043-1054. 
General Discussion 
161 
Engleberg, N. C., A. Heath, K. Vardaman and V. J. DiRita. 2004. Contribution of CsrR-
regulated virulence factors to the progress and outcome of murine skin 
infections by Streptococcus pyogenes. Infect Immun. 72: 623-628. 
Eriksson, A. and M. Norgren. 2003. Cleavage of antigen-bound immunoglobulin G by 
SpeB contributes to streptococcal persistence in opsonizing blood. Infect 
Immun. 71: 211-217. 
Eriksson, B. K., J. Andersson, S. E. Holm and M. Norgren. 1999. Invasive group A 
streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B 
in combination with selective lack of toxin-neutralizing antibodies are associated 
with increased risk of streptococcal toxic shock syndrome. J Infect Dis. 180: 
410-418. 
Friães, A., J. P. Lopes, J. Melo-Cristino and M. Ramirez. 2013a. Changes in 
Streptococcus pyogenes causing invasive disease in Portugal: evidence for 
superantigen gene loss and acquisition. Int J Med Microbiol. 303: 505-513. 
Friães, A., M. P. Machado, C. Pato, J. Carrico, J. Melo-Cristino and M. Ramirez. 2015. 
Emergence of the Same Successful Clade among Distinct Populations of emm89 
Streptococcus pyogenes in Multiple Geographic Regions. MBio. 6: e01780-
01715. 
Friães, A., F. R. Pinto, C. Silva-Costa, M. Ramirez and J. Melo-Cristino. 2012. Group A 
streptococci clones associated with invasive infections and pharyngitis in 
Portugal present differences in emm types, superantigen gene content and 
antimicrobial resistance. BMC Microbiol. 12: 280. 
Friães, A., F. R. Pinto, C. Silva-Costa, M. Ramirez and J. Melo-Cristino. 2013b. 
Superantigen gene complement of Streptococcus pyogenes-relationship with 
other typing methods and short-term stability. Eur J Clin Microbiol Infect Dis. 
32: 115-125. 
Friães, A., M. Ramirez and J. Melo-Cristino. 2007. Nonoutbreak surveillance of group 
A streptococci causing invasive disease in Portugal identified internationally 
disseminated clones among members of a genetically heterogeneous population. 
J Clin Microbiol. 45: 2044-2047. 
Graham, M. R., L. M. Smoot, C. A. Migliaccio, K. Virtaneva, D. E. Sturdevant, S. F. 
Porcella, M. J. Federle, G. J. Adams, J. R. Scott and J. M. Musser. 2002. 
Virulence control in group A Streptococcus by a two-component gene 
regulatory system: global expression profiling and in vivo infection modeling. 
Proc Natl Acad Sci U S A. 99: 13855-13860. 
Hasegawa, T., A. Okamoto, T. Kamimura, I. Tatsuno, S. N. Hashikawa, M. Yabutani, 
M. Matsumoto, K. Yamada, M. Isaka, M. Minami and M. Ohta. 2010. Detection 
of invasive protein profile of Streptococcus pyogenes M1 isolates from 
pharyngitis patients. APMIS. 118: 167-178. 
Haukness, H. A., R. R. Tanz, R. B. Thomson, Jr., D. K. Pierry, E. L. Kaplan, B. Beall, 
D. Johnson, N. P. Hoe, J. M. Musser and S. T. Shulman. 2002. The 
heterogeneity of endemic community pediatric group a streptococcal pharyngeal 
isolates and their relationship to invasive isolates. J Infect Dis. 185: 915-920. 
CHAPTER IV 
162 
Henriet, S., F. Kaguelidou, P. Bidet, M. Lorrot, A. De Lauzanne, S. Dauger, F. 
Angoulvant, J. C. Mercier, C. Alberti, E. Bingen and A. Faye. 2010. Invasive 
group A streptococcal infection in children: clinical manifestations and 
molecular characterization in a French pediatric tertiary care center. Eur J Clin 
Microbiol Infect Dis. 29: 341-346. 
Herwald, H., H. Cramer, M. Morgelin, W. Russell, U. Sollenberg, A. Norrby-Teglund, 
H. Flodgaard, L. Lindbom and L. Bjorck. 2004. M protein, a classical bacterial 
virulence determinant, forms complexes with fibrinogen that induce vascular 
leakage. Cell. 116: 367-379. 
Hollands, A., R. K. Aziz, R. Kansal, M. Kotb, V. Nizet and M. J. Walker. 2008. A 
naturally occurring mutation in ropB suppresses SpeB expression and reduces 
M1T1 group A streptococcal systemic virulence. PLoS One. 3: e4102. 
Hollands, A., M. A. Pence, A. M. Timmer, S. R. Osvath, L. Turnbull, C. B. Whitchurch, 
M. J. Walker and V. Nizet. 2010. Genetic switch to hypervirulence reduces 
colonization phenotypes of the globally disseminated group A streptococcus 
M1T1 clone. J Infect Dis. 202: 11-19. 
Horstmann, N., M. Saldana, P. Sahasrabhojane, H. Yao, X. Su, E. Thompson, A. Koller 
and S. A. Shelburne, 3rd. 2014. Dual-site phosphorylation of the control of 
virulence regulator impacts group a streptococcal global gene expression and 
pathogenesis. PLoS Pathog. 10: e1004088. 
Horstmann, R. D., H. J. Sievertsen, M. Leippe and V. A. Fischetti. 1992. Role of 
fibrinogen in complement inhibition by streptococcal M protein. Infect Immun. 
60: 5036-5041. 
Ikebe, T., M. Ato, T. Matsumura, H. Hasegawa, T. Sata, K. Kobayashi and H. 
Watanabe. 2010. Highly frequent mutations in negative regulators of multiple 
virulence genes in group A streptococcal toxic shock syndrome isolates. PLoS 
Pathog. 6: e1000832. 
Ikebe, T., A. Wada, Y. Inagaki, K. Sugama, R. Suzuki, D. Tanaka, A. Tamaru, Y. 
Fujinaga, Y. Abe, Y. Shimizu and H. Watanabe. 2002. Dissemination of the 
phage-associated novel superantigen gene speL in recent invasive and 
noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect Immun. 70: 
3227-3233. 
Imohl, M., R. R. Reinert, C. Ocklenburg and M. van der Linden. 2010. Epidemiology of 
invasive Streptococcus pyogenes disease in Germany during 2003-2007. FEMS 
Immunol Med Microbiol. 58: 389-396. 
Kansal, R. G., V. Datta, R. K. Aziz, N. F. Abdeltawab, S. Rowe and M. Kotb. 2010. 
Dissection of the molecular basis for hypervirulence of an in vivo-selected 
phenotype of the widely disseminated M1T1 strain of group A Streptococcus 
bacteria. J Infect Dis. 201: 855-865. 
Kansal, R. G., A. McGeer, D. E. Low, A. Norrby-Teglund and M. Kotb. 2000. Inverse 
relation between disease severity and expression of the streptococcal cysteine 
protease, SpeB, among clonal M1T1 isolates recovered from invasive group A 
streptococcal infection cases. Infect Immun. 68: 6362-6369. 
General Discussion 
163 
Kapur, V., J. T. Maffei, R. S. Greer, L. L. Li, G. J. Adams and J. M. Musser. 1994. 
Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta 
convertase) protects mice against challenge with heterologous group A 
streptococci. Microb Pathog. 16: 443-450. 
Kotarsky, H., A. Thern, G. Lindahl and U. Sjobring. 2000. Strain-specific restriction of 
the antiphagocytic property of group A streptococcal M proteins. Infect Immun. 
68: 107-112. 
Kuo, C. F., J. J. Wu, K. Y. Lin, P. J. Tsai, S. C. Lee, Y. T. Jin, H. Y. Lei and Y. S. Lin. 
1998. Role of streptococcal pyrogenic exotoxin B in the mouse model of group 
A streptococcal infection. Infect Immun. 66: 3931-3935. 
Lin, J. N., L. L. Chang, C. H. Lai, H. H. Lin and Y. H. Chen. 2014. Association 
between polymorphisms in the csrRS two-component regulatory system and 
invasive group A streptococcal infection. Eur J Clin Microbiol Infect Dis. 33: 
735-743. 
Lintges, M., M. van der Linden, R. D. Hilgers, S. Arlt, A. Al-Lahham, R. R. Reinert, S. 
Plucken and L. Rink. 2010. Superantigen genes are more important than the 
emm type for the invasiveness of group A Streptococcus infection. J Infect Dis. 
202: 20-28. 
Luca-Harari, B., J. Darenberg, S. Neal, T. Siljander, L. Strakova, A. Tanna, R. Creti, K. 
Ekelund, M. Koliou, P. T. Tassios, M. van der Linden, M. Straut, J. Vuopio-
Varkila, A. Bouvet, A. Efstratiou, C. Schalen, B. Henriques-Normark and A. 
Jasir. 2009. Clinical and microbiological characteristics of severe Streptococcus 
pyogenes disease in Europe. J Clin Microbiol. 47: 1155-1165. 
Lukomski, S., C. A. Montgomery, J. Rurangirwa, R. S. Geske, J. P. Barrish, G. J. 
Adams and J. M. Musser. 1999. Extracellular cysteine protease produced by 
Streptococcus pyogenes participates in the pathogenesis of invasive skin 
infection and dissemination in mice. Infect Immun. 67: 1779-1788. 
Lukomski, S., S. Sreevatsan, C. Amberg, W. Reichardt, M. Woischnik, A. Podbielski 
and J. M. Musser. 1997. Inactivation of Streptococcus pyogenes extracellular 
cysteine protease significantly decreases mouse lethality of serotype M3 and 
M49 strains. J Clin Invest. 99: 2574-2580. 
Maamary, P. G., M. L. Sanderson-Smith, R. K. Aziz, A. Hollands, J. N. Cole, F. C. 
McKay, J. D. McArthur, J. K. Kirk, A. J. Cork, R. J. Keefe, R. G. Kansal, H. 
Sun, W. L. Taylor, G. S. Chhatwal, D. Ginsburg, V. Nizet, M. Kotb and M. J. 
Walker. 2010. Parameters governing invasive disease propensity of non-M1 
serotype group A streptococci. J Innate Immun. 2: 596-606. 
Maripuu, L., A. Eriksson and M. Norgren. 2008. Superantigen gene profile diversity 
among clinical group A streptococcal isolates. FEMS Immunol Med Microbiol. 
54: 236-244. 
Mayfield, J. A., Z. Liang, G. Agrahari, S. W. Lee, D. L. Donahue, V. A. Ploplis and F. 
J. Castellino. 2014. Mutations in the Control of Virulence Sensor Gene from 
Streptococcus pyogenes after Infection in Mice Lead to Clonal Bacterial 
CHAPTER IV 
164 
Variants with Altered Gene Regulatory Activity and Virulence. PLoS One. 9: 
e100698. 
McMillan, D. J., P. A. Dreze, T. Vu, D. E. Bessen, J. Guglielmini, A. C. Steer, J. R. 
Carapetis, L. Van Melderen, K. S. Sriprakash and P. R. Smeesters. 2013. 
Updated model of group A Streptococcus M proteins based on a comprehensive 
worldwide study. Clin Microbiol Infect. 19: E222-229. 
Meisal, R., I. K. Andreasson, E. A. Hoiby, I. S. Aaberge, T. E. Michaelsen and D. A. 
Caugant. 2010. Streptococcus pyogenes isolates causing severe infections in 
Norway in 2006 to 2007: emm types, multilocus sequence types, and 
superantigen profiles. J Clin Microbiol. 48: 842-851. 
Miyoshi-Akiyama, T., J. Zhao, T. Uchiyama, J. Yagi and T. Kirikae. 2009. Positive 
correlation between low adhesion of group A Streptococcus to mammalian cells 
and virulence in a mouse model. FEMS Microbiol Lett. 293: 107-114. 
Montes, M., C. Ardanuy, E. Tamayo, A. Domenech, J. Linares and E. Perez-Trallero. 
2011. Epidemiological and molecular analysis of Streptococcus pyogenes 
isolates causing invasive disease in Spain (1998-2009): comparison with non-
invasive isolates. Eur J Clin Microbiol Infect Dis. 30: 1295-1302. 
Neely, M. N., W. R. Lyon, D. L. Runft and M. Caparon. 2003. Role of RopB in growth 
phase expression of the SpeB cysteine protease of Streptococcus pyogenes. J 
Bacteriol. 185: 5166-5174. 
Norrby-Teglund, A., K. Pauksens, S. E. Holm and M. Norgren. 1994. Relation between 
low capacity of human sera to inhibit streptococcal mitogens and serious 
manifestation of disease. J Infect Dis. 170: 585-591. 
Olafsdottir, L. B., H. Erlendsdottir, J. Melo-Cristino, D. M. Weinberger, M. Ramirez, 
K. G. Kristinsson and M. Gottfredsson. 2014. Invasive infections due to 
Streptococcus pyogenes: seasonal variation of severity and clinical 
characteristics, Iceland, 1975 to 2012. Euro Surveill. 19: 5-14. 
Olsen, R. J., D. R. Laucirica, M. E. Watkins, M. L. Feske, J. R. Garcia-Bustillos, C. Vu, 
C. Cantu, S. A. Shelburne, 3rd, N. Fittipaldi, M. Kumaraswami, P. R. Shea, A. 
R. Flores, S. B. Beres, M. Lovgren, G. J. Tyrrell, A. Efstratiou, D. E. Low, C. A. 
Van Beneden and J. M. Musser. 2012. Polymorphisms in regulator of protease B 
(RopB) alter disease phenotype and strain virulence of serotype M3 group A 
Streptococcus. J Infect Dis. 205: 1719-1729. 
Olsen, R. J., A. Raghuram, C. Cantu, M. H. Hartman, F. E. Jimenez, S. Lee, A. Ngo, K. 
A. Rice, D. Saddington, H. Spillman, C. Valson, A. R. Flores, S. B. Beres, S. W. 
Long, W. Nasser and J. M. Musser. 2015. The Majority of 9,729 Group A 
Streptococcus Strains Causing Disease Secrete SpeB Cysteine Protease: 
Pathogenesis Implications. Infect Immun. 83: 4750-4758. 
Rivera, A., M. Rebollo, E. Miro, M. Mateo, F. Navarro, M. Gurgui, B. Mirelis and P. 
Coll. 2006. Superantigen gene profile, emm type and antibiotic resistance genes 
among group A streptococcal isolates from Barcelona, Spain. J Med Microbiol. 
55: 1115-1123. 
General Discussion 
165 
Sanderson-Smith, M., D. M. De Oliveira, J. Guglielmini, D. J. McMillan, T. Vu, J. K. 
Holien, A. Henningham, A. C. Steer, D. E. Bessen, J. B. Dale, N. Curtis, B. W. 
Beall, M. J. Walker, M. W. Parker, J. R. Carapetis, L. Van Melderen, K. S. 
Sriprakash and P. R. Smeesters. 2014. A systematic and functional classification 
of Streptococcus pyogenes that serves as a new tool for molecular typing and 
vaccine development. J Infect Dis. 210: 1325-1338. 
Sandin, C., F. Carlsson and G. Lindahl. 2006. Binding of human plasma proteins to 
Streptococcus pyogenes M protein determines the location of opsonic and non-
opsonic epitopes. Mol Microbiol. 59: 20-30. 
Shelburne, S. A., 3rd, C. Granville, M. Tokuyama, I. Sitkiewicz, P. Patel and J. M. 
Musser. 2005. Growth characteristics of and virulence factor production by 
group A Streptococcus during cultivation in human saliva. Infect Immun. 73: 
4723-4731. 
Siemens, N., N. Patenge, J. Otto, T. Fiedler and B. Kreikemeyer. 2011. Streptococcus 
pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte invasion via 
integrin-integrin-linked kinase (ILK) pathways and protects from macrophage 
killing. J Biol Chem. 286: 21612-21622. 
Silva-Costa, C., A. Friães, M. Ramirez and J. Melo-Cristino. 2015a. Macrolide-resistant 
Streptococcus pyogenes: prevalence and treatment strategies. Expert Rev Anti 
Infect Ther. 13: 615-628. 
Silva-Costa, C., M. Ramirez and J. Melo-Cristino. 2015b. Declining macrolide 
resistance in Streptococcus pyogenes in Portugal (2007-13) was accompanied by 
continuous clonal changes. J Antimicrob Chemother. 70: 2729-2733. 
Smeesters, P. R., D. J. McMillan, K. S. Sriprakash and M. M. Georgousakis. 2009. 
Differences among group A Streptococcus epidemiological landscapes: 
consequences for M protein-based vaccines? Expert Rev Vaccines. 8: 1705-
1720. 
Steer, A. C., I. Law, L. Matatolu, B. W. Beall and J. R. Carapetis. 2009. Global emm 
type distribution of group A streptococci: systematic review and implications for 
vaccine development. Lancet Infect Dis. 9: 611-616. 
Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, 
S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya and J. C. Wade. 
2005. Practice guidelines for the diagnosis and management of skin and soft-
tissue infections. Clin Infect Dis. 41: 1373-1406. 
Sugareva, V., R. Arlt, T. Fiedler, C. Riani, A. Podbielski and B. Kreikemeyer. 2010. 
Serotype- and strain- dependent contribution of the sensor kinase CovS of the 
CovRS two-component system to Streptococcus pyogenes pathogenesis. BMC 
Microbiol. 10: 34. 
Sumby, P., A. R. Whitney, E. A. Graviss, F. R. DeLeo and J. M. Musser. 2006. 
Genome-wide analysis of group a streptococci reveals a mutation that modulates 
global phenotype and disease specificity. PLoS Pathog. 2: e5. 
CHAPTER IV 
166 
Tamayo, E., M. Montes, J. M. Garcia-Arenzana and E. Perez-Trallero. 2014. 
Streptococcus pyogenes emm-types in northern Spain; population dynamics over 
a 7-year period. J Infect. 68: 50-57. 
Trevino, J., N. Perez, E. Ramirez-Pena, Z. Liu, S. A. Shelburne, 3rd, J. M. Musser and 
P. Sumby. 2009. CovS simultaneously activates and inhibits the CovR-mediated 
repression of distinct subsets of group A Streptococcus virulence factor-
encoding genes. Infect Immun. 77: 3141-3149. 
Turner, C. E., J. Abbott, T. Lamagni, M. T. Holden, S. David, M. D. Jones, L. Game, A. 
Efstratiou and S. Sriskandan. 2015. Emergence of a New Highly Successful 
Acapsular Group A Streptococcus Clade of Genotype emm89 in the United 
Kingdom. MBio. 6: e00622. 
Ulrich, R. G. 2008. Vaccine based on a ubiquitous cysteinyl protease and streptococcal 
pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic 
shock. J Immune Based Ther Vaccines. 6: 8. 
Wajima, T., S. Y. Murayama, K. Sunaoshi, E. Nakayama, K. Sunakawa and K. 
Ubukata. 2008. Distribution of emm type and antibiotic susceptibility of group 
A streptococci causing invasive and noninvasive disease. J Med Microbiol. 57: 
1383-1388. 
Waldemarsson, J., M. Stalhammar-Carlemalm, C. Sandin, F. J. Castellino and G. 
Lindahl. 2009. Functional dissection of Streptococcus pyogenes M5 protein: the 
hypervariable region is essential for virulence. PLoS One. 4: e7279. 
Walker, M. J., T. C. Barnett, J. D. McArthur, J. N. Cole, C. M. Gillen, A. Henningham, 
K. S. Sriprakash, M. L. Sanderson-Smith and V. Nizet. 2014. Disease 
manifestations and pathogenic mechanisms of group A Streptococcus. Clin 
Microbiol Rev. 27: 264-301. 
Walker, M. J., A. Hollands, M. L. Sanderson-Smith, J. N. Cole, J. K. Kirk, A. 
Henningham, J. D. McArthur, K. Dinkla, R. K. Aziz, R. G. Kansal, A. J. 
Simpson, J. T. Buchanan, G. S. Chhatwal, M. Kotb and V. Nizet. 2007. DNase 
Sda1 provides selection pressure for a switch to invasive group A streptococcal 
infection. Nat Med. 13: 981-985. 
Zhu, L., R. J. Olsen, W. Nasser, I. de la Riva Morales and J. M. Musser. 2015. Trading 
Capsule for Increased Cytotoxin Production: Contribution to Virulence of a 
Newly Emerged Clade of emm89 Streptococcus pyogenes. MBio. 6: e01378-
01315. 
 
 
 
 
 
  
 
 
 
 
APPENDIX I
 
1Scientific RepoRts | 5:12057 | DOi: 10.1038/srep12057
www.nature.com/scientificreports
Consequences of the variability of 
the CovRS and RopB regulators 
among Streptococcus pyogenes 
causing human infections
Ana Friães*, Catarina Pato*, José Melo-Cristino & Mario Ramirez
To evaluate the importance of covRS and ropB mutations in invasive disease caused by Group A 
Streptococci (GAS), we determined the sequence of the covRS and ropB genes of 191 isolates from 
invasive infections and pharyngitis, comprising a diverse set of emm types and multilocus sequence 
types. The production of SpeB and the activity of NAD glycohydrolase (NADase) and streptolysin S 
(SLS) were evaluated. The results support the acquisition of null covS alleles (predicted to eliminate 
protein function), resulting in downregulation of SpeB and upregulation of NADase and SLS, as a 
mechanism possibly contributing to higher invasiveness. Among the isolates tested, this mechanism 
was found to be uncommon (10% of invasive isolates) and was not more prevalent among clones 
with enhanced invasiveness (including M1T1) but occurred in diverse genetic backgrounds. In lineages 
such as emm64, these changes did not result in upregulation of NADase and SLS, highlighting the 
diversity of regulatory pathways in GAS. Despite abrogating SpeB production, null alleles in ropB 
were not associated with invasive infection. The covRS and ropB genes are under stabilising selection 
and no expansion of isolates carrying null alleles has been observed, suggesting that the presence of 
these regulators is important for overall fitness.
Streptococcus pyogenes (Group A Streptococci, GAS) is a human pathogen that can asymptomatically 
colonize the oropharynx, but is also responsible for a variety of human diseases, ranging from uncom-
plicated superficial infections of the respiratory tract and skin, such as pharyngitis and impetigo, to 
severe invasive infections associated with high morbidity and mortality, like necrotizing fasciitis and 
streptococcal toxic shock syndrome (STSS)1.
The recognition of the ability of strains belonging to the highly invasive M1T1 clone to acquire muta-
tions in the covRS genes during skin and soft tissue infection in mice suggested that GAS could increase 
its capacity to invade deeper tissues by altering its regulatory networks in order to produce a switch to 
an invasive transcriptome profile2,3. The adjacent and cotranscribed genes covR and covS encode the 
two-component regulatory system CovRS (also known as CsrRS). The DNA-binding response regulator 
CovR acts mostly as a repressor of transcription upon phosphorylation by the sensor kinase/phosphatase 
CovS, which responds to stress factors, such as elevated temperatures, high saline concentrations, and 
decreased pH4. CovRS is estimated to directly or indirectly influence the expression of 10–15% of the 
GAS genome. Although it is also involved in the regulation of metabolic genes, it is mostly known for 
controlling the expression of a large number of genes encoding factors that promote GAS virulence and 
evasion of the host immune system5,6. Most studies indicate that mutations impairing CovRS function 
result in the upregulation of genes encoding the hyaluronic acid capsule, streptolysins S and O, streptoki-
nase, DNases, the interleukin-protease SpyCEP, and NAD-glycohydrolase (NADase), among others, and 
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in the downregulation of proteins like the extracellular cysteine protease SpeB and the protein-G-related 
α 2-macroglobulin-binding protein GRAB7,8. However, contrasting results have been reported regarding 
the effect of covRS mutations in some of those virulence factors, which may be partly explained by the 
interaction of CovRS with other transcriptional regulators, resulting in complex regulation patterns that 
can vary between different strains8,9.
Mutations in CovRS and in the stand-alone transcriptional regulator RopB have been identified 
in isolates recovered from human infections7,10–12. RopB (also known as Rgg) is encoded by the 
ropB (rgg) gene, which is located 940 bp away from speB, in the opposite DNA strand, and directly 
binds the promoter of the latter gene to activate its transcription13. In some strains, this regulator 
has been reported to affect the transcription of other virulence factors, including DNases, the 
hyaluronic acid capsule, NADase, streptokinase, streptolysins, and phage-encoded superantigens, 
among others10,11.
The downregulation of SpeB, which is usually observed as a consequence of CovRS and RopB muta-
tions, is considered to be a determining step in the transition to an invasive phenotype, since this potent 
protease degrades several extracellular GAS virulence factors that play an important role in the invasive 
process, including the M protein, the F1 protein, C5a peptidase, streptokinase, and SmeZ14. In agree-
ment, SpeB production has been inversely correlated with disease severity, in both human infections 
and murine models15,16. SpeB is initially synthesised and secreted as an inactive 42-kDa zymogen, which 
is then autocatalytically processed through a series of intermediates to form the 28-kDa mature active 
protease. Each stage from transcription to mature SpeB involves tight regulatory controls, including 
post-transcriptional and post-translational mechanisms14.
Some studies suggest that covRS and ropB mutations occur more frequently among isolates from 
invasive infections, while others found them in a similar proportion among non-invasive isolates7,11,12. 
Contrasting observations have also been reported regarding the impact of alterations in these regulators 
on virulence using animal models, as well as on the expression of virulence factors like SpeB and the 
streptolysins2,3,5,7,8,11,17–20. Given these discrepancies and the fact that most of the studies have focused on 
particular emm types, especially emm1 and emm3, the importance of the acquisition of these mutations 
for the overall invasiveness and virulence of GAS strains is still not completely understood.
In order to address these questions, we sequenced the covRS and ropB genes in a collection of 191 
GAS isolates presenting a high diversity of emm types and multilocus sequence types (STs), including 
the most prevalent clones causing pharyngitis and invasive infections in Portugal and in a majority of 
other countries from temperate climate regions21–23. The genetic diversity of the genes was evaluated, and 
the respective alleles were correlated with the activity of SpeB and of two other virulence factors whose 
expression has been suggested to be under the influence of CovRS and RopB, at least in some strains, 
namely the NADase and the streptolysin S (SLS)7,11,18,24.
Results
Genetic variation of the covR, covS and ropB genes. In the present work, the sequence of the 
covR, covS, and ropB genes was determined for a collection of 191 isolates (Supplementary Table S1) 
comprising one third of the isolates of each emm type present in a larger collection of strains recovered 
from pharyngitis and invasive infections in Portugal, which has been characterized elsewhere21. In addi-
tion, all isolates of emm types 1 and 64 were included in this study, since these two emm types were 
shown to be significantly associated with invasive disease.
The three genes presented a high allelic diversity in the studied GAS collection, with Simpson’s 
index of diversity (SID) values close to the ones obtained for emm type and ST (Table  2). The allelic 
diversity of the covR genes was lower than that of covS (P = 0.0140) and of the ST (P = 0.0137). Overall, 
isolates sharing the same emm type or ST frequently shared the same covR, covS, and ropB alleles 
(Supplementary Table S2). This association was stronger for covR, in line with the lower allelic diversity 
of this gene. These results indicate that the covR, covS, and ropB alleles present in a given isolate were 
Gene
No. 
alleles 
(this 
study)
No. amino 
acid 
sequences 
(this study)
No. 
alleles 
with 
indels
No. alleles 
with 
nonsense 
mutations
Nucleotide 
diversity Ka/Ks P value
covR 54 (19) 32 (5) 1 2 0.0058 0.19 0.0032
covS 121 (43) 83 (26) 28a 11 0.0043 0.14 0.0029
ropB 78 (37c) 56 (21c) 7b 2 0.0055 0.23 0.0015
Table 1.  Type of amino acid alteration, nucleotide diversity, and Ka/Ks values associated with the 
covR, covS, and ropB alleles described in this study and those previously reported in GenBank. aThree 
of the covS indels are in frame. bTwo of the ropB indels are in frame, but one of these deletes a considerable 
portion of the protein (119 residues). cExcluding the isolate with a complete ropB deletion.
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essentially clonal properties, although some level of intra-clonal diversity was observed, particularly for 
covS and ropB.
Together with the alleles previously deposited in GenBank, we identified a total of 54 alleles for covR, 
121 for covS, and 78 for ropB (Table 1). One of the isolates in our study is devoid of the ropB gene due to a 
previously characterized deletion that also involves the speB gene25. Alterations relative to the nucleotide 
sequence of the three genes in strain SF370 are depicted in Fig. 1. For each of the genes, more than half 
of the alleles result in alterations in the amino acid sequence, with ropB presenting the highest proportion 
of distinct amino acid sequences relative to the total number of alleles. However, all the Ka/Ks ratios 
were significantly lower than 1 (Table 1), indicating that all three genes are under stabilising selection. 
Ka/Ks is the ratio of the number of nonsynonymous substitutions per nonsynonymous site to the num-
ber of synonymous substitutions per synonymous site. This measure is often used to evaluate deviations 
from neutral evolution. A value of Ka/Ks < < 1 indicates that the protein is under stabilising selection, 
i.e. selection favours alleles that do not change the amino acid sequence. In contrast, a value of Ka/Ks 
> > 1 is strong evidence for positive selection, indicating that selection drove changes to the protein26. 
Nucleotide diversity was also similar for the three genes, with differences in the total number of alleles 
basically reflecting the different sizes of the genes (687 bp for covR, 1503 bp for covS, and 843 bp for 
ropB). Null alleles were defined as those presenting changes predicted to result in a complete absence of 
protein function – including nonsense mutations, indels that result in frameshifts, large in-frame indels 
( ≥ 357 bp), and complete gene deletions. In spite of similar diversity, the covS gene presented more null 
alleles than covR (P = 0.0004).
Mutations in covR, covS, and ropB, and association with emm type and invasiveness. For 
covR and ropB, the reference alleles (those present in SF370) were the most common among the 191 
GAS isolates analysed in this study [n = 67 (35%), and n = 69 (36%), respectively]. The SF370 covS allele 
was present in only five isolates, but 68 isolates (36%) presented only synonymous nucleotide changes 
(15 alleles). Since our collection was enriched in emm1 isolates, the most common covS allele (covS-02, 
28%) included a missense mutation characteristic of the M1T1 clone, namely I332 V. Other missense 
mutations were also commonly identified in isolates of specific emm types, in both covS and ropB genes.
In addition to the coding sequence of the genes, the region upstream of covR, which includes the 
covRS promoter, was also analysed for all isolates, but no nucleotide changes were found in the identi-
fied −35 and −10 regions, in the transcription start site, nor in the consensus sequences that have been 
identified as binding targets for CovR auto-repression27.
The overall distribution of emm types differed significantly between the isolates carrying missense 
or null alleles of covR, covS, or ropB and those with no amino acid alterations (P < 0.0001). Null alleles 
were not associated with any particular emm type, occurring in isolates of seven different emm types for 
covS (SID = 0.909 [CI95% 0.822–0.996]) and of four different emm types in the case of ropB (SID = 0.867 
[CI95% 0.738–0.995]). Missense mutations in covS and ropB were significantly more prevalent in isolates 
of certain emm types due to the presence of clonal alleles in specific lineages, i.e. alleles carrying amino 
acid changes that occur in several isolates of that emm type (Supplementary Table S1).
According to the SID values, the allele diversity of the three genes was similar for the subsets of iso-
lates associated with pharyngitis and with invasive infections (Table 2). The overall distribution of covS 
and ropB alleles was significantly different between the two subsets (P < 0.0001), but no specific covR, 
covS, or ropB allele presented a significant association with either infection type after correcting for the 
false discovery rate (FDR), except for ropB-23, which was significantly associated with invasive infections 
(P = 0.0109). This association is explained by the fact that ropB-23 was present in all emm64 isolates and 
not found in any other emm type (Supplementary Table S1), and emm64 was significantly associated with 
invasive infections in Portugal21. This allele presents only two synonymous nucleotide changes, which are 
not likely to be the cause of the high invasiveness of this lineage.
Gene
All isolates (n = 191) Invasive isolates (n = 87) Pharyngitis isolates (n = 104)
No. 
partitions SID [CI95%]
No. 
partitions SID [CI95%]
No. 
partitions SID [CI95%]
covR 19 0.831 [0.793–0.870] 17 0.816 [0.752–0.880] 13 0.839 [0.794–0.885]
covS 43 0.893 [0.861–0.925] 31 0.870 [0.811–0.930] 25 0.905 [0.873–0.938]
ropB 38 0.850 [0.805–0.896] 23 0.806 [0.729–0.883] 29 0.879 [0.828–0.929]
emm type 26 0.877 [0.844–0.910] 20 0.833 [0.769–0.898] 20 0.900 [0.868–0.932]
ST 41 0.894 [0.861–0.927] 27 0.860 [0.798–0.922] 32 0.910 [0.876–0.945]
Table 2.  Simpson’s index of diversity (SID) and corresponding 95% confidence intervals (CI95%) of 
the alleles of covR, covS, and ropB, the emm types, and the STs identified among the 191 GAS isolates 
analysed in this study.
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Figure 1. Nucleotide alterations identified in the covR (A), covS (B), and ropB (C) alleles reported 
in this study and previously deposited in GenBank, relative to the alleles present in strain SF370 
(AE004092). Each gene is indicated by a grey arrow and a nucleotide numbering scale is represented below 
each one. Each sequence variation is indicated in the respective nucleotide position by a letter corresponding 
to the variant nucleotide, or the sequence or number of base-pairs inserted (ins), deleted (del), or duplicated 
(dup). Synonymous nucleotide changes are represented in black; missense mutations and short in-frame 
indels ( ≤ 6 bp) are represented in blue; changes predicted to result in null alleles, including nonsense 
mutations, indels that generate frameshifts, and long in-frame indels ( ≥ 357 bp) are represented in red.
www.nature.com/scientificreports/
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The presence of an altered amino acid sequence in general was not associated with infection type for 
any of the genes. However, null covS alleles were significantly overrepresented among the invasive isolates 
(P = 0.0247) (Table 3), even though they were only present in nine of these isolates (10%).
SpeB production. In this study, the presence or absence of extracellular proteolytic activity was tested 
for all isolates using a spectrophotometric assay based on the degradation of azocasein by culture super-
natants, as well as by a plate assay in which the strains were cultured in solid medium containing casein. 
To confirm that the proteolytic activity detected by these two methods was essentially due to SpeB, which 
has been described as the major extracellular protease of GAS28, Western blot analysis using monoclo-
nal anti-SpeB antibodies was performed in a subset of six isolates of emm types 1, 64 and 89. For each 
emm type, one protease-positive and one protease-negative isolate were randomly chosen. The presence 
of a 28-kDa band similar to the one detected for SF370 was considered as a positive result (Fig. 2). The 
Western blot results were concordant with those of the two proteolytic activity assays for this subset of 
isolates. The emm1 strains SF370 and MGAS5005 were used as controls in all assays. As expected, strain 
SF370, which encodes a functional CovRS, presented proteolytic activity in both assays and was positive 
for mature SpeB production by Western blotting. In contrast, almost undetectable amounts of mature 
SpeB and no proteolytic activity were observed for MGAS5005, which harbours a frameshift mutation 
in covS (Fig. 2 and Fig. 3). Taken together, these results confirm that SpeB is the major protease of GAS, 
allowing us to use the total proteolytic activity as a proxy for SpeB activity. Western blot was also per-
formed for all isolates in which the azocasein and casein-plate results were discordant (n = 31). In these 
cases, the Western blot result was considered as final.
Of a total of 191 isolates, 153 (80%) presented SpeB activity, while for the remaining 38 (20%) no 
SpeB activity could be detected (Fig. 3 and Supplementary Table S1). All isolates with null alleles, either 
in covS or in ropB, were associated with an absence of SpeB activity (P < 0.0001 for both). In contrast, 
the prevalence of missense alleles among the SpeB-negative and SpeB-positive isolates was similar, except 
for non-clonal missense alleles in ropB (i.e. missense alleles that were not identified in other isolates of 
the same emm type in this study or in the GenBank database), which were associated with the absence of 
Allele type
Invasive 
(n = 87)
Pharyngitis 
(n = 104)
covR Null 0 0
Missense 2 2
covS Null 9 2
Missense 51 61
ropB Null 3 3
Missense 13 26
covRS/ropB Null 12 5
Missense 56 72
Table 3.  Number of isolates from invasive infections and pharyngitis presenting null and missense 
alleles in the covR, covS, and ropB genes.
Figure 2. Representative Western blot result for detection of mature SpeB (28 kDa) expression by GAS 
isolates. The blot shown was cropped to the region of interest.
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Figure 3. SpeB production and NADase and SLS activity determined for the 191 isolates analysed in 
this study, according to emm type. The emm types represented by < 5 isolates are grouped into “Others” 
and include emm 9, 11, 18, 29, 43, 53, 58, 74, 77, 78, 87, 94, 102 and 113. The results of reference strains 
SF370 and MGAS5005 are also presented.
www.nature.com/scientificreports/
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SpeB production (P = 0.0008). Only two SpeB-negative isolates presented alleles encoding the reference 
amino acid sequence in all three genes. The absence of SpeB activity in isolates carrying non-null alleles 
in the three genes could be due to alterations in the speB gene, its promoter, or in other mechanisms 
involved in the post-transcriptional or post-translational regulation of SpeB14.
There was no significant association between the SpeB activity of the isolates and infection type. The 
overall distribution of emm types differed significantly between SpeB-producing isolates and those with-
out protease activity (P = 0.0030), but after FDR correction, only emm types 89 and 6 were significantly 
associated with the absence of SpeB (P = 0.0354 for both).
NADase activity. In this work, the NADase activity of the isolates was measured by an endpoint titre 
method based on the degradation of β -NAD by culture supernatants, which results in a reduction of the 
fluorescence emitted by the reduced form of β -NAD. GAS emm1 strains SF370 and MGAS5005 were 
used as controls of the assay. As expected, SF370 presented a low NADase activity (NADase ≤ 3), while 
MGAS5005 was found to have the highest NADase activity level measured (NADase = 192) (Fig. 3). The 
high NADase activity of the latter strain can be attributed to the null covS allele, as well as to a different 
NADase locus from the one carried by old emm1 strains such as SF37029.
The gene encoding the GAS NADase, known as spn or nga, presents multiple variants and has been 
shown to be diverging into NADase-active and -inactive subtypes, which are correlated with emm pat-
terns and tissue tropism30. Therefore, variations in the levels of NADase activity exhibited by distinct 
GAS lineages, which may encode different nga alleles, are expected and were observed among the iso-
lates analysed in this study (Fig.  3 and Supplementary Table S1). Despite this lineage-specific varia-
tion, it was possible to identify a significant association between the highest activity values, namely 
NADase = 96 and NADase = 192, and the presence of null alleles in covS (P = 0.0005), while covR and 
ropB changes did not significantly contribute to an increased NADase activity. In agreement, all the 
strains carrying covS null alleles expressed higher levels of NADase activity than the majority of the 
isolates of the same emm type, except for two emm64 isolates (Fig. 3). The absence of NADase activity 
could be an intrinsic characteristic of this lineage, regardless of the CovRS alleles, due to alterations in 
the nga gene, its promoter, or other regulatory pathways. It is also possible that nga is not part of the 
CovRS regulon in the emm64 clone. Both inter- and intra-serotype differences in the regulatory activity 
of CovRS have been proposed9.
Despite the association between high levels of NADase activity and covS null mutations, it was 
not possible to detect any significant association between the level of NADase activity and invasive 
disease.
Streptolysin S activity. The SLS activity of the isolates was evaluated by an endpoint titre method 
based on the amount of released haemoglobin from sheep erythrocytes during incubation with cul-
ture supernatants. Although the majority of the isolates (n = 179, 94%) presented an SLS activity ≤ 3, it 
was possible to identify multiple isolates with increased SLS activity and that also carried alterations in 
CovRS (Fig. 3). Accordingly, the SLS activity determined for the reference strains SF370 (SLS ≤ 3) and 
MGAS5005 (SLS = 12) were consistent with a de-repression of the sag operon in the latter due to the 
null allele in covS, and a significant association between activity values of SLS = 12 and SLS = 48 and 
covS null alleles was observed (P = 0.0003 and 0.0040, respectively). In fact, all isolates with an SLS ≥ 12 
presented null alleles in covS (Fig. 3 and Supplementary Table S1). Four isolates carrying null alleles and 
belonging to emm types 6, 44, and 64 did not exhibit an increased SLS activity. The coherent low NADase 
and SLS activity among emm64 isolates independent of the CovRS alleles is consistent with a potentially 
different CovRS regulon in these isolates. Among emm6 and emm44 isolates, it is possible that the sag 
operon, which encodes SLS activity, is not regulated by CovRS. Alternatively, SLS activity may not be 
significantly increased in these isolates due to mutations in the sag operon, which have been infrequently 
reported among S. pyogenes isolates31.
It was not possible to detect any significant associations of SLS activity levels with the presence or 
absence of changes in covR and ropB, nor with infection type.
Discussion
Variations at the level of the regulatory networks governing GAS gene expression may constitute key 
elements differentiating strains with a high invasive ability from those that carry the same virulence 
genes, but cause mild infections or asymptomatically colonise the host. Mutations impairing the function 
of the two-component system CovRS and the stand-alone regulator RopB could play this role and have 
been shown to be important in animal models of infection, mostly using representatives of the M1T1 
clone2,3,11,17. However, the actual impact of these mechanisms in invasive human GAS infections remains 
unclear.
In the characterised collection, all three genes (covR, covS, and ropB) presented a high genetic diver-
sity and the allele distribution was closely associated with emm type and ST. Some studies, mostly based 
on murine infection models, suggest that isolates of the highly invasive M1T1 clone have a higher ability 
to acquire covRS mutations than strains of other emm types17,32. However, in our study mutations in the 
covR, covS, and ropB genes were not more prevalent in emm1 or any other emm type. We conclude that 
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among the GAS population causing human infections, the acquisition of mutations in any of the three 
genes can occur in isolates of diverse lineages, in agreement with data from Japan and Taiwan11,12. We 
also did not find a higher prevalence of covRS mutations in isolates carrying the DNase gene sda1 (data 
not shown), although it has been suggested that the presence of the phage encoding this gene exerts a 
selective pressure that favours the acquisition of covRS mutations, at least in the M1T1 genetic back-
ground33.
Null covS alleles were found to have a significant association with invasive infections, while the 
missense alleles in covS and all null and missense alleles in covR and ropB were not differently 
distributed among isolates from pharyngitis and from invasive disease. According to these results, 
only the null alleles in covS would contribute to the transition to invasive infection. In addition, the 
fact that null alleles are significantly more common in covS than in covR supports the hypothesis 
that during the infection process, the acquisition of mutations that impair signalling through CovS, 
while keeping CovR functional and possibly responsive to phosphorylation by other kinases, such 
as SP-STK, may favour the progression to invasive infection19,34. However, this mechanism of transi-
tion to an invasive phenotype seems to be uncommon, since it was found in a minority of invasive 
isolates (10%).
The absence of expansion of isolates carrying null alleles in any of the three analysed genes and the 
fact that they are all under stabilising selection suggests that although mutations compromising the 
activity of these regulators may favour the progression to invasive disease, they are not beneficial to the 
overall fitness of S. pyogenes. Strains carrying covRS null alleles presented decreased ability to survive in 
human saliva and to persist in the murine nasopharynx, leading to the proposal that these strains would 
have an impaired colonisation and transmission capacity19,35. In a murine skin and soft tissue infection 
model, infection with a mixed population containing both the wild-type strain and a derivative covRS 
mutant resulted in higher virulence than infection with either strain alone, highlighting the importance 
of the presence of isolates carrying a functional CovRS2. Therefore, in spite of promoting a switch to a 
phenotype that favours the survival of GAS in deeper tissues, the loss of CovS may affect the success of 
the initial stages of infection8.
In order to evaluate the phenotypic impact of mutations in the covRS and ropB genes, we determined 
the activity of three extracellular proteins that are known to be involved in GAS pathogenesis and to be 
under the direct or indirect influence of these regulators, namely SpeB, NADase, and SLS. A functional 
RopB is considered an absolute requirement for speB transcription13, while the influence of covS muta-
tions in speB expression is more controversial2,5,7,8,17–19,32. Our results support a role of both CovRS and 
RopB in the expression of SpeB, since null alleles in both covS and ropB were associated with the absence 
of SpeB production. Overall, the absence of SpeB activity was significantly more common among emm 
types 6 and 89, both frequently reported among invasive infections, especially emm89, which is one of 
the leading emm types among invasive isolates in several European countries23. However, the emm types 
that have been found to be significantly overrepresented among invasive infections in Portugal, namely 
emm1 and emm6421, were not associated with an increased proportion of SpeB-negative isolates. In 
agreement, the absence of SpeB activity was not associated with invasive infection, indicating that, in 
spite of preserving several virulence factors that are regarded as important for the invasive process, the 
abrogation of SpeB activity cannot explain by itself the higher ability of certain clones to cause invasive 
disease.
Several studies report a significant influence of RopB on the expression of virulence factors other 
than SpeB, including NADase and SLS, either directly or due to the regulation of SpeB or the interaction 
with other transcriptional regulators10,11,24. However, it has been demonstrated that the RopB regulon is 
highly variable, even among strains of the same emm type and that the core regulon is limited to the 
speB and spi genes36. Our results are in agreement with this observation, since changes in ropB were not 
significantly associated with altered NADase or SLS activities. This suggests that, despite the influence 
that the regulator may have in the expression of these proteins in particular lineages, in the overall GAS 
population and under the growth conditions used in this study, RopB does not contribute significantly to 
the expression of the nga and sag operons. In contrast, covS null alleles were significantly associated with 
an increased activity of both NADase and SLS, which is consistent with a repression of the corresponding 
operons by phosphorylated CovR, as demonstrated for the sag promoter18. However, exceptions were 
noted in isolates of specific emm types, including emm64, supporting the existence of differences in the 
CovRS regulon of distinct GAS lineages9. Although both NADase and SLS have been shown to contrib-
ute to GAS cytotoxicity and virulence37,38, their individual activities were not correlated with the type of 
infection caused by the isolates.
The association of missense alleles with invasiveness and with the activities of the studied virulence 
factors is harder to evaluate. Most of the alleles corresponding to amino acid changes in CovS and RopB 
occurred in multiple (often all) isolates of the same emm type, indicating that these are clonal mutations 
and probably do not represent the mechanism described for GAS in which mutations leading to a hyper-
virulent phenotype are acquired during infection2,3. Missense changes can have distinct effects on protein 
function depending on the nature of the amino acid replacement and the region where they occur. It is 
not possible to know from the current data if an altered phenotype in isolates carrying missense alleles 
is due to amino acid changes in these regulators or to some other characteristic of that specific lineage. 
Possibly reflecting this, the prevalence of missense alleles in ropB, covR, and covS could not be associated 
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with the phenotypes tested. When considering only the non-clonal missense alleles, an association with 
SpeB-negative isolates, but not with invasive disease, was observed in the case of ropB. Non-clonal mis-
sense alleles in covRS were not associated with any particular phenotype regarding the tested virulence 
factors, nor with disease presentation.
Null covS alleles are associated with invasive isolates and present phenotypes consistent with the 
ablation of this regulatory system. However, none of the phenotypes is itself associated with invasive-
ness, indicating that other factors under covRS regulation may be responsible for this higher virulence. 
In agreement, impairment of RopB function, known to result in SpeB downregulation, is not associated 
with invasiveness. The data presented supports the abrogation of CovS function as a mechanism con-
tributing to the pathogenesis of invasive GAS infections, although this is not specifically associated with 
lineages identified as having enhanced invasiveness, but occurred in isolates of diverse emm types and 
STs. This mechanism is uncommon and the acquisition of such changes, despite being beneficial in the 
specific context of invasive disease, may incur an overall fitness cost for GAS, preventing their fixation 
in the population.
Materials and Methods
Bacterial strains and culture conditions. GAS isolates used in this study (104 recovered from phar-
yngeal exudates of patients with pharyngitis and 87 associated with invasive disease, recovered from 
normally sterile sites) are listed in Supplementary Table S1 online. The strains were randomly selected 
among a collection of 480 non-duplicate isolates recovered from human infections between 2000 and 
2005 that have been previously characterised21, so as to include one third of the isolates of each emm type 
present in the collection with n ≥ 3, as well as all isolates of emm types 1 and 64. Strains SF370 (CECT 
5109, obtained from Colección Española de Cultivos Tipo) and MGAS5005 (BAA-947, obtained from 
American Type Culture Collection) were used as controls. Strains were grown at 37 °C in Todd Hewitt 
broth (THB) (BD, Sparks, MD, USA) or in Tryptone Soya Agar (Oxoid, Basingstoke, UK) supplemented 
with 5% defibrinated sheep blood.
Molecular typing. In addition to the molecular characterisation of the isolates that had been previ-
ously performed21, multilocus sequence typing analysis was completed for all isolates.
Gene sequencing and analysis. Genomic DNA of the isolates was extracted using cetyl trimeth-
ylammonium bromide (CTAB)39. All PCR and sequencing primers used in this study are listed in 
Supplementary Table S3. The sequences obtained for each isolate were assembled and compared with 
the corresponding regions of the genome of strain SF370 (GenBank AE004092), considered to be the 
reference wild-type alleles.
Geneious R7 (Biomatters, Auckland, New Zealand) was used to search the GenBank database 
(accessed on April 7th 2014) using BLAST for all previously deposited sequences of covR, covS, and ropB 
of S. pyogenes, and align them with the trimmed sequences of the isolates analysed in this study, using 
the MUSCLE algorithm with default settings.
The subset of non-duplicate alleles without indels was used to calculate the ratio of the number of 
nonsynonymous substitutions per nonsynonymous site to the number of synonymous substitutions per 
synonymous site (Ka/Ks), and the respective Z test for stabilising selection, using MEGA5, with the 
Mega-Kumar method (Kimura 2-paramether). Values of P < 0.05 were considered statistically significant. 
Nucleotide diversity was calculated using DnaSP v.5.10.1.
Determination of protease activity. Azocasein assay. SpeB protease activity in stationary phase GAS 
culture supernatants was determined using an adapted azocaseinolytic assay already modified for the 
96-well plate format40,41. Briefly, 24 h-cultures of each strain were diluted 1:10 in fresh THB and grown for 
18 h, in 96-well plates. Bacteria-free supernatants were obtained by centrifugation at 3220 × g for 10 min, 
and transferred to a new microtitre plate. An equal volume of activation buffer (0.1 M sodium acetate 
[pH 5], 1 mM EDTA, 20 mM dithiothreitol) was added and the plate was incubated for 1 h at 40 °C. After 
activation, 2% azocasein (Sigma-Aldrich, St. Louis, MO, USA) (w/v in activation buffer) was added and 
incubated for 6 h at 40 °C. Samples were then precipitated with 2.5 volumes of 6% trichloroacetic acid 
and centrifuged at 15000 × g for 5 min. The optical density at 450 nm of the resulting supernatants was 
determined. The corresponding proteolytic activities were calculated using a calibration curve performed 
for each plate with known concentrations of proteinase K (Roche Diagnostics). Three independent assays 
were performed for each strain. The presence of proteolytic activity was considered positive when at least 
two of the three assays showed a value ≥0.0025 U.
Casein-plate assay. GAS expression of extracellular cysteine protease was determined by a plate assay 
as previously described16. Briefly, single GAS colonies were stab-inoculated into plates of medium 
containing 0.5-strength Columbia broth (BD), 3% w/v skim milk (BD), and 1% w/v agar (Oxoid). 
Protease-expressing strains produced a translucent zone surrounding the site of inoculation after 24-h 
incubation at 37 °C. Three independent assays were performed for each strain. The presence of proteo-
lytic activity was considered positive when at least two of the three assays presented a translucent zone 
of size similar to the one of strain SF370.
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SpeB Western blot analysis. For Western blot analysis, bacterial cultures were grown to late sta-
tionary phase (18 h) and centrifuged at 3200 × g for 15 min. Sterile-filtered supernatants were separated 
by electrophoresis on a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane (Whatman, 
Dassel, Germany) using a Mini Trans-Blot (Bio-Rad, Hercules, CA, USA). Immunodetection was per-
formed by chemiluminescence using monoclonal anti-SpeB antibody (Toxin Technology, Serasota, FL, 
USA) and goat anti-rabbit IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology, 
Dallas, TX, USA). Detection was performed with ECL detection reagents (Thermo Scientific, Waltham, 
MA, USA) according to the manufacturer’s instructions.
Determination of NADase activity. The NADase activity of each strain was determined by an 
endpoint titre method based on previously published assays37. Briefly, bacteria-free supernatants of 
stationary-phase cultures of GAS strains were obtained as described for the azocasein assay and serially 
diluted (three-fold for the first dilution and two-fold for the second dilution onwards, up to 1/384) in 
β -NAD (Sigma-Aldrich) dissolved in PBS for a final concentration of 0.67 mM, in black 96-well plates 
(transparent bottom) (Greiner Bio-One, Frickenhausen, Germany). Wells containing sterile THB serially 
diluted in PBS and in β -NAD/PBS were used as controls, for each plate. After incubation for 1 h at 37 °C 
in the dark, an equal volume of NaOH was added, for a final concentration of 2 N, and the plates were 
incubated for 1 h at room temperature, in the dark. Fluorescence was measured with excitation at 340 nm 
and emission detection at 460 nm. For each strain, the NADase activity was expressed as the inverse of 
the highest dilution prior to a greater or equal to two-fold increase in the fluorescence value. This method 
has a limit of detection of 3, and strains for which a two-fold increase was not observed and with values 
similar to the THB + β -NAD control were considered to have a NADase activity of ≤3. A minimum of 
three independent assays were performed for each strain, and the majority rule was used to determine 
the final NADase activity.
Determination of streptolysin (SLS) activity. The streptolysin activity of each strain was 
determined by an endpoint titre method adapted from a previously published assay20. Briefly, 
bacteria-free supernatants of stationary-phase cultures of GAS strains were obtained as described 
for the azocasein assay. The supernatants (or sterile THB for control of spontaneous haemolysis – 
blank) were serially diluted in PBS in microplate wells (three-fold for the first dilution and two-fold 
for the second dilution onwards, up to 1/192), and an equal volume of a 2.5% (v/v) suspension of 
defibrinated sheep erythrocytes was added. Two complete haemolysis controls were included in 
each plate, by incubating the erythrocytes suspension with 1% Triton X-100 (positive controls). 
The blank for these wells consisted only of PBS and the erythrocyte suspension. After incubation 
at 37 °C for 1 h, erythrocytes were pelleted and the absorbance at 570 nm of the supernatants was 
measured. For each well, the percentage of haemolysis relative to the positive control was calculated 
as follows:
−
−
×
( )
Abs sample Abs blank
Abs positive control Abs PBS blank
100
1
570 570
570 570
The streptolysin activity was expressed as the inverse of the highest dilution prior to a ≥ two-fold 
decrease in the percentage of haemolysis. This method has a limit of detection of 3, and strains for 
which a two-fold decrease was not observed were considered to have a streptolysin activity of ≤ 3. A 
minimum of three independent assays were performed for each strain, and the majority rule was used 
to determine the final streptolysin activity. In four strains, two with functional covRS alleles (SF370 
and SH0959A in Supplementary Table S1) and another two, of the same emm types, with null covS 
alleles and increased NADase activity (SH1025A and SH0421A in Supplementary Table S1), streptolysin 
assays were also performed in the presence of 33.3 μ g/ml of trypan blue (Sigma-Aldrich) or of 16.7 μ g/
ml cholesterol (Sigma-Aldrich). In all four strains, the results were not significantly changed by the 
presence of cholesterol, while trypan blue completely inhibited haemolysis, indicating that streptolysin 
O does not contribute to the haemolytic activity determined under these conditions, in agreement with 
previous reports20.
Statistical analysis. The allelic diversity of the covR, covS, and ropB genes in the studied collec-
tion of GAS isolates was evaluated using the Simpson’s index of diversity (SID) and corresponding 
95% confidence intervals (CI95%)42. The overall association between covR, covS, or ropB alleles and 
the emm type and ST was evaluated with the Adjusted Wallace coefficient with corresponding 
CI95%43.
Unless otherwise specified, the statistical significance of pairwise associations was evaluated by calcu-
lating the respective odds ratios (when applicable) and the two-tailed Fisher’s exact test, correcting the 
P values for multiple testing through the FDR linear procedure44.
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